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Abstract 
Leishmania species are protozoan parasites which have a complex life cycle, which is 
coordinated with its cell cycle. There are 11 cyclin dependent kinases (CDKs) and 11 
cyclins present in the Leishmania genome reflecting the complexity of cell cycle control in 
this parasite, perhaps due to the requirement for synchronisation with the life cycle. 
Leishmania mexicana CRK3, a cdc2-related serine/threonine protein kinase of the CDK 
family, is essential for transition through the G2-M-phase checkpoint of the Leishmania 
cell cycle. The Trypanosoma brucei homologue of CRK3, with 78% identity to L. 
mexicana CRK3, has been shown to form an active kinase complex with the CYC6 cyclin. 
Using this knowledge a putative mitotic cyclin, CYC6, from Leishmania major was 
identified. Monomeric CRK3 does not have protein kinase activity, but was activated in 
vitro with CYC6 to produce a protein kinase complex with histone H1 kinase activity. 
CRK3his and CYC6his were co-expressed and co-purified from Escherichia coli via metal 
affinity and gel filtration chromatography to obtain a 1:1 ratio of CRK3:CYC6 proteins, 
which formed a stable protein kinase complex. Using histone H1 as a substrate, active 
CRK3:CYC6 was used to develop a radiometric assay suitable for low to medium 
throughput compound screening and then an assay suitable for high throughput screening 
(HTS) using IMAPTM fluorescence polarization technology. This HTS assay was used to 
screen a 25,000 compound chemical library to identify hits which significantly reduced 
CRK3:CYC6 protein kinase activity. Two main pharmacophores with the highest potency 
towards CRK3:CYC6 protein kinase activity were identified from the high throughput 
screen. Structure Activity Relationship (SAR) analysis of the hits identified the chemical 
groups attached to the scaffold structures which are essential for the inhibition of 
CRK3:CYC6 protein kinase activity. The CRK3:CYC6 hits were subsequently counter-
screened against a panel of 11 mammalian kinases including human CDK1:CYCB (the 
functional orthologue of CRK3:CYC6), human CDK2:CYCA and human CDK4:CYCD1 
to determine their selectivity. Compound hits that were selective towards CRK3:CYC6, 
were tested against Leishmania in vitro. Progress towards synthesising potent and selective 
derivatives of the HTS hits will be discussed, with the view to evaluating their potential for 
the development of novel therapeutics against leishmaniasis. 
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Chapter 1 
Introduction 
1.1 The trypanosomatids. 
Several species of trypanosomatid protozoa are the etiological agents of parasitic diseases 
in mammals, including humans. These organisms have been the subject of extensive 
scientific research because of their involvement in a range of diseases, resulting in both 
medical and economical issues. Current therapeutics used in the treatment of African 
trypanosomiasis and leishmaniasis, such as the arsenical-based Melarsoprol (Mel B, 
ArsobalTM) and the antimonial based Sodium stibogluconate (Pentostam®, SSG) are 
unsatisfactory for a number of reasons including toxicity and drug resistance (Croft and 
Coombs, 2003; Fairlamb, 2003; Croft et al., 2006b). As a result, new targets for anti-
parasite chemotherapy are being continuously sought after because of the medical and 
economical implications involved. There have been recent advances in research into 
possible anti-parasite therapeutic targets, and one such area is that of cyclin dependent 
kinases (CDKs) in the parasite life cycle. Several protein kinases play essential roles in the 
cell cycle, and thus provide an attractive area of study for drug design to treat parasitic 
diseases. 
1.1.1 Parasitic trypanosomatids: 
1.1.1.1 Leishmania species. 
Leishmania parasites are parasitic protozoa belonging to the family Trypanosomatidae. 
There are over 20 known species and sub species of Leishmania prevalent in 88 countries 
worldwide which are grouped into old world (Africa, Asia and Europe) and new world (the 
Americas and Australasia) species according to their geographic distribution. 
(www.who.int/tdr/diseases/leish/diseaseinfo). They are the etiological agents of the 
leishmaniases, a group of diseases transmitted to mammals by the bite of blood feeding 
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female sand flies (Phlebotomus spp. in the old world and Lutzomyia spp. in the new world) 
(Reithinger et al., 2007).  
1.1.1.2 African trypanosomes. 
African trypanosomes are parasitic protozoa from the genus Trypanosoma of which there 
are a number of subspecies prevalent in 36 countries in sub-Saharan Africa. They are 
transmitted by the bite of the blood feeding tsetse fly (Glossina spp.) and cause debilitating 
diseases from a health and economical standpoint. Trypanosoma brucei brucei is the 
etiological agent of N’gana, a muscle wasting disease in cattle and other wild mammals, 
but cannot infect humans (www.who.int/tdr/diseases/tryp/diseaseinfo). Trypanosoma 
brucei gambiense causes the chronic form of human African trypanosomiasis (HAT), also 
known as African sleeping sickness, which is distributed throughout central and Western 
Africa. Trypanosoma brucei rhodesiense is the causative agent of the acute form of HAT 
prevalent mainly in Eastern and Southern Africa. It is estimated that 60 million people are 
at risk of infection and the World Health Organisation estimate that approximately 0.5 
million people carry the infection, of which there are 50 000 deaths per annum (Barrett et 
al., 2003). Post infection, early symptoms include fever and an enlarged spleen 
(splenomegaly). This is followed by headaches, anaemia and swollen tissues. The parasites 
then invade the central nervous system (CNS) where symptoms progress to mental 
retardation, coma and in all cases results in death 
(www.who.int/tdr/diseases/tryp/diseaseinfo).  
1.1.1.3 American trypanosomes. 
Trypanosoma cruzi are American trypanosomes which are parasitic protozoa belonging to 
the Trypanosoma genus. They are transmitted by the bite of the blood feeding triatomine 
insect (sub-family Triatominae), also known as “Assassin bugs”. The faeces of the insect 
contain the parasites which can enter the human host via the wound left after a blood meal, 
usually when it is scratched or rubbed. T. cruzi is the causative agent of Chagas disease 
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also known as human American trypanosomiasis and it is estimated that between 8 and 11 
million people are infected with the disease (www.cdc.gov/chagas/factsheet.html). The 
disease is prevalent in 18 countries in two ecological zones: the Southern cone, where the 
vector insects live inside human homes; and Northern South America, Central America 
and Mexico where the vector insects live both inside and outside human dwellings. Post 
infection, symptoms include a small sore where the parasite enters the body and if this has 
occurred near the eye, the eyelid becomes swollen which is known as Romaña’s sign. The 
disease occurs in acute and chronic forms. Swollen lymph nodes and fever can develop 
within a few days and this initial acute phase can result in illness and death, especially in 
young children. More commonly, patients are subject to the chronic phase of the disease 
which shows no visible symptoms and can last several months or years. During this time, 
the parasites invade most of the organs in the body, causing heart, intestinal and 
oesophageal damage and progressive weakness. In 32% of those infected, substantial 
damage to the heart and intestinal tract occurs which is fatal to the patient. 
(www.who.int/tdr/diseases/chagas/diseaseinfo). 
1.2 Leishmaniasis. 
Leishmaniasis is a vector-borne disease from which an estimated 350 million people are at 
risk of infection (Reithinger et al., 2007). An estimated 12 million individuals are infected 
worldwide. There is an annual incidence of 0.5 million of the visceral form of the disease 
and 1.5-2 million cases of the cutaneous form of the disease (Croft et al., 2006b). Several 
clinical forms of the disease occur. 
1.2.1 Cutaneous leishmaniasis (CL). 
CL can result in the production of a large number of lesions or skin ulcers (sometimes up 
to 200) which usually form on exposed areas, such as the face, arms and legs. These 
usually heal within a few months invariably leaving the patient permanently scarred, a 
stigma which can cause serious social prejudice. 
  
4 
(www.who.int/tdr/diseases/leish/diseaseinfo, www.who.int/topics/leishmaniasis/en/). CL 
can be classified into three forms. 
1.2.1.1 Diffuse cutaneous leishmaniasis (DCL). 
DCL is mainly caused by L. aethiopica, L. amazonensis and L. mexicana. The disease 
results in widely spread and chronic skin lesions (www.who.int/topics/leishmaniasis/en/). 
Multiple parasite laden non-ulcerative nodules arise from the initial site of infection which 
may cover an individual’s entire body (Reithinger et al., 2007). This form of the disease is 
difficult to treat and patients do not self cure. 
1.2.1.2 Localised cutaneous leishmaniasis (LCL). 
LCL is caused by all species of Leishmania. A small erythema develops at the bite site 
which develops into a papule and then a nodule which progressively develops into an 
ulcerative skin lesion. Lesions typically self heal within 2-6 months of development 
(Reithinger et al., 2007). 
1.2.1.3 Mucocutaneous leishmaniasis (MCL). 
MCL is mainly caused by L. braziliensis and L. panamensis. The disease results in lesions 
which can partially or totally destroy the mucous membranes of the nose, mouth and throat 
cavities and surrounding tissues (www.who.int/topics/leishmaniasis/en/). It is difficult to 
diagnose and treat this form of the disease (Herwaldt, 1999), with secondary bacterial 
infections common and it can be fatal (Reithinger et al., 2007). 
1.2.2 Visceral leishmaniasis (VL). 
VL is caused by L. donovani and L. infantum. Also known as kala-azar, this is the most 
serious form of the disease. It is characterised by symptoms including high fever, 
substantial weight loss, enlargement of the liver and spleen and other secondary effects 
such as anaemia and diarrhoea. If left untreated the disease has a fatality rate of 100% 
within two years (www.who.int/topics/leishmaniasis/en/). 
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1.2.3 Post-kala-azar dermal leishmaniasis (PKDL). 
PKDL occurs as a complication of visceral leishmaniasis and is characterised by a rash of 
which the most common form is a nodular rash. This form of the disease has been 
described in India and Sudan in patients who have recovered from visceral leishmaniasis. 
The rash originates at the mouth and then spreads to other parts of the body depending on 
the severity (Zijlstra et al., 2003). 
1.3 Leishmania life cycle. 
Leishmania parasites possess a highly complex biphasic life cycle (Figure 1.1), whereby 
they survive in their sand fly vector and mammalian host. Leishmania parasites exist in 
five major morphological forms: procyclic promastigotes, nectomonad promastigotes, 
leptomonad promastigotes, metacyclic promastigotes and amastigotes. Procyclic 
promastigotes are present in the abdominal midgut of the sand fly. They are a flagellated, 
weakly motile, replicative form of the parasite. After a few days, the parasites slow their 
replication and develop into elongate, strongly motile nectomonad promastigotes, where 
they move towards the anterior midgut until they reach the stomodeal valve, which guards 
the junction between foregut and midgut (Bates, 2007). Once the parasites reach the 
stomodeal valve, they transform into leptomonad promastigotes, shorter forms of the 
parasite which resume replication (Gossage et al., 2003). Some of the 
nectomonad/leptomonad promastigotes also differentiate into haptomonad promastigotes. 
The leptomonad promastigotes differentiate into mammalian infective metacyclic 
promastigotes in the mouthparts of the sand fly (Rogers et al., 2002). After transfer of the 
metacyclic promastigotes to the mammalian host by the sand fly bite, Leishmania invade 
host macrophage cells where they transform into the non-motile amastigote form and live 
within the phagosomal compartment of the host macrophage. As the number of 
amastigotes increases, the macrophage eventually dies releasing the amastigotes, which 
then go on to infect other macrophages. This process continues until the infected 
macrophages are taken up in the blood meal of another feeding sand fly. In the gut of the 
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sand fly, the amastigotes emerge from macrophages and differentiate into procyclic 
promastigotes and the life cycle then repeats. 
 
 
 
 
 
Figure 1.1 – Schematic representation of the Leishmania species life cycle in 
Lutzomyia longipalpis. Taken from the International Journal for Parasitology (Gossage et 
al., 2003). 
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1.4 Current antileishmanial chemotherapy. 
The chemotherapy currently available for leishmaniasis is far from satisfactory. The 
demand for new antileishmanial drugs has been driven by the parasite acquired resistance 
to the pentavalent antimonial drugs, the first line chemotherapy against the disease, which 
are now almost obsolete in India (Croft and Coombs, 2003; Croft et al., 2005). Antimonial 
based treatments recommended for VL and CL were introduced in 1945 and remain 
effective treatments for certain forms of leishmaniasis (Croft and Coombs, 2003). 
However, the requirement for new antileishmanials is paramount.  
There are a number of drugs currently recommended for the treatment of leishmaniasis 
such as the pentavalent antimonials Sodium stibogluconate (Pentostam®, SSG) and 
Meglumine antimoniate (Glucantime®). Also included are Amphotericin B and its lipid 
formation AmBisome® and Pentamidine (Croft and Coombs, 2003). Miletefosine 
(Impavido®) and Paromomycin have also been registered to treat leishmaniasis. Those that 
remain in clinical trials include Imiquimod and Sitamaquine. These drugs exhibit a variety 
of modes of action and structures (Figure 1.2). 
The antimonials, introduced over 60 years ago have been the recommended drugs used to 
treat CL and VL for over 20 years (Croft and Coombs, 2003; Croft et al., 2005). However, 
they require parenteral administration for up to 28 days and exhibit varying efficacies 
against CL and VL. Perhaps the most significant factor limiting the usefulness of these 
drugs is the emergence of drug resistance. A prime example of this limiting factor, as 
mentioned, is in India where the pentavalent antimonials are almost no longer used to treat 
leishmaniasis in this part of the world. 
Amphotericin B is a highly effective polyene antibiotic used in the treatment of antimonial 
resistant L. donovani VL and certain cases of MCL (Croft and Coombs, 2003). It has 
selective activity against fungi as well as Leishmania and Trypanosoma cruzi. Its efficacy 
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is due to the higher selectivity towards ergosterol, the main sterol in these organisms over 
cholesterol, the predominant sterol in mammals (Croft et al., 2006b). However, it is an 
unpleasant drug due to its acute toxicity and the need for slow infusion parenteral 
administration over four hours (Croft and Coombs, 2003). 
Numerous Amphotericin B lipid formulations developed in the 1980s for the treatment of 
immunocompromised patients with systemic mycoses have proved effective as anti-
leishmanials. These lipid formulations have a reduced toxicity and been shown to have an 
extended half life, in comparison to the parent drug, for the treatment of fungal infections 
(Croft and Coombs, 2003). AmBisome®, the liposomal formulation of Amphotericin B, 
was first shown to cure a case of VL in 1991 and is currently registered for the treatment of 
VL as a first line drug by the Food and Drug Administration (Croft and Coombs, 2003; 
Croft et al., 2005). However, high cost has limited its use as an antileishmanial drug. 
The diamidine Pentamidine was introduced in 1952 and has been used to treat those with 
VL, CL and DCL. It is primarily used as a second line treatment in cases where antimonial 
resistance occurs and the antimonials are ineffective (Croft and Coombs, 2003; Croft et al., 
2006b). The primary mode of action is unclear and Pentamidine is not a widely used drug 
to treat leishmaniasis (Croft et al., 2006b).  
The antileishmanial activity of Miltefosine (Impavido®) (hexadecylphosphocholine) was 
identified at Wellcome, and although originally identified as an anticancer agent, had its 
antileishmanial activity proven by 1985. It is a lysophospholipid analogue and the first oral 
treatment produced for VL whilst also being effective against CL (Croft et al., 2005). 
Miltefosine, registered in India in 2002 and in phase IV clinical trials, is used in cases of 
antimonial resistance. However, there is a number of limitations regarding Miltefosine. 
The main limitation being its teratogenicity and therefore women of child bearing age are 
excluded from its use (Croft and Coombs, 2003). Furthermore, there are concerns 
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regarding the long half life of the drug which might encourage drug resistance and there is 
also a narrow therapeutic window with Miltefosine (Croft et al., 2006a). 
 Imiquimod [1-(2-methylpropyl)-1H-imidazo(4,5-c)quinolin-4-amine] is an antiviral 
compound commonly used to treat genital warts caused by the human papillomavirus. It 
has been shown to have an effect in experimental infections of CL and successfully treat 
patients with cutaneous lesions, who did not respond to antimonial treatment alone (Croft 
et al., 2006a). 
Paromomycin (Aminosidine) is an aminoglycoside-amino-cyclitol antibiotic originally 
identified as an antileishmanial in the 1960s (Croft and Coombs, 2003). It is used to treat 
VL in a parenteral formulation and CL in topical and parenteral formulations(Croft et al., 
2005; Croft et al., 2006b). It is currently in phase III clinical trials in Africa and was 
registered in 2006 to treat Leishmaniasis in India (www.dndi.org). 
Sitamaquine is an 8-aminoquinoline derivative (4-methyl-6methoxy-8-aminoquinoline) 
whose antileishmanial activity was identified in the 1970’s at the Walter Reed Army 
Institute of Research (WRAIR) (Croft and Coombs, 2003; Croft et al., 2006a). It is 
currently in development at GlaxoSmithKline (GSK) in phase II clinical trials for the 
treatment of VL (Croft and Coombs, 2003; Croft et al., 2006b). Sitamaquine toxicity 
seems to be reasonably mild, causing mild methaemglobinaemia (Croft and Coombs, 
2003).
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Figure 1.2 – Structures and modes of action of current antileishmanial drugs. Upper 
panel: Structures of current antileishmanial drugs. Lower panel: modes of action of current 
antileishmanials. Both were taken from TRENDS in Parasitology (Croft and Coombs, 
2003).
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1.5 The eukaryotic cell cycle. 
The generalised eukaryotic cell cycle is divided into four main stages: G1, S, G2 and M-
phase (Figure 1.3). However, there is another cell cycle stage, called gap 0 (G0). G1 is the 
first gap phase where the cell grows and prepares for S-phase. During G1, the cell makes 
the decision to continue, pause or exit the cell cycle process. Cells that should cease 
division enter G0 where they leave the cell cycle and quit dividing, which can be a 
temporary resting period or more permanent. Cells continuing the division process then 
enter a restriction point referred to as START, which is where they are committed to 
completing the cell cycle. This proceeds into S-phase where the cell replicates its genome. 
The cell then progresses into G2, the second gap phase where it again grows and prepares 
itself for the onset of M-phase. M-phase or mitosis is the process by which the cell 
segregates its duplicated chromosomes into two separate nuclei. The final process is 
cytokinesis where the cell separates into two identical daughter cells which marks the 
completion of the cell cycle (Johnson and Walker, 1999).  
1.5.1 Cyclin-dependent kinase regulation. 
Cyclin dependent protein kinases (CDKs) are a class of enzymes shown to be vital for the 
regulation and progression of the cell cycle (Nurse, 1990; Pines and Hunter, 1990) and are 
ubiquitously expressed in eukaryotic organisms. CDKs are serine/threonine protein kinases 
which catalyse a phosphotransfer reaction whereby the γ-phosphate from ATP is 
transferred onto a serine or threonine residue of a substrate. At least six mechanisms 
govern and control the activity of CDKs; cyclin subunit binding, CDK phosphorylation, 
inactivation by CDK inhibitory subunits (CKIs), inactivation by regulatory kinases 
(Morgan, 1997), CDK cellular localisation and CDK structure.  
CDKs are catalytic subunits which are inactive as monomers and require the binding of a 
regulatory cyclin subunit to become activated, thereby forming an active protein kinase 
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complex (Moreno et al., 1989; Solomon et al., 1990). Homology among cyclins is usually 
limited to a relatively well conserved domain of approximately 100 amino acids, termed 
the “cyclin box”, which is responsible for CDK binding and activation (Kobayashi et al., 
1992; Lees and Harlow, 1993) via a PSTAIRE binding motif in the CDK. However, recent 
analysis of the human genome has identified the cyclin box as being comprised of 150 
amino acids (Malumbres and Barbacid, 2005). Cyclin function is primarily controlled by 
changes in cyclin levels which increase and decrease throughout the cell cycle as required. 
Their degradation involves ubiquitin-mediated proteolysis, requiring a recognition motif, 
termed the “destruction box” near the amino terminus end of the cyclin (Glotzer et al., 
1991).  
In addition to cyclin binding, complete CDK activation requires phosphorylation at a 
conserved threonine residue, in a region called the T-loop, by a CDK activating kinase 
(CAK) (Morgan, 1995). CAK was identified and shown to phosphorylate and activate 
Cdc2 (Ducommun et al., 1991; Solomon et al., 1992). Civ1, a CAK from Saccharomyces 
cerevisiae was shown to tightly bind and phosphorylate CDC28 in vivo and to be essential 
for cell viability (Thuret et al., 1996). Additional work on mammalian CDKs has shown 
that phosphorylation is vital for CDK1-cyclinB activity, where cyclin binding alone has 
little effect on activity, or CDK2-cyclinA activity, where high affinity cyclin binding can 
not occur without phosphorylation (Desai et al., 1995). CDK1 (Cdc2) is phosphorylated on 
Thr 161 and CDK2 on Thr 160 (Morgan, 1995) which has been shown to be carried out by 
CDK7-cyclinH-MAT1, the mammalian CAK (Fesquet et al., 1993; Fisher and Morgan, 
1994). An interesting point, however, is that activation of some complexes such as CDK5-
p35 and CDK7-cyclinH-MAT1 itself do not require phosphorylation (Nigg, 1996; Qi et al., 
1995) and CDK8-cyclinC does not contain a phosphorylatable residue at the analogous site 
in the T-loop (Tassan et al., 1995b).  
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CDK-cyclin complexes can also be inhibited by phosphorylation as seen with human 
CDK1 and CDK2 on the Thr 14 and Tyr 15 residues (Morgan, 1995). Phosphorylation of 
these residues is important in the control of CDK1 activation at mitosis. CDK1-cyclinB 
complexes are maintained in an inactive state until dephosphorylation of these residues 
occurs at the end of G2 and CDK1 becomes active (Morgan, 1995). Tyr 15 of CDK1 has 
been shown to be phosphorylated by the kinase Wee1; however, it does not phosphorylate 
Thr 14. This is carried out by a dual specificity, membrane-bound kinase encoded by Myt1 
(Borgne and Meijer, 1996). Thr 14 and Tyr 15 are both dephosphorylated by a dual 
specificity phosphatase termed CDC25 which promotes CDK1 activity (Morgan, 1995). 
The fourth mechanism of CDK regulation is the association with a diverse family of 
proteins, termed cyclin-dependent kinase inhibitors (CKIs) which bind and inactivate 
CDK-cyclin complexes. A number of CKIs are present in yeast; FAR1 and p40 in S. 
cerevisiae and PHO81 in S. pombe (Morgan, 1995). There are currently two families of 
CKIs identified in mammals, the Cip/Kip and Ink4 families (Laine et al., 2007; Johnson 
and Walker, 1999).  The Cip/Kip family is comprised of p21Cip1, p27Kip1 and p57Kip2 which 
can act on most CDK-cyclin complexes (Johnson and Walker, 1999) and are known to 
inhibit CDK2 and CDK4/6-cyclin complexes involved in G1 and G1-S control (Johnson 
and Walker, 1999; Morgan, 1995; Morgan, 1997). The Ink4 family is comprised of 
p15INK4b, p16INK4a, p18INK4c and p19INK4d, which have a relatively narrow specificity for 
CDK4/6-cyclinD complexes, preventing their association (Morgan, 1997; Johnson and 
Walker, 1999; Carnero and Hannon, 1998).  
The cellular localisation of CDKs can also regulate their function. For example, the 
function of human CDK1 is partially dependent on it and its cyclin binding partner’s 
location within the cell. CDK1:CycB1 colocalizes with cytoplasmic microtubules during 
interphase (Porter and Donoghue, 2003; Migone et al., 2006), and then translocates to the 
nucleus to initiate mitosis. However, the CDK1:CycB2 complex colocalizes with the golgi 
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apparatus whereas CDK1:CycB3 is permanently located in the nucleus (Porter and 
Donoghue, 2003). 
Finally, the structure of CDKs has a role in their activation. This has been elucidated from 
detailed studies carried out mainly on CDK2 and one of its binding partners, CycA. For 
example, when CycA binds CDK2, by comparison with free CDK2, large conformational 
changes occur in the active site. These changes to the PSTAIRE helix and the T-loop 
realign active site residues and makes the active site accessible, which in turn, activates 
CDK2 (Jeffrey et al., 1995).  
1.5.2 The yeast cell cycle. 
Pioneering work has been carried out in the field of yeast molecular genetics which has 
heightened our understanding of the eukaryotic cell cycle. The yeast cell cycle is governed 
by a single CDK. This is Cdc28 in the budding yeast Saccharomyces cerevisiae and Cdc2 
in the fission yeast Schizosaccharomyces pombe (Morgan, 1997). Cdc28 was shown to 
have a key role in the cell cycle (Hartwell, 1974) where it initiated the first step in the cell 
cycle, termed START (Hereford and Hartwell, 1974). Cdc28 was necessary to activate two 
independent pathways, one leading to DNA replication and nuclear division and the other 
to bud emergence and cytokinesis (Hartwell et al., 1974; Hartwell, 1991). It was shown 
that the gene product of Cdc28 had a dual role in two phases of the cell cycle (Piggott et 
al., 1982) and that that Cdc28 was indeed a protein kinase (Reed et al., 1985).  Work on 
the distantly related yeast S. pombe identified the Cdc28 homologue, Cdc2, which was 
required for entry into the cell cycle and for controlling the onset of mitosis (Nurse and 
Bissett, 1981). Cdc2 was shown to have 62% identity to Cdc28, and Cdc2 encoded a 34 
kDa gene product (Hindley and Phear, 1984) which was determined to be a protein kinase 
(Simanis and Nurse, 1986). These protein kinases are involved in all stages of the cell 
cycle of their respective species of yeast.  
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The ability to control cell cycle progression is in part due to the association of protein 
kinases (CDKs) with cyclin proteins which activate the CDKs. Cyclins were discovered 
due to their oscillating levels in abundance during sea urchin cleavage divisions (Evans et 
al., 1983; Nasmyth, 1993). Numerous cyclin proteins have been identified since whose 
biochemical properties help promote the correct timing of CDK activity during the cell 
cycle (Loog and Morgan, 2005). In S. cerevisiae, two families of cyclins (Cln and Clb (B-
type)) control the cell cycle; based on sequence, function and timing of expression, they 
can be grouped into three categories: the G1 cyclins Cln1, Cln2 and Cln3, the S-phase 
cyclins Clb5 and Clb6, and the mitotic cyclins Clb1, Clb2, Clb3 and Clb4 (Jackson et al 
2006). The G1 cyclins, Cln1 Cln2 and Cln3 are essential for START. None of these Cln 
genes are essential for cell division; however, deletion of all three genes is lethal causing 
cells to arrest in G1 (Richardson et al., 1989). Clb5 and Clb6 trigger the transition from G1 
to S-phase (Basco et al., 1995; Epstein and Cross, 1992; Kuhne and Linder, 1993; Schwob 
and Nasmyth, 1993) and play redundant roles in the initiation of S-phase (Nasmyth, 1993). 
Either Clb5 or Clb6 can promote entry into S-phase on schedule (Basco et al., 1995; 
Epstein and Cross, 1992; Schwob and Nasmyth, 1993); however, Clb5 but not Clb6 is 
required for timely progression through S-phase (Epstein and Cross, 1992; Schwob and 
Nasmyth, 1993). Mitosis is then governed by Clb1, Clb2, Clb3 and Clb4 where these 
proteins are necessary for the formation and function of the mitotic apparatus (Fitch et al., 
1992; Richardson et al., 1992; Surana et al., 1991), and deletion of Clb2 alone greatly 
delays the onset of mitosis (Surana et al., 1991).  
In S. pombe, four cyclin proteins control the cell cycle, Cig1, Cig2, Cdc13 and Puc1. Cig1 
Cig2 and Cdc13 are B-type cyclins, whereas Puc1 is more closely related to S. cerevisiae 
Cln cyclins (Fisher and Nurse, 1996; Stern and Nurse, 1996). The B-type cyclins are 
essential for entry into S-phase and mitosis (Fisher and Nurse, 1996; Hayles et al., 1994; 
Martin-Castellanos et al., 1996; Mondesert et al., 1996) and also promote G1 progression 
past START (Martin-Castellanos et al., 1996; Obara-Ishihara and Okayama, 1994). Cig2 
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regulates entry into S-phase (Martin-Castellanos et al., 1996; Mondesert et al., 1996; 
Obara-Ishihara and Okayama, 1994) while Cig1 also contributes to the onset of S-phase 
(Fisher and Nurse, 1996; Mondesert et al., 1996). Cdc13 controls entry into mitosis 
(Booher et al., 1989; Moreno et al., 1989) and Puc1 has been shown to play an important 
regulatory role in the G1 phase of the cell cycle (Martin-Castellanos et al., 2000). As 
cyclins have an important regulatory role in the cell cycle, it is evident that they are tightly 
controlled. Two regulatory processes identified in cyclin control have been identified, gene 
transcription and protein degradation (Morgan, 1997).    
However, although only one CDK controls the cell cycle in yeast, it is important to realise 
that there are other CDKs involved in yeast cellular processes. For example, in S. 
cerevisiae, five CDKs function to regulate transcription; Kin28, Srb10, Ctk1, Sgv1 and 
Pho85. Three of these CDKs, Kin28 (Valay et al., 1993), Srb10 (Liao et al., 1995) and 
Ctk1 (Sterner et al., 1995; Lee and Greenleaf, 1991), regulate mRNA synthesis by 
phosphorylating the carboxyl-terminal domain (CTD) of RNA polymerase II. Sgv1 
regulates transcription, possibly also as a CTD kinase, as its mammalian orthologue 
CDK9, functions as a CTD kinase (Prelich and Winston, 1993). Lastly, Pho85 functions to 
inhibit gene transcription in response to phosphate levels (Lenburg and Oshea, 1996). 
However, Pho85 also has a secondary role in cell cycle progression, promoting the G1-S-
phase transition in the absence of the G1 cyclins, Cln1 and Cln2 (Espinoza et al., 1994; 
Measday et al., 1994).   
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Figure 1.3 – Schematic of the eukaryotic cell cycle. Quiescence: Cells which are not 
proliferating are said to be quiescent or in "G0" phase. G1 Phase: Cells grow in size in 
response to mitogenic signals, which may trigger a commitment to entering the next phase 
of the cell cycle. During G1 phase protein kinases become active and thereby send a signal 
that the cell division process has begun.  The Restriction Point: Late in G1, many cell 
types become committed to entering the next phase of the cell cycle at a time termed the 
restriction point or START. S-Phase: Soon after the restriction point a cell begins to 
replicate its genetic material. Cells synthesize an exact replica of their DNA genome 
replicating of all their chromosomes. G2 Phase: At the completion of S-phase, DNA 
replication ceases and cells enter the G2 phase of the cell cycle where they grow and 
prepare for the onset of mitosis. Mitosis: Mitosis is the phase of the cell cycle in which 
cells segregate their duplicated chromosomes into two separate nuclei and physically 
divide into two separate daughter cells. Cytokinesis is the process whereby the cytoplasm 
of a single cell is divided to spawn two daughter cells. It usually initiates during the late 
stages of mitosis to complete the cell cycle. The cell cycle schematic was taken from 
www.images.clinicaltools.com. 
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1.5.3 The mammalian cell cycle. 
The mammalian cell cycle, by comparison with yeast, is controlled by a number of CDKs. 
At present, 13 CDK proteins have been identified in the human and mouse genomes and 
around 29 cyclins have been identified in man (Malumbres and Barbacid, 2005). A 
summary of mammalian CDKs and their cyclin partners is shown in Table 1.1. 
Mammalian CDK function has been determined from biochemical studies with human 
tumor cell lines and by their ability to complement yeast CDK mutants. Additional 
research has been carried out using genetic manipulation of mouse models which is 
considered the gold standard method of establishing CDK function and essentiality.  
Homologues of Cdc2 were identified in human cells by their ability to complement yeast 
mutants (Draetta et al., 1987; Lee and Nurse, 1987). Human Cdc2 was named CDK1, the 
first mammalian CDK identified and is functionally homologous to Cdc2/Cdc28 in yeast 
(Morgan, 1997). CDK1 binds preferentially to A-type (A1 and A2) and B-type (B1, B2 
and B3) cyclins which are involved in the G2 and M phases of the cell cycle (Malumbres 
and Barbacid, 2005). At the end of S-phase, A-type cyclins associate with CDK1 and are 
involved in cell cycle progression into G2-phase. During G2, the A-type cyclins are 
degraded by ubiquitin-mediated proteolysis and the B-type cyclins are synthesised 
(Malumbres and Barbacid, 2005). As a result, CDK1 complexes with the B-type cyclins, 
preferentially binding to cyclins B1 and B2. The CDK1-cyclinB complexes are thought to 
regulate several events during both the G2-M transition and progression through mitosis 
itself (Nigg, 2001) where CDK1-cyclinB is also known as the M-phase promoting factor 
(MPF) (Morgan, 1997). Finally, the inactivation of CDK1-cyclinB complexes is required 
for the successful exit from mitosis occurring via ubiquitin-mediated degradation of the B-
type cyclins. Genetic manipulation has recently shown that CDK1 can execute all the 
events that are required to drive cell division in the absence of other CDKs (Santamaria et 
al., 2007). CDK1 can functionally compensate in the absence of interphase CDKs (CDK2, 
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CDK3, CDK4 and CDK6), by binding the G1 cyclins (D and E-type cyclins). This shows 
that CDK1 is the only essential CDK and is sufficient to drive the mammalian cell cycle.  
CDK2 was cloned by three independent approaches based on the complementation of S. 
cerevisiae Cdc28 mutants, differential display or interaction with Cyclin A (Elledge and 
Spottswood, 1991; Paris et al., 1991; Tsai et al., 1991; Ninomiya-Tsuji et al., 1991). Like 
CDK1, CDK2 is functionally homologous to Cdc2/Cdc28 in yeast but primarily  associates 
with the A-type (A1 and A2) and E-type (E1 and E2) cyclins (Morgan, 1997) and CDK2-
cyclinE is required for the G1-S-phase transition (Tsai et al., 1993). CDK2 interacts with 
the A and E-type cyclins at the beginning of S-phase to induce the initiation of DNA 
synthesis, and then binds cyclin A throughout S-phase for DNA synthesis (Morgan, 1997). 
Genetic approaches to study CDK2 have been carried out showing that CDK2 is not 
essential for the mammalian cell cycle, since CDK2 knockout mice are viable (Berthet et 
al., 2003).  
CDK3 is closely related to Cdc2 and CDK2 and can complement Cdc28 mutants in S. 
cerevisiae (Meyerson et al., 1992). CDK3 interacts with the A and E-type cyclins 
suggesting it may have a similar role to CDK2 during interphase of the cell cycle. It also 
complexes with cyclin C during the G0-G1 transition (Ren and Rollins, 2004). Little 
genetic analysis of CDK3 has been carried out in mice because most laboratory strains of 
mice are deficient in CDK3 due to a naturally occurring mutation (Ye et al., 2001). 
CDK4 was originally identified as PSK-J3, later renamed CDK4 (Hanks, 1987) and 
associates exclusively with the D-type cyclins (D1, D2 and D3) (Malumbres and Barbacid, 
2005). Along with CDK6, CDK4 is the principle contributor of cell cycle initiation and 
required for progression through G1 into S-phase (Matsushime et al., 1994). CDK4 
knockout mice have shown that loss of CDK4 is not detrimental to cell cycle progression 
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and that cell proliferation continues (Malumbres et al., 2004), although, S-phase entry is 
delayed (Tsutsui et al., 1999).  
CDK5 was originally identified as PSSALRE, later renamed CDK5 (Hellmich et al., 1992) 
and is primarily involved in neuronal function (Kesavapany et al., 2003). CDK5 is 
activated by non-cyclin partners p35 and p39, two proteins that are almost uniquely 
expressed in brain (Cruz and Tsai, 2004; Kesavapany et al., 2004). It has been shown that 
targeted disruption of the CDK5 locus in mice results in embryonic lethality (Ohshima et 
al., 1996) where the embryos show abnormalities in the development and structure of their 
nervous system. Furthermore, p35:p39 double mutant mice show similar phenotypes to 
mice lacking CDK5, further validating these proteins as essential CDK5 partners (Ko et 
al., 2001).    
CDK6 was originally identified as PLSTIRE and later renamed CDK6. CDK6, like CDK4 
associates with the D-type cyclins (D1, D2 and D3) (Meyerson and Harlow, 1994). CDK6-
cyclinD complexes are required for progression through G1-phase of the cell cycle by 
repressing the retinoblastoma (Rb) protein through phosphorylation (Meyerson and 
Harlow, 1994). As with CDK2 and CDK4, it has been shown that loss of CDK6 does not 
greatly affect cell proliferation (Malumbres et al., 2004). 
CDK7 was originally identified as p40-MO15 and later renamed CDK7 because it was 
found to associate with cyclin H  (Fisher and Morgan, 1994; Mäkelä et al., 1994). CDK7-
cyclinH associates with an assembly factor MAT1 (Tassan et al., 1995a) and has been 
shown to be a component of the RNA polymerase II transcription factor complex, TFIIH. 
CDK7-cyclinH-MAT1 is the CAK in mammals which phosphorylates and activates other 
CDKs involved in the cell cycle (Lolli and Johnson, 2005). Limited genetic analysis of 
CDK7 or Cyclin H has been carried out in mice; however, the disruption of MAT1 results 
in an inability to enter S-phase of the cell cycle (Rossi et al., 2001). 
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CDK8 was identified and shown to be a putative kinase binding partner for cyclin C 
(Tassan et al., 1995b). CDK8-cyclinC regulates transcription through phosphorylation of 
the C-terminal domain of the large subunit of RNA polymerase II and is a component of 
the RNA polymerase holoenzyme. CDK8-cyclinC complexes also phosphorylate cyclin H 
to inhibit CAK activity (Akoulitchev et al., 2000). It has recently been show that CDK8 is 
essential in mice during the pre-implantation phase of embryonic development (Westerling 
et al., 2007). 
CDK9, originally identified as PITALRE is a Cdc2-related protein kinase that was shown 
to phosphorylate the Rb protein (Grana et al., 1994b) and renamed CDK9. CDK9 
complexes with cyclins K and T to form P-TEFb transcription factors. CDK9-cyclinT 
complexes also regulate transcription in the same manner as CDK8-cyclinC complexes 
(Malumbres and Barbacid, 2005). 
CDK10, originally identified as PISSLRE is a Cdc2-related protein kinase and was 
renamed CDK10 (Grana et al., 1994a). No cyclin partner has been identified for CDK10 so 
far (Kasten and Giordano, 2001). CDK10 was shown to be involved in regulating the G2-
M-phase of the cell cycle (Li et al., 1995) and has also been shown to inhibit 
transactivation of the Ets2 transcription factor, a regulator of CDK1 expression (Kasten 
and Giordano, 2001).  
CDK11, originally identified as PITSLRE (Xiang et al., 1994), binds the L-type cyclins 
(L1 and L2) and interacts with RNA polymerase II, playing a role in transcript production 
and regulation of RNA processing (Loyer et al., 2005). As with CDK8, CDK11 has been 
shown to be required for pre-implantation in mice, with loss of CDK11 resulting in 
embryonic lethality (Li et al., 2004). 
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CDK12 was originally named CrkRS and is a Cdc2-related protein kinase. CrkRS was 
shown to associate with the L-type cyclins (L1 and L2) and was renamed CDK12 (Chen et 
al., 2006). CDK12-cyclinL complexes regulate alternative splicing. 
CDK13 was originally identified as CDC2L5 with strong sequence homology to CDK12. 
CDC2L5 was shown to interact with the L-type cyclins (L1 and L2) and was renamed 
CDK13 (Chen et al., 2007). CDK13 also regulates alternative splicing. 
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Alternative RNA   
splicing_L1, L2PITAIVRECDK13
Alternative RNA    
splicing_L1, L2PITAIVRECDK12
Transcription,            
Cell cycle (M)
CK2, RNA pol II,    
14-3-3, elF3
L1, L2 (D)SMSACRECDK11
Transcription,             
Cell cycle (G2-M)Ets2UnknownPISSLRECDK10
Transcription_T1, T2, KPITALRECDK9
Transcription_C (K?)SMSACRECDK8
Cdk-activating kinase, 
TranscriptionMAT1HNRTALRECDK7
Cell cycle (G1-S)_D1, D2, D3PLSTIRECDK6
Senesence,    
Postmitotic neurons_
p35, p39                         
(D-, E- and G-type 
cyclins)
PSSALRECDK5
Cell cycle (G1-S)MyoDD1, D2, D3PISTVRECDK4
Cell cycle (G0-G1-S)E2F/DPE1, E2, A1, A2, C          PSTAIRECDK3
Cell cycle (G1-S)_A1, A2, E1, E2                
(D1, D2, B1, B3)
PSTAIRECDK2
Cell cycle (G2-M)CksA1, A2, B1, B2                 
(B3, D1, D2, E)
PSTAIRECDK1
Cellular 
function
Other 
interacting 
proteins
Main activating 
cyclin (other 
cyclins)
PSTAIRE 
motif
CDK
 
Table 1.1 – Currently identified mammalian CDKs and their known cyclin binding 
partners. Included is the PSTAIRE motif involved in cyclin binding, known interacting 
proteins and a general description of the cellular function of these protein kinases. 
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1.5.4 The trypanosomatid cell cycle. 
Studies on the yeast and mammalian cell cycles have established the key CDKs and cyclins 
that are involved in cell cycle regulation. This work is relevant to the study of the parasite 
cell cycle as many of these cell cycle proteins are homologous to those in parasites such as 
CDK1 in humans and CRK3 in Leishmania (Grant et al., 1998). Due to their pivotal role in 
the cell cycle, these proteins offer an attractive area for drug discovery and development 
against trypanosomatids.  
The CDK family in trypanosomatids is relatively large with 11 in T. brucei and L. major 
and 10 in T. cruzi (Table 1.2, upper panel). Analysis of the genome of the three 
trypanosomatids identified 10 putative cyclins, CYC2-11 (Table 1.2, lower panel) (Naula 
et al., 2005). CYC1 from T. brucei, originally identified as a mitotic-like cyclin 
(Affranchino et al., 1993), was subsequently shown to lack the characteristics of a mitotic-
like cyclin (Hammarton et al., 2000). L. major has an additional cyclin, CYCA, named so 
because there is no homologue of this cyclin in T. brucei, where T. brucei cyclins have 
been named CYC2, CYC3 etc. 
1.5.4.1 The Leishmania cell cycle. 
Two Cdc2-related protein kinase genes, CRK1 and CRK3 have been cloned from L. 
mexicana (Mottram et al., 1993; Grant et al., 1998) and studied in detail. CRK1 encodes a 
34 kDa protein kinase with 56% amino acid identity to human Cdc2 (CDK1). CRK1 is 
present in all life cycle stages; however, it has stage regulated histone H1 kinase activity 
restricted to the insect stages of the parasite, both proliferative promastigotes and non-
dividing metacyclic promastigotes (Mottram et al., 1993). Gene disruptions showed CRK1 
is essential in promastigotes (Mottram et al., 1996) where attempts to create null mutants, 
replacing the alleles with hygromycin (hyg) and phleomycin (ble), were unsuccessful. 
Second round transfections with a ble-targeting fragment produced two forms of mutants, 
neither of which was null. First, the transfected fragment formed an episome; second, the 
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transfectants contained wild-type CRK1 alleles in addition to hyg and ble cassettes showing 
plasticity in chromosome number (Mottram et al., 1996). This is accepted as an indication 
of retaining an essential gene as it is not possible to obtain a null mutant (Barrett et al., 
1999; Cruz et al., 1993; Mottram et al., 1993; Mottram et al., 1996). T. brucei CRK1 
encodes a protein which shares 72% identity with L. mexicana CRK1 (Mottram and Smith, 
1995) and was shown to complement L. mexicana CRK1 function (Mottram et al., 1996). 
Although, the precise function of L. mexicana CRK1 is yet to be determined, T. brucei 
CRK1 function has been indicated by ribonucleic acid interference (RNAi) experiments 
indicating a redundant function for these proteins in the two parasites (Section 1.5.4.2).  
CRK3 is predicted to encode a 35.6 kDa protein with 54% identity to human Cdc2 and 
78% identity to T. brucei CRK3. It is a single copy gene whose product has protein kinase 
activity towards histone H1 (Grant et al., 1998). Sequence analysis showed the Leishmania 
CRK3 contains the domains and residues characteristic of a serine/threonine protein 
kinase. Furthermore, CRK3 contains residues and domains conserved in other organisms; 
Thr-14 and Tyr-15 which are required for ATP binding, and Thr-161 which is predicted to 
be phosphorylated by a CDK activating kinase (Grant et al., 1998). X-ray crystallography 
showed the PSTAIRE box in CDKs is the region, which binds the cyclin partner (Jeffrey et 
al., 1995). This is a highly conserved region and consists of 16 amino acids 
EGVPSTAIREISLLKE. The equivalent domain found in Leishmania CRK3 is 
EGIPQTALREVSILQE and has six substitutions by comparison (Grant et al., 1998) and is 
identical to that found in T. brucei CRK3 (Mottram and Smith, 1995). The presence of this 
domain in CRK3 suggests that specific cyclin binding plays an important role in CRK 
regulation (Grant et al., 1998).  
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Gene disruption was carried out to establish whether CRK3 was essential for the cell cycle 
progression of L. mexicana (Hassan et al., 2001). Attempts were carried out to replace both 
CRK3 alleles with hyg and ble resistance cassettes. Southern blot analysis indicated that 
mutants heterozygous for CRK3 had been successfully disrupted by hyg and ble constructs. 
Double resistant clones were found to contain hyg and ble resistance cassettes indicating 
the two alleles had been successfully replaced. However, the wild type CRK3 gene 
remained and as seen with CRK1, ploidy changes had occurred to retain the CRK3 gene 
(Hassan et al., 2001). This confirmed that CRK3 is essential for cell cycle progression in L. 
mexicana as a CRK3 null mutant could not be generated.  
L. major CRK3 was shown to complement a temperature sensitive S. pombe cdc2 null 
mutant (Wang et al., 1998). L. major CRK3 shares 99% identity with L. mexicana CRK3 
suggesting these two proteins are functional homologues of cdc2 and therefore mammalian 
CDK1. Indeed as discussed in 1.8.1.1, L. mexicana CRK3 inhibition causes a G2-M cell 
cycle block further indicating its role as a functional homologue of mammalian CDK1.  
1.5.4.2 The T. brucei cell cycle. 
There is a large family of putative CDKs and cyclins in T. brucei (Table 1.2) but few have 
been characterised in detail. Gene functions in T. brucei can be analysed by RNAi, which 
has been carried out on CRK1, 2, 3, 4 and 6 (Tu and Wang, 2004; Tu and Wang, 2005). 
Downregulation of CRK1 in both procyclic and bloodstream form trypanosomes resulted 
in a reduced growth rate and an accumulation of cells in the G1-phase of the cell cycle. 
This indicated a role in the G1-S transition in both forms of T. brucei (Tu and Wang, 2004; 
Tu and Wang, 2005). Simultaneous downregulation of CRK1 and either CRK2, 4 and 6 
enhanced the phenotype seen with CRK1 downregulation only, suggesting a 
supplementary role for these three CRKs.  
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Table 1.2 – Cdc2-related kinases, cyclins and accessory proteins predicted from the L. 
major and T. brucei genomes. Taken from Biochimica et Biophysica Acta (Naula et al., 
2005).
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Downregulation of CRK3 in both procyclic and bloodstream form trypanosomes resulted 
in a mitotic block and growth arrest. CRK3 was found to associate with two cyclins; CYC2 
and a mitotic cyclin homologue CYC6 (Van Hellemond et al., 2000; Hammarton et al., 
2003a; Li and Wang, 2003; Hammarton et al., 2004), and downregulation of these two 
cyclins correlated with CRK3 downregulation. CYC2 downregulation by RNAi caused an 
irreversible growth arrest in procyclic and bloodstream form trypanosomes (Hammarton et 
al., 2004; Li and Wang, 2003) and CRK3:CYC2 was shown to be the protein kinase 
complex required for progression through the G1-S phase transition in both forms of 
trypanosomes. CYC6 downregulation resulted in a mitotic block in both procyclic and 
bloodstream form trypanosomes. Therefore, the CRK3:CYC6 protein kinase complex has 
the properties of a G2-M phase kinase required for the transition into mitosis showing 
CRK3 is a functional homologue of mammalian CDK1.  
1.5.4.3 The T. cruzi cell cycle. 
As with L. mexicana, two CDKs, CRK1 and CRK3, have been studied in T. cruzi (Gomez 
et al., 1998; Gomez et al., 2001; Santori et al., 2002; da Cunha et al., 2005). CRK1 was 
active throughout G1 and S-phases of the cell cycle whereas CRK3 is a possible CDK1 
homologue as its activity peaked at the G2-M boundary (Santori et al., 2002). Both CRKs 
are cyclin-dependent kinases as they were able to interact with mammalian cyclins. 
However, interestingly, CRK1 was active as a recombinant protein, highlighting that cyclin 
binding may not be as vital for its activity(Gomez et al., 1998). CRK3 and to a lesser 
extent CRK1 was capable of phosphorylating histone H1 where the activity peaked at the 
G1-S and G2-M phase transitions. It is known that histone H1 phosphorylation varies 
during the life cycle of T. cruzi (da Cunha et al., 2005) but the relevance of histone H1 
phosphorylation by CRK3 has not been identified. 
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1.6 Protein kinases as drug targets. 
A number of diseases are attributed to defects in protein kinase-controlled cell signalling 
pathways. Protein kinases therefore represent an attractive area for therapeutics by way of 
inhibitor design. There are 518 protein kinases encoded in the human genome (termed the 
kinome), representing approximately 2% of all genes (Manning et al., 2002) which are 
grouped by class. Tyrosine kinases transfer a phosphate group from ATP onto a tyrosine 
residue of a protein. Two classes of tyrosine kinase are present in the human genome, non-
receptor tyrosine kinases such as SRC and receptor tyrosine kinases such as vascular 
endothelial growth factor receptor (VEGFR) and endothelial growth factor receptor 
(EGFR). An example of targeting a receptor tyrosine kinase is with the commercially 
available drug Gefitinib (Iressa®) (www.iressa.com) (Figure 1.5, lower left). It is a small 
molecule inhibitor that binds to the EGFR receptor kinase domain and is registered for the 
treatment of metastatic non-small cell lung cancer (NSCLC) (Barker et al., 2001). Other 
protein kinases such as GSK-3 are inhibited in healthy patients as part of the signalling 
pathway triggered by insulin when it binds to its receptor. However, in patients with adult 
onset or Type 2 Diabetes, GSK-3 is not inhibited due to a defective insulin receptor. 
Therefore, GSK-3 phosphorylates and inactivates glycogen synthase, thereby inhibiting 
glycogen synthesis, resulting in high blood glucose levels. As a result, GSK-3 is the focus 
of inhibitor design for diabetes (Engler et al., 2004) (www.cyclacel.com). CDKs, which 
are serine/threonine protein kinases will be discussed in greater detail as potential drug 
targets in section 1.6.1. 
1.6.1 CDKs as potential drug targets. 
The search for chemical inhibitors of CDKs was initiated due to their potential as anti-
tumour agents (Meijer, 1995). The involvement of CDKs in a number of cellular events 
and disorders has resulted in CDKs being the focus of research as potential drug targets in 
a number of other disease areas (Figure 1.4). 
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The effects of CDK inhibitors on the cell cycle and their potential value for the treatment 
of cancer have been extensively studied (Sielecki et al., 2000; Malumbres and Barbacid, 
2001). Many CDKs are over expressed in cancer, and it is known that inhibition of CDKs 
arrest cells in G1 (Soni et al., 2001) or G2-M (Damiens et al., 2001) and also triggers 
apoptosis (Edamatsu et al., 2000). To date, CDK1, 2, 4 and 6 have been the most explored 
targets; however, CDK7, 8 and 9 are also appealing targets.  
A number of neurodegenerative disorders such as Alzheimer’s disease (AD) and 
amyotrophic lateral sclerosis (ALS) are associated with abnormal regulation of CDK5, 
which is highly expressed in the nervous system (Fischer et al., 2003). A characteristic of 
AD is the aggregation of the microtubule protein tau, which is phosphorylated by a number 
of kinases including CDK5 (Tsai et al., 2004). ALS leads to the loss of motor neurones, 
resulting in paralysis and death (Bajaj, 2000) and CDK5 has been implicated in ALS 
pathogenesis (Nguyen et al., 2001). The increasing evidence that neuronal cell death is 
associated with increased CDK activity suggests that CDK5 inhibition may influence the 
outcome of some of these diseases (Knockaert et al., 2002; Fischer et al., 2003).   
In recent years, pharmacological inhibitors of CDKs have been reported to prevent viral 
replication in vitro (Schang, 2001). Viral replication is known to be frequently coordinated 
with the cell cycle and a number of viruses require CDKs for their replication and in some 
cases they express their own cyclins (Knockaert et al., 2002; Fischer et al., 2003). 
Therefore, targeting cellular kinases may be effective as a way of establishing anti-viral 
therapeutics. 
Glomerulonephritis is a disease of the renal system where inflammation of glomeruli and 
small blood vessels occurs in the kidney. IgA nephropathy, the leading cause of 
glomerulonephritis worldwide, is characterised by abnormal, but non-tumoral mesangial 
cell proliferation (D'amico, 1987; Donadio and Grande, 2002). Glomerular diseases 
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constitute potential targets for treatment with pharmacological inhibitors of CDKs, as 
illustrated in HIV-associated nephropathy (Nelson et al., 2001). 
CDKs may also be targeted when treating cardiovascular diseases. The proliferation of 
smooth muscle cells is a common feature of atherosclerosis and restenosis. Atherosclerosis 
is an inflammatory response in the walls of arteries, commonly referred to as “hardening” 
or “furring”, and is the leading cause of coronary heart disease (Lusis, 2000). Restenosis is 
a common consequence of balloon angioplasty, the main intervention for symptomatic 
atherosclerotic lesions (Dangas and Kuepper, 2002). These proliferative cardiac disorders 
are potential areas for therapeutic treatment with cell cycle inhibitors (Sriram and 
Patterson, 2001). 
The involvement of CDKs in reproductive biology has been evaluated for the in vitro 
production of animal embryos. The use of CDK inhibitors to arrest nuclear oocyte 
maturation (meiotic divisions), while allowing oocyte cytoplasmic maturation in vitro 
(final growth and developmental) is under investigation (Fischer et al., 2003). After the 
reversible inhibition of nuclear maturation by the CDK inhibitors and in vitro fertilisation, 
the embryos can be obtained with no loss of developmental ability (Ponderato et al., 2001). 
CDK inhibition in inflammatory diseases such as rheumatoid arthritis (RA) is being 
investigated as a possible treatment. A characteristic of RA is the overgrowth of synovial 
fibroblast cells, highlighting an increase in cell cycle activity. Treatment of animal models 
with collagen-induced arthritis with flavopiridol proved successful, where joint destruction 
due to RA was suppressed (Sekine et al., 2008). 
A promising area of investigating CDKs as drug targets is in unicellular parasites. As this 
is of particular relevance to this project, it will be focused on and discussed in section 1.8. 
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Figure 1.4 – Some of the potential applications of CDK inhibitors. As CDKs are 
involved in cell proliferation, apoptosis, neuronal function, and transcription, 
pharmacological inhibitors of CDKs are of serious interest in tackling diseases and 
disorders related to these cellular functions. Taken from TRENDS in pharmaceutical 
Sciences (Knockaert et al., 2002). 
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1.7 Protein kinase inhibitors. 
Protein kinase inhibitors fall into four main groups: substrate-specific inhibitors, ATP-
competitive inhibitors, activation inhibitors and irreversible inhibitors where the ideal 
protein kinase inhibitor prevents activation rather than competing with ATP or the 
substrate. The first protein kinase inhibitors were developed over 20 years ago (Cohen, 
2002), and formation of derivatives of these compounds have found widespread 
application, which has formed the basis for much of what is currently known about the 
physiological roles of their targets (Knight and Shokat, 2005). There is a vast number of 
protein kinase inhibitors currently in various stages of development which have been 
extensively reviewed, a number of which have been patented (Fischer and Gianella-
Borradori, 2005; Pevarello and Villa, 2005; Rosania and Chang, 2000). This highlights the 
interest and financial commitment in this area of drug development put in by academia, 
biotechnology and pharmaceutical industries to develop protein kinase inhibitors to treat a 
number of diseases.  
The discovery of staurosporine (Figure 1.7, right), an antifungal agent produced by 
bacteria of the genus Streptomyces, which was a nanomolar inhibitor of protein kinase C 
(PKC), resulted in the pharmaceutical industry taking interest in this area of 
pharmacological inhibitors (Cohen, 2002). As a result, a number of kinase inhibitors have 
been developed and approved for clinical use for a variety of disorders. Most notably is 
Imatinib (Gleevec®) (Figure 1.5, upper right), a tyrosine kinase inhibitor used to treat 
Chronic Myeloid Leukaemia (CML). It was the first important drug which targeted a 
protein kinase specifically, the Ableson tyrosine kinase (Abl) (Cohen et al., 2002a; Cohen 
et al., 2002b) (www.gleevec.com). However, it has been shown to be equipotent towards 
two other tyrosine kinase receptors, platelet derived growth factor receptor (PDGFR) and 
c-Kit (Knight and Shokat, 2005). A further example of a small molecule protein kinase 
inhibitor is HA1077 (Fasudil®) (Figure 1.5, lower right), which is not used in the 
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treatment of cancer. It was approved for the treatment of cerebral vasospasm after surgery 
for subarachnoid haemorrhage, and associated cerebral ischaemic symptoms. At 
micromolar concentrations, it inhibits several protein kinases, such as the RHO-dependent 
protein kinase ROCK (Cohen, 2002). These examples highlight that protein kinase 
inhibitors which target single or multiple protein kinases in the cell, can be fully developed 
to become commercially available drugs to treat a variety of diseases.       
1.7.1 CDK inhibitors. 
The majority of the known pharmacological CDK inhibitors are ATP-antagonistic 
inhibitors of multiple CDK functions (Fischer, 2004). The first reported CDK inhibitor was 
6-dimethylaminopurine (6-DMAP) (Figure 1.5, upper left), discovered as a puromycin 
analogue. It is a purine based compound which inhibited CDK1 with an IC50 value of 
120µM (Rosania and Chang, 2000). 2, 6, 9-trisubstituted purines are the CDK inhibitors 
most structurally similar to ATP, whose binding they antagonise (Fischer, 2003). 
Screening a series of purine inhibitors, lead to the discovery of olomoucine and roscovitine 
(Figure 1.6, left) which both inhibited CDK1 with IC50 values of 7µM and 460nM, 
respectively (Rosania and Chang, 2000). Olomoucine is also an inhibitor of CDK2:CycA, 
CDK2:CycE and CDK5, whose discovery has lead to the synthesis of many purines to 
identify more active and specific CDK inhibitors. One of these, roscovitine, is a close 
analogue of olomoucine and inhibits cyclin complexes of CDKs 1, 2, 5, 7 and 9 with low 
micromolar (µM) to high nanomolar (nM) IC50 values, but shows a lesser potency towards 
CDKs 4 and 6 (Fischer, 2003). CYC-202 (Seliciclib), a defined form of R-roscovitine, 
developed at Cyclacel Ltd, Dundee, inhibits cyclin complexes of CDKs  2, 7 and 9 with 
similar potency; CDKs 1 and 4 are also targeted but to a lesser extent (Fischer, 2004). 
CYC-202 induces apoptotic cancer cell death and is currently undergoing Phase IIb clinical 
trials for the treatment of NSCLC  (www.cyclacel.com).  
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The co-crystal structures of CDK2 with olomoucine and roscovitine contributed to the 
discovery of purvalanols (Figure 1.6, right), which exhibit a similar selectivity profile and 
are among the most potent CDK2 inhibitors reported (Fischer, 2003). Purvalanols were 
reported as some of the best CDK inhibitors at the turn of the century (Rosania and Chang, 
2000). Purvalanol B inhibits CDKs 1 and 2 with IC50 values <10nM but it has no effect on 
cell proliferation unlike purvalanol A, due to the lack of cellular uptake (Fischer, 2003).  In 
summary, it was seen that 2, 6, 9-trisubstituted purines were selective towards some 
cellular CDKs, essentially inhibiting CDK1, CDK2, CDK5, CDK7 and CDK9, but not 
CDK4 and CDK6 (Meijer and Raymond, 2003). They inhibit cellular proliferation leading 
to cell cycle arrest in G1 and G2 and can induce apoptosis in mitotic cells.  
There are a number of other classes of CDK inhibitors that have been the subject of 
interest. These include indirubins (Hoessel et al., 1999) (Figure 1.8, left), specifically 
indirubin-3-monoxime and indirubin-5-sulfonate which are selective towards CDK1 and 
CDK2 (Marko et al., 2001). These have been investigated further showing that the 
indirubin derivatives also target glycogen synthase kinase 3 (GSK-3) (Polychronopoulos et 
al., 2004). Another class of inhibitors, paullones (Figure 1.8, right), were found to be 
potent CDK inhibitors; kenpaullone is a selective inhibitor of CDKs 1, 2 and 5 with nM 
activity with the most potent in the series named alsterpaullone (Schultz et al., 1999). 
However, perhaps the greatest success with CDK inhibitors to date is alvocidib 
(Flavopiridol®) (Figure 1.7, left), the first CDK inhibitor to reach clinical trials 
(Senderowicz, 1999). Developed by the National Cancer Institute (NCI), Flavopiridol is a 
non-purine CDK inhibitor, most potent against CDKs 1 (IC50 for CDK1 = 400nM (Rosania 
and Chang, 2000)) , 4, 6 and 9 and can inhibit CDKs 2 and 7 as well as a number of other 
protein kinases (Fischer, 2004; Fischer and Gianella-Borradori, 2005). It can induce cell 
cycle arrest at both the G1-S and G2-M boundaries (Rosania and Chang, 2000) and tumor 
growth inhibition in a number of solid tumor cell lines (Shapiro, 2004). It has undergone 
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several phase II and phase III trials, but without living up to the initial expectations of a 
CDK inhibitor. It has, however, recently showed activity in patients suffering from 
refractory chronic lymphocytic leukaemia (Byrd et al., 2007). 
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             Olomoucine (R1 = H2, R2 = Me)          Purvalanol A (R1 = iPr, R2 = H) 
      Roscovitine (R1 = Et, R2 = iPr)            Purvalanol B (R1 = iPr, R2 = COOH) 
 
Figure 1.6 – The chemical structures of a variety of 2, 6, 9-trisubstituted purine                                         
CDK inhibitors. 
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                                    Flavopiridol®                                              Staurosporine 
Figure 1.7 – The chemical structures of Flavopiridol® and staurosporine protein 
kinase inhibitors. 
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                   Indirubins:                                                        Paulones: 
                   3’-Monoxime (R1 = NOH, R2 = H)                  Kenpaullone (R = Br) 
                   5’-Sulfonate (R1 = O, R2 = SO3H)                   Alsterpaullone (R = NO2)        
 
      Figure 1.8 – The chemical structures of indirubin and paullone protein kinase 
inhibitors. 
        
  
39 
 
1.8 The parasite kinome as a target for anti-parasite drug discovery. 
Protein kinases are attractive drug targets due to the success of drugs such as imatinib 
(Gleevec®) and other kinase inhibitors, as previously discussed. However, before these 
drugs were developed against cellular kinases, it was viewed in the pharmaceutical 
industry that protein kinases were not viable targets (Renslo and McKerrow, 2006). This 
was largely due to the belief that it would prove difficult to produce selective kinase 
inhibitors due to the vast number of kinases present in the genome (the kinome). 
Identifying kinase targets and screening compound libraries against kinases has now 
become a promising area of drug discovery research in a variety of scientific fields, 
including parasitology. Furthermore, the discovery and use of anti-parasitic kinase 
inhibitors may prove to be influential in establishing and dissecting signalling pathways 
within parasitic organisms (Naula et al., 2005).   
The recent availability of the T. brucei, T. cruzi and L. major (TriTryp) genome sequences 
has facilitated the search for novel drug targets and has established the number of protein 
kinases encoded by these parasites. The TriTryp kinomes are closely related and encode 
179, 156 and 167 distinct eukaryotic protein kinases (ePKs) in L. major (Ivens et al., 
2005), T. brucei (Berriman et al., 2005) and T. cruzi (El Sayed et al., 2005), respectively, 
as well as 17, 20 and 19 atypical protein kinases (aPKs), respectively (El Sayed et al., 
2005; Parsons et al., 2005). This is approximately 30% of the number present in the human 
host, double that of the malaria parasite, Plasmodium falciparum, and one third larger than 
in S. cerevisiae (El Sayed et al., 2005; Parsons et al., 2005; Ward et al., 2004). 
Trypanosomatid protein kinases represent approximately 2% of each genome suggesting a 
key role for phosphorylation in parasite biology. The knowledge from the genome projects 
and that there is complex regulation of cell division in unicellular parasites provides a wide 
variety of potential targets for novel anti-parasitic agents.  
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1.8.1 Trypanosomatid CDKs as drug targets 
Trypanosomatid CDKs belong to the CMGC (CDKs, MAP kinase, Glycogen synthase 
kinase and CDK-like) group of kinases which is highly represented (e.g., 45 in L. major as 
compared to 61 in humans) (Parsons et al., 2005). Despite 40-60% identity with human 
CDKs, protozoan protein kinases diverge significantly from the closest mammalian 
homologues (Doerig et al., 2002). This highlights a potential therapeutic window where 
structural differences between the parasite and host CDKs may result in different affinities 
for inhibitory compounds. Therefore, there is value in investigating analogues of 
compounds which are active against mammalian CDKs, as they may display different 
efficacy and/or selectivity towards the parasite CDK. An example of this was with 
mammalian CDK and Erk-selective purvalanol compounds, which targeted casein kinase 1 
in four different species of unicellular parasites (Knockaert et al., 2000). This highlights 
that parasite CDKs can be targeted by inhibitors, which is a potential avenue for drug 
development against trypanosomatids. 
1.8.1.1 Leishmania CDKs as drug targets. 
As discussed, most work on parasite CDKs to date has been carried out on CRK1 and 
CRK3, two cdc2-related protein kinases. As mentioned L. mexicana CRK1 is an essential 
gene in promastigotes; however, its role in amastigotes has yet to be defined. For this 
reason, it therefore remains to be determined whether CRK1 could be a useful drug target 
(Mottram et al., 1993). 
L. mexicana CRK3 was established as an essential gene and additional studies were carried 
out using known CDK inhibitors to attempt to significantly reduce CRK3 protein kinase 
activity. Flavopiridol was shown to be a potent inhibitor of L. mexicana CRK3his protein 
kinase activity in vitro and inhibited growth of promastigotes in a dose dependent manner, 
with higher concentrations resulting in cell death. At lower concentrations, Flavopiridol® 
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arrested L. mexicana at the G2-M-phase of the cell cycle (Hassan et al., 2001). This 
provided chemical validation of CRK3 as a target for rational drug design. 
Following CRK3his inhibition by Flavopiridol®, a number of chemical inhibitors were 
screened against CRK3his for antileishmanial activity (Grant et al., 2004). The chemical 
library screen identified additional inhibitors which had antileishmanial activity, which 
disrupted cell cycle progression and had an irreversible catastrophic effect on cell structure 
and morphology. These inhibitors caused growth arrest and inhibited macrophage infection 
in vitro, which provided further evidence that L. mexicana CRK3 was a valid drug target. 
The inhibitors with antileishmanial activity were grouped into four chemical classes. 
Group one were 2, 6, 9-trisubstituted purines, including the C-2-alkynylated purines, group 
two were indirubins, group three were paullones and group four were derivatives of 
staurosporine, a non-specific protein kinase inhibitor (Grant et al., 2004). Of the four 
groups, indirubins were found to be the most potent and were studied further with the 
cellular effects of the drugs observed. It was seen that they exerted a number of effects 
consistent with that of cell cycle disruption (Grant et al., 2004). This confirmed that CRK3 
could be targeted by chemical inhibition, providing evidence that drug development 
against CRK3 is an attractive avenue to pursue. 
1.9 Antitrypanosomatid drug discovery: 
1.9.1 Target assessment for antiparasitic drug discovery 
The Drug Discovery Unit at the University of Dundee has recently devised molecular-
target assessment criteria for assessing and prioritising parasitic drug targets, termed the 
“traffic-light” system (Figure 1.9) (Frearson et al., 2007). Each of the six criteria has an 
attributed scoring system in the colours of a traffic light. This enables the scoring of 
particular targets, highlighting any weaknesses with each, and allowing their prioritisation 
in terms of which are the most suitable for entering the drug discovery pipeline (Figure 
1.10). When considering Leishmania CRK3:CYC6 in terms of the traffic light system for 
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target assessment, it scores favourably. Target validation, druggability, assay feasibility, 
resistance potential and structural information are all green, with only toxicity in the amber 
section due to the presence of the human homologue of CRK3, CDK1. 
Criterion  
 
Red  
 
Amber  
 
Green  
 
Target 
validation 
No or weak evidence that 
the target is essential for 
growth or survival 
Either genetic or chemical 
evidence that target is 
essential for growth or 
survival 
Genetic and chemical 
evidence that target is 
essential for growth or 
survival 
Druggability 
No drug-like inhibitors are 
known and active site of 
target is not druggable 
Drug-like inhibitors are 
known or active site is 
druggable potentially 
Drug-like inhibitors are 
known and druggable active 
site (i.e. clinical precedent 
within the target family) 
Assay 
feasibility 
No in vitro assay developed 
and/or significant problems 
with reagents (cost or 
supply) 
In vitro assay exists, 
development into plate format 
feasible but not achieved 
Assay ready in plate format 
and protein supply assured 
within appropriate timelines 
Toxicity 
Human homologue present 
and little or no structural or 
chemical evidence that 
selective inhibition is 
possible 
Human homologue present 
but some structural or 
chemical evidence that 
selective inhibition is possible 
No human homologue 
present or human 
homologue known to be 
non-essential 
Resistance 
potential 
Target has multiple gene 
copies or isoforms within 
the same species and is 
subject to escape from 
inhibition 
Target has isoforms within 
the same species or might be 
subject to escape from 
inhibition 
Target has no known 
isoforms within the same 
species and is not subject to 
escape from inhibition 
Structural 
information 
No structure of target or 
closely related homologue 
Structure without ligand 
available and/or poor 
resolution (>2.3 Å) or 
opportunity to build a good 
homology model 
Ligand-bound structure of 
target (or ligand in closely 
related homologue) 
available at high resolution 
(<2.3 Å) 
 
Figure 1.9 – Traffic-light definitions for target assessment. Taken from TRENDS in 
Parasitology (Frearson et al., 2007). 
1.9.2 The drug discovery process and criteria. 
The discovery of novel therapeutics for neglected diseases is more difficult than other 
areas for some aspects. This includes factors such as cost of goods, compound/formulation 
stability and the requirement to dose children and pregnant women. Despite these areas, 
the progression from “hit to lead” to “drug candidate” (Figure 1.10) for antiparasitic drug 
discovery follows the same pattern as for other drugs.  
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Figure 1.10 – Schematic representation of the drug development pathway. Drug 
discovery initiates with molecular biology and biochemistry to identify and validate 
molecular drug targets. Compounds are assayed to establish activity against the target and 
those that are active are defined as hits, (see figure 1.11) which can be considered for 
testing in animal models. Pharmacokinetic studies are performed on the hits at this stage in 
the pipeline. Compounds active in animal models and considered “drug like” or “lead like” 
are defined as leads, (see figure 1.11) which require further optimisation via iterative 
chemistry. Compounds which can be considered for human testing are then considered 
drug candidates (see figure 1.11). From here, a compound then undergoes preclinical and 
clinical studies before becoming a commercially available drug. Taken from Nature 
Reviews Drug Discovery (Pink et al., 2005). 
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Hit 
At the start of a screening campaign, compound that is: 
• Active in vitro against whole protozoa with IC50 of 1 g per ml (for protozoa), or 
inhibiting mobility of helminths in vitro to, for example, 75% at 10 g per ml. 
• Selective (at least tenfold more active against parasite than against a mammalian cell line, 
such as MRC-5). 
 
Lead 
At the start of a screening campaign, compound that is: 
• Active in vivo against parasites at a dose 100 mg per kg.  
• Not overtly toxic in animals at efficacious dose.  
• Active in vitro against relevant parasite types (for example, drug-resistant parasites).  
• Chemically tractable (analogues can be obtained). 
 
During the campaign, criteria are made more stringent. A candidate for lead optimization should 
be: 
• Active in vitro with activity approaching that of standard drugs.  
• Active in vivo against parasites in the relevant small animal model (for example, chronic or 
late-stage disease), when delivered by a relevant route (preferably oral) in an acceptable 
formulation at a reasonable dose (<< 100 mg per kg).  
• Show good selectivity when tested against several mammalian cell lines. 
 
Drug development candidate 
Compound that has emerged from a lead optimization process and looks likely to fulfill at least the 
essential criteria in the desired product profile. It should: 
• Be active in vivo with activity comparable to or exceeding that of standard drugs in the 
most relevant animal models. 
• Be effective against desired range of parasites (for example, drug-resistant parasites and 
different species).  
• Pass early toxicity/mutagenicity criteria.  
• Have an acceptable metabolic profile in vitro and in vivo (preferably with no major 
species differences).  
• Have an acceptable pharmacokinetic profile.  
• Be amenable to cost-effective scale-up.  
• Preferably have a mode of action that is well understood. 
 
Clinical development candidate 
Drug development candidate for which additional criteria have been met in studies of detailed 
pharmacology, pharmacokinetics/absorption, distribution, metabolism and excretion, mutagenicity 
and toxicity, formulation, scale-up for production, cost of goods and so on. 
 
 
 
 
Figure 1.11 – The criteria for antiparasitic hits, leads and drug candidates. Taken 
from Nature Reviews Drug Discovery (Pink et al., 2005). 
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1.9.3 The requirement for new antileishmanial therapeutics.  
There is an urgent need to develop new therapeutic agents against eukaryotic parasites 
such as Leishmania and Trypanosoma. Although many of the current drugs are dated, 
chemotherapy remains the main method for disease control. However, these current 
therapies are unsatisfactory for a variety of reasons such as acute toxicity, poor efficacy, 
undesirable route of administration, cost of administration and the emergence of drug 
resistance. There have, however, been recent advances in areas of research to identify and 
develop possible antileishmanial therapeutic agents. One such area is that of cyclin 
dependent kinases (CDKs) in the Trypanosomatid cell cycle. As many protein kinases are 
essential to the cell cycle and because of the recent successes of imatinib (Gleevec) and 
other kinase inhibitors, this provides a promising and attractive area of study for drug 
discovery and development (Renslo and McKerrow, 2006). 
1.10 Project aims. 
The aim of this study was to identify specific Leishmania CRK3 inhibitors in order to 
contribute to combating leishmaniasis. A variety of approaches were used to identify and 
develop novel families of CDK inhibitors against CRK3 from Leishmania and possibly 
African Trypanosomes because of CRK3 shared identity. The project looked to shorten the 
drug discovery process by working in collaboration with Cyclacel Limited in Dundee and 
adopting a piggy-back approach to drug discovery, exploiting their expertise, technology 
and compound libraries for the identification and design of CDK inhibitors. Nowadays, 
some companies see value in supporting tropical disease drug discovery as a way to boost 
their lead discovery efforts (Nwaka and Hudson, 2006). 
The main goal of the drug discovery project was to identify lead compounds against 
parasite CRK3 that can be developed for clinical trials. These would be small molecules, 
which significantly reduce and/or abolish the activity of parasite CRK3 in vivo. The 
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running hypothesis was that unique aspects of CRK3 biochemistry can be exploited for the 
design of specific small molecule inhibitors.  
In order to achieve this objective, active recombinant L. mexicana CRK3 was produced via 
bacterial protein expression, for use in low and high throughput assay development and 
screening. An assay system using IMAPTM fluorescent polarization technology was 
developed, suitable for high throughput screening, which involved screening a chemical 
compound library at Cyclacel consisting of approximately 25,000 compounds. Once lead 
hits were identified and analysed, these were tested against Leishmania in vitro to establish 
their biological activity with the view to carrying out in vivo studies and initiating 
pharmacokinetic studies on the lead compounds.  
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Chapter 2 
Materials and methods 
2.1 Buffers and reagents. 
Adenosine triphosphate (ATP): Stock solution is 100mM in distilled water. Stored at      
-20ºC. Used at the concentration relevant for the described assays. 
Ammonium persulfate: 10% working solution prepared in distilled water. Stored at          
-20ºC. 
Ampicillin: Stock solution is 50mg ml-1 in distilled water. Used at 50µg ml-1. Stored at      
-20ºC. 
Anion exchange column elution buffer: 50mM Tris, 5mM EDTA pH 7.0 and 1M NaCl. 
Assay development buffer (ADB): 20mM MOPS, pH 7.0, 25mM β-glycerophosphate, 
5mM EGTA, 1mM NaVO3, 1mM DTT and 15mM MgCl2. Freshly prepared. 
Blocking solution 1: 5% (w/v) milk powder in PBS-Tween. Freshly prepared. 
Blocking solution 2: 3% (w/v) milk powder in PBS-Tween. Freshly prepared. 
Chloramphenicol: Stock solution is 34mg ml-1 in ethanol. Used at 34µg ml-1. Stored at     
-20ºC.  
Complete reaction buffer (CRB): 10mM Tris-HCl, pH 7.2, 10mM MgCl2, 0.05% NaN3, 
0.01 % Tween-20 and 1mM DTT. Made up fresh. 
Coomassie blue R250: 45% ethanol, 45% distilled water, 10% glacial acetic acid, 0.25% 
Coomassie blue R250. 
Coomassie blue R250 destain: 45% ethanol, 45% distilled water, 10% glacial acetic acid. 
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Dithiothreitol (DTT): Stock solution is 1M in distilled water. Used at 1mM. Stored at        
-20ºC.  
DNA loading buffer (6x): 15% Ficoll, 0.25% bromophenol blue, 0.25% xylene cyanol 
FF. Stored at 4ºC. 
DNAse-1: Stock solution is 10mg ml-1. Used at 10µg ml-1. Stored at -20ºC. 
Electroporation buffer (EPB): 21mM HEPES pH 7.5, 137mM NaCl, 5mM KCl, 0.7mM 
Na2PO4 and 5mM glucose. Stored at -20ºC. 
Enzyme dilution buffer (EDB): 20mM Tris-HCl pH, 0.5mg ml-1 BSA, 2.5% glycerol and 
0.006% Brij-35. 
Ethidium bromide: Stock solution is 10mg ml-1 in distilled water. Stored at room 
temperature. Used at 0.2mg ml-1. 
Gel filtration buffer/enzyme storage buffer: 20mM HEPES pH 7.4, 50mM NaCl, 2mM 
EGTA, 2mM DTT and 0.02% Brij-35. 
Giemsa’s stain: 100% Giemsa’s R66 solution. Prepared to a 10% working concentration 
in distilled water.  
Histone H1: Stock solution is 2mg ml-1 in distilled water. Used at 0.4mg ml-1. Stored at      
-20ºC. 
IMAPTM progressive binding reagent: Proprietary buffer from Molecular Devices plus 
tri-valent metal containing nanoparticles. Freshly prepared. 
Isopropyl-β-D-Thiogalactopyranoside (IPTG): Stock solution is 1M in distilled water. 
Used at relevant concentrations for the proteins described. Stored at -20ºC. 
Kanamycin: Stock solution is 30mg ml-1 in distilled water. Used at 30µg ml-1. Stored at     
-20ºC. 
Kinase assay buffer (KAB): 50mM MOPS pH 7.2, 20mM MgCl2, 10mM EGTA and 
2mM DTT. 
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Leishmania lysis buffer: 50mM  MOPS pH 7.2, 100mM NaCl, 10% (v/v) glycerol and 
1% (v/v) Triton X-100. 
Luria-Bertani (LB) agar: LB-media plus 0.8% (w/v) agar. Autoclaved to sterilise and 
stored at room temperature. 
Luria-Bertani (LB) media: 1% (w/v) bacto tryptone, 0.5% (w/v) yeast extract and 0.5% 
(w/v) NaCl. Prepared in distilled water and autoclaved for sterilisation. Stored at room 
temperature. 
Lysozyme: Stock solution is 100mg ml-1. Used at 100µg ml-1. Stored at -20ºC. 
Neomycin (G418): Stock solution is 10mg ml-1. Used at 10µg ml-1. Stored at -20ºC. 
Ni2+ column loading/wash buffer: 50mM Na2H2PO4, 300mM NaCl pH 8.0 and 20-50mM 
imidazole. 
Ni2+ column elution buffer: 50mM Na2H2PO4, 300mM NaCl pH 8.0 and 500mM 
imidazole. 
NuPage transfer buffer (20x): 500mM bicine, 500mM Bis-Tris, 20.5mM EDTA and 
1mM chlorobutanol. Stored at 4ºC.  
PBS-Tween (PBST): PBS buffer plus 0.1% Tween-20. 
PCR mix (10x): 450mM Tris-HCl, pH 8.8, 110mM ammonium sulphate, 45mM MgCl2, 
67mM β-mercaptoethanol, 44mM EDTA, pH 8.0, 1.13mg ml-1 BSA, 10mM dATP, 10mM 
dCTP, 10mM dGTP and 10mM dTTP. Stored at -20ºC. 
Phosphate buffered saline (PBS): 10mM phosphate buffer, 2.7mM KCl, 137mM NaCl, 
pH 7.4. Stored at room temperature.  
Protease inhibitor cocktail (1x): 100µg ml-1 leupeptin, 500µg ml-1 pefabloc, 5µg ml-1 
pepstatin, 1mM phenanthroline, 1mM EDTA and 1mM EGTA. 
Puromycin: Stock solution is 10mg ml-1 in distilled water. Stored at -20ºC. Used at 50µg 
ml-1. 
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RF-1: 100mM RbCl, 50mM MnCl2, 30mM potassium acetate, 10mM CaCl2 and 15% 
glycerol, pH 5.8. 
RF-2: 10mM MOPS, 10mM RbCl, 75mM CaCl2 and 15% glycerol, pH 6.8. 
Roche EDTA-free, complete protease inhibitors: Proprietary mixture of protease 
inhibitors inhibiting a broad range of serine and cysteine proteases. 
SDS: 10% solution prepared in distilled water and stored at room temperature. 
SDS-PAGE running buffer (10x): 25mM Tris, 192mM glycine and 0.1% SDS. 
SDS-PAGE sample buffer (4x): 564mM Tris, 2.04mM EDTA, 0.88mM Serva Blue 
G250, 0.7mM Phenol red, 40% glycerol and 8% LDS, pH 8.5. 
SYBR safe: 10,000 x stock solution in DMSO. Used at 0.2 x and stored at room 
temperature. 
TEMED: Stock solution stored at 4ºC. 
Tris: Working solutions prepared in distilled water and stored at room temperature.  
Tris-Borate-EDTA (TBE) (10x): 0.9M Tris-HCl, 0.9M boric acid, 25mM EDTA. Stored 
at room temperature. 
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2.2 Molecular biology methods: 
2.2.1 Bacterial strains. 
The bacterial strains used throughout this project are described in table 2.1. 
Novagen
Protein expression providing 
rare codon translation and 
increasing protein folding
∆ara-leu7697 ∆lacX74 ∆phoA PvuII phoR
araD139 ahpC galE galK rpsL(DE3)                       
F ' [lac+ laclq pro] gor522::Tn 10 trxB
pLysS (CamR. KanR, StrR, TetR)   
Rosetta-Gami (DE3) pLys-
S
Novagen
Protein expression providing 
rare codon translation
F - ompT hsdSB(r B
-m B
-) gal dcm(DE3) 
pLysSRARE26 (CamR)
Rosetta (DE3) pLys-S
Novagen
Protein expression increasing 
protein folding 
∆ara-leu7697 ∆lacX74 ∆phoA PvuII phoR
araD139 ahpC galE galK rpsL
F ' [lac+ laclq pro] (DE3) gor522::Tn 10 
trxB pLysS (CamR. KanR, StrR, TetR) 
Origami (DE3) pLys-S
InvitrogenHigh level protein expression
F - ompT hsdSB(r B
-m B
-) gal dcm(DE3) 
∆(srl-recA)306::Tn 10 pLysS (CamR, TetR)BL21 (DE3) pLys-S
Invitrogen
Cloning of recombinant 
plasmids
F- φ80dlacZM15 (lacZYA-argF)U169 deoR
recA1 endA1 hsdR17(r k
-, m k
+) phoA
supE44 thi-1 gyrA96 relA1 λ-
DH5 Alpha
Stratagene
Cloning of recombinant 
plasmids
recA1 endA1 gyrA96 thi-1 hsdR17 supE44 
relA1 lac [F´ proAB lacIqZ∆M15 Tn10 
(TetR)]
XL1-Blue
Manufactur
er
ApplicationGenotypeBacterial strain
 
Table 2.1 – Bacterial strains used for plasmid cloning and protein expression.  
2.2.2 Bacterial culture. 
LB-agar was melted and cooled before the addition of relevant antibiotics, and poured into 
Petri dishes to set. Transformed bacterial cells were plated on LB-agar plates with a glass 
spreader sterilised in ethanol, and incubated at 37ºC overnight. Using a sterile cocktail 
stick, a single colony was used to inoculate 5-10ml of LB-medium with the appropriate 
antibiotics. Bacterial cultures were grown at 37ºC in an incubator with agitation for the 
appropriate time depending on the bacterial strain being prepared. 
2.2.3 Bacterial stabilate preparation (Glycerol stocks). 
Transformed bacterial cells were plated on LB-agar plates complete with the relevant 
antibiotics and incubated at 37ºC overnight. A single colony was used to inoculate 5-10ml 
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of LB-media complete with the relevant antibiotics and the bacterial culture grown at 37ºC 
overnight. 0.5ml of the bacterial culture was added to 0.5ml of 2% peptone/40% glycerol 
and the cells store at -80ºC.  
2.2.4 Preparation of competent cells: 
2.2.4.1 Rubidium chloride method. 
A single colony was used to inoculate 5ml of LB-media complete with relevant antibiotics 
and the culture grown at 37ºC overnight. The culture was diluted 1:100 in 50ml of fresh 
LB-media and grown until an optical density of 0.6 was reached at a wavelength of 600nm 
(O.D.600nm). The culture was incubated on ice for 10 minutes and harvested at 2000 x g for 
15 minutes at 4ºC. The cell pellet was resuspended in 16ml of pre-chilled RF-1 buffer, 
mixed by slow vortexing and incubated on ice for 15 minutes. The suspension was 
harvested at 2000 x g for 15 minutes at 4ºC and the cell pellet resuspended in 4ml of pre-
chilled RF-2 buffer. The suspension was incubated on ice for 1 hour, aliquoted in 200µl 
volumes and snap-frozen in ethanol pre-chilled at -20ºC. Competent cells were stored at -
80ºC. 
2.2.4.2 Calcium chloride method. 
A single colony was used to inoculate 5ml of LB-media complete with relevant antibiotics 
and the culture grown at 37ºC overnight. The culture was diluted 1:100 in 25ml of fresh 
LB-media and grown until an optical density of 0.4 was reached at a wavelength of 595nm 
(O.D.595nm). The culture was harvested at 2000 x g for 10 minutes at 4ºC. The cell pellet 
was resuspended in 12.5ml of pre-chilled, sterile 50mM CaCl2 buffer by slow pipetting and 
incubated on ice for 30 minutes. The suspension was harvested at 2000 x g for 10 minutes 
at 4ºC and the cell pellet resuspended in 2.5ml of pre-chilled, sterile 50mM CaCl2 buffer. 
The suspension was aliquoted in 200µl volumes and snap-frozen in dry ice. Glycerol was 
added to a final concentration of 10% and competent cells stored at -80ºC.  
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2.2.5 DNA vectors and plasmid constructs. 
The DNA vectors used throughout this project and plasmids constructed are described in 
tables 2.2 and 2.3, respectively. 
University of 
Glasgow
Ribosomal integration expression 
construct 
No tagpRIB
University of 
Glasgow
Episomal protein expression constructNo tagpXG
GE Healthcare
GST-tagged protein expression 
construct
GST-tagpGEX
Novagen
His-tagged protein expression 
construct
C-terminal His-tagpET-28a
Novagen
His-tagged protein expression 
construct
N-terminal His-tagpET-21a
Novagen
His-tagged protein expression 
construct
N-terminal His-tagpET-15b
Promega
His-tagged protein expression 
construct
His-tagpET5a
PromegaGene cloning vectorNo tagpGEM-T Easy
StratageneGene cloning vectorNo tagPCR-Script
ManufacturerDescriptionProtein tagVector
 
Table 2.2 – DNA vectors used for gene cloning and protein expression. 
Ribosomal integration of N-terminally            
HA-tagged CYC6
L. major CYC6No tagpRIBpGL1484
Ribosomal integration of C-terminally            
HA-tagged CYC6
L. major CYC6No tagpRIBpGL1483
Episomal expression of N-terminally            
HA-tagged CYC6
L. major CYC6No tagpXGpGL1391
Episomal expression of C-terminally            
HA-tagged CYC6
L. major CYC6No tagpXGpGL1390
His-tagged L. major CYC6L. major CYC6N-terminal His-tagpET15bpGL1218
L. major CYC6 geneL. major CYC6No tagPCR ScriptpGL1169
His-tagged L. mexicana CRK3L. mexicana CRK3C-terminal His-tagpET28apGL751a
GST-tagged CIV1                                   
(Yeast CDK activating kinase)
Yeast CIV1GST-tagpGEXpGL716
L. mexicana CRK3 T-loop mutantL.mexicana CRK3T178EHis-TagpET5apGL665
DescriptionGene of interestProtein tagBackbonePlasmid
   
Table 2.3 – Plasmid constructs generated and used throughout the project. 
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2.2.6 Polymerase chain reaction (PCR). 
Polymerase chain reactions were used to amplify DNA fragments for subsequent cloning 
or colony PCR to analyse DNA ligations. Reactions were carried out in a final volume of 
20µl comprising 2µl of 10x PCR mix, 10pmol of each oligonucleotide primer (sense and 
antisense), 1µl of template DNA, 0.5µl of Taq/Deep Vent DNA polymerase (New England 
BioLabs, NEB) and milli-Q H2O added to 20µl. For colony PCR, a single colony was 
picked with a sterile cocktail stick and added directly to the 20µl reaction mixture. This 
supplied the template DNA for the reaction. Typically, reactions were carried out as 
follows: 
DNA denaturing    -       95ºC for 5 minutes    
DNA denaturing    -       92ºC for 30 seconds 
Primer annealing   -       55ºC for 2 minutes             25 cycles 
Initial DNA extension - 72ºC for 90 seconds 
Final DNA extension  -  72ºC for 10 minutes 
DNA storage  -                4ºC overnight  
2.2.7 Plasmid preparation and purification. 
Molecular biology kits from Qiagen were used to prepare and purify genomic DNA 
(gDNA) (DNeasy) from Leishmania, DNA fragments and plasmids for subsequent 
sequencing and cloning. Plasmids were sequenced using The Sequencing Service at the 
University of Dundee, where 200-300ng of double stranded plasmid was provided per 
sequencing reaction required.  QIAquick PCR purification kits (QIAGEN) were used to 
purify DNA fragments obtained from PCR. QIAprep spin miniprep kits (QIAGEN) were 
used to obtain high purity plasmid DNA (up to 20µg) with both kits used according to the 
manufacturer’s protocol.  
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2.2.8 Restriction enzyme digests. 
Restriction enzymes (NEB) were used according to the manufacturer’s recommendations 
with the buffers supplied. Plasmid digestions were normally carried out in a final volume 
of 30µl, digesting plasmid DNA with appropriate enzymes and buffers for 2-3 hours at 
37ºC. Digest volumes were scaled where appropriate depending on the individual digest. 
Digests were stopped by the addition of DNA loading buffer to a 1 x final concentration 
from a 6 x concentrated stock and analysed by DNA gel electrophoresis.  
2.2.9 DNA gel electrophoresis. 
DNA agarose gels were prepared by adding 0.5 x TBE buffer to powdered agarose and 
melted. Gels contained 0.8-1.2% agarose (w/v) according to the size of the DNA fragment 
to be separated. Ethidium bromide (0.2mg ml-1) or SYBR Safe (1 in 5000 dilution) 
(Invitrogen) was added to the molten gel prior to the gel setting. DNA samples were mixed 
with 6 x DNA loading buffer to a final concentration of 1 x loading buffer and 
electrophoresed at 80-120 volts, until the dye front was three quarters of the length of the 
gel. Gels were viewed under ultra violet illumination in a Bio-Rad gel documentation 
system and photographed for analysis. 
2.2.10 DNA purification from agarose gels. 
DNA agarose gels were prepared as described in 2.1.8 and the DNA fragments 
electrophoresed. The gels were viewed under low intensity ultraviolet light to minimise 
mutagenesis of the DNA band of interest. The band of interest was excised from the gel 
with a scalpel blade. The DNA band was processed with a QIAquick gel extraction kit 
(QIAGEN) to purify the DNA fragment and was performed in accordance with the 
manufacturer’s protocol.  
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2.2.11 DNA ligations. 
Ligation of DNA fragments into pET expression vectors (Novagen) was carried out in a 
final volume of 10µl comprising the DNA insert, plasmid vector, 200units of T4 DNA 
ligase, 1x T4 DNA ligase buffer and milli-Q H2O added to 10µl. The ligation mixture was 
incubated at room temperature for at least 1 hour and then for 10 minutes at 65ºC before 
being stored on ice until required for bacterial transformations.  
2.2.12 Bacterial transformations. 
Competent cells were transformed by heat shock. The DNA ligation mixture was added to 
50µl of competent cells (see section 2.1.4) and mixed gently with a pipette tip. The 
transformation was incubated on ice for 15 minutes. The transformation was heat shocked 
by incubating at 42ºC for 45 seconds and placed back on ice for 2 minutes to incorporate 
the plasmid of interest into the competent cells. Cells were then plated onto LB-agar plates 
and incubated overnight at 37ºC. Correct clones were identified by colony PCR (section 
2.2.6). 
2.3 Mouse methods: 
2.3.1 Macrophage (mΦ) extraction and purification. 
Sufficient fresh RPMI 1640 media (PAA cat no. E15-842) supplemented with 10% (v/v) 
heat inactivated foetal calf serum (HIFCS) and 1% (v/v) Gentamicin antibiotic was 
prepared for the number of mice to be processed. Institute for Cancer Research (ICR) mice 
were killed by inhalation of CO2 gas prior to their necks being broken by forceps. Mice 
were sprayed with 70% EtOH and laid on their back with legs splayed. Mouse skin was cut 
at the belly, between the top of the hips, by pulling the skin taught with forceps and 
removed by pulling off the skin from the abdomen. The inside of the mouse was sprayed 
with 70% EtOH to sterilise. Using forceps, the membrane at the sternum was pulled taught 
and a 21G needle inserted with the bevel facing upwards, just underneath the membrane. 
The cavity was filled with 10ml RPMI supplemented with 10% HIFCS and 1% 
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Gentamicin. The base of the tail and shoulders were held and the mouse shaken for 30 
seconds to release the macrophages. A 26G needle with an empty 10ml syringe was 
inserted into the mouse’s side with the bevel facing into the body. The skin was pulled 
taught against the needle and the fluid removed. Macrophages were harvested at 1000 x g 
for 10 minutes at 4°C and the supernatant retained. The cells were resuspended in fresh 
RPMI supplemented with 10% HIFCS and the cell density counted as described in 2.3.2. 
Macrophages were diluted to a cell density of 5 x 105 cells ml-1 in RPMI supplemented 
with 10% HIFCS. 100µl of macrophages were added to each well of a 16-well Lab-tek 
cavity slide (50,000 mφ/well) and incubated at 37°C, 5% CO2 for subsequent experiments. 
2.4 Leishmania major methods: 
2.4.1 Leishmania cell lines. 
The cell line used in this project was L. major wild type promastigotes (Friedlin strain: 
WHO designation MHOM/JL/81/Friedlin). All transgenic cell lines developed, originated 
from this parent cell line. 
2.4.2 Tissue culture. 
L. major promastigote cells were grown at 25ºC in HOMEM medium (Invitrogen cat no. 
041-94699111) supplemented with 10% (v/v) HIFCS and 1% (v/v) penicillin/streptomycin 
antibiotics. Cells were inoculated into fresh medium at approximately 1 x 106 cells ml-1 
and were passaged into fresh medium when cultures reached a late log or early stationary 
phase (approximately 1-2 x 107 cells ml-1). 
Transgenic L. major cell lines were maintained with Puromycin antibiotic (Calbiochem) 
used at a concentration of 50µg ml-1 and Neomycin (G418) antibiotic (Calbiochem) used at 
a concentration of 10µg ml-1. 
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L. major promastigote cells were diluted and fixed by adding 50µl of cells to 50µl of 2% 
(v/v) formaldehyde in PBS. The cell mixture was loaded onto a haemocytometer and 
counted under microscopy to determine the cell density. 
Cells were harvested by centrifugation at 1000 x g for 10 minutes 4°C. The cell pellets 
were resuspended gently in 10ml of ice-cold, PBS sterilised through a 0.2µm filter, to wash 
the cells and harvested as before. Cell pellets were used immediately for all subsequent 
experiments.  
2.4.3 DNA transfections: 
2.4.3.1 DNA precipitation and sterilization.  
Purified DNA for each construct had sodium acetate (NaAc) added to a final concentration 
of 0.3M. Two volumes worth of 100% ethanol (EtOH) were added and the preparations 
kept at -20°C for 30 minutes. Samples were centrifuged at 12000 x g for 30 minutes and 
the supernatant removed under sterile conditions. The pellet was washed twice in 70% 
EtOH and the excess supernatant removed. The pellet was allowed to dry under sterile 
conditions before resuspension in 20µl of sterile H2O, ready for transfection.  
2.4.3.2 Bio-Rad electroporator transfection. 
Mid-log stage L. major cells at a density of 5 x 107 cells ml-1 were harvested at 1000 x g 
for 10 minutes. Cells were washed in half the original cell volume with electroporation 
buffer (EPB) before being resuspended at 1 x 108 cells ml-1 in ice-cold EPB and kept on 
ice. 10 to 50µg of DNA was added to a 2mm gap ice cold cuvette with 400µl of cells and 
mixed. Cells were electroporated once in a Bio-Rad Gene Pulser II with Capacitance 
Extender II at 0.45kV and capacitance 500µF with the resulting time constant of 4.8ms 
(range from 4.6 to 5.1ms). The transfected cells were allowed to recover on ice for 10 
minutes before being transferred to 10ml of fresh HOMEM medium with 20% (v/v) 
HIFCS and incubated at 25ºC overnight. The following day, Neomycin (G418) antibiotic 
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was added to a final concentration of 10µg ml-1 (v/v) to select for transfected clones and 
cultures incubated at 25ºC. 
2.4.3.3 Amaxa nucleofector transfection. 
Transfections were carried out using a human T-cell Amaxa nucleofector kit (Amaxa 
Biosystems) according to the manufacturer’s protocol. 5 x 107 mid-log phase L.  major 
cells were harvested at 1000 x g for 10 minutes and resuspended in 100µl of the Amaxa 
nucleofector buffer. 1-5µg of DNA was added and mixed. Cells were electroporated using 
the U-14 Amaxa programme used for high cell viability before being transferred to 10ml of 
fresh HOMEM medium with 10% (v/v) HIFCS. 10ml cultures were split into two 5ml 
cultures to select for independent transfection events and incubated at 25ºC overnight. The 
following day, Puromycin antibiotic (Calbiochem) was added to a final concentration of 
100µg ml-1 to select for transfected clones. 100µl of cells were plated out in 96-well plates 
and incubated at 25ºC until the control cell lines were dead and the transfected cells grew 
up. 
2.4.4 Protein preparation.  
Mid-log phase L. major parasites were grown to a cell density of 1 x 107 cells ml-1 in 
200ml of HOMEM medium supplemented with 10% HIFCS and 1% 
penicillin/streptomycin antibiotics (Sigma). Cells were harvested at 1000 x g for 10 
minutes at 4ºC. The cell pellets were resuspended gently in 10ml of ice-cold PBS, 
sterilised through a 0.2µm filter, to wash the cells and the cells harvested as before. Cell 
pellets were gently resuspended in 3ml of ice-cold, filter sterile Leishmania lysis buffer 
supplemented with a protease inhibitor cocktail. Cells were incubated on ice for 1 hour and 
harvested in an ultra centrifuge at 100,000 x g for 1 hour at 7ºC. The S100 supernatant 
fraction was analysed by Coomassie R250 gel staining (see section 2.5.1) and Western 
blotting for protein detection (see section 2.5.2). 
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2.4.5 Leishmania stabilate preparation. 
0.5ml of mid-log phase L. major promastigote cultures were added to 0.5ml pre-chilled 
HOMEM medium supplemented with 20% HIFCS and 10% DMSO per cryovial. 
Cryovials were placed in a cotton wool insulated container, and stored at -80οC overnight. 
This was to allow gradual temperature reduction ensuring maximum survival of cells 
during the freezing process. Cryovials were subsequently transferred to liquid nitrogen for 
long term storage.   
2.4.6 Alamar blue absorption assays and drugging.  
Compounds to be assayed were made up to double the final screening concentration 
desired in HOMEM medium supplemented with 10% HIFCS.  Five-fold or ten-fold serial 
dilutions of the compounds were carried out into HOMEM medium supplemented with 
10% HIFCS. 100µl of each drug concentration were added to a 96 well plate in duplicate. 
100µl of five-fold or ten-fold serial dilutions of 1mM Pentamidine (Sigma) and 100% 
DMSO solvent were included as positive and negative controls, in duplicate, respectively. 
L. major promastigote cells were diluted to a cell density of 2 x 106 cells ml-1 in HOMEM 
media supplemented with 10% HIFCS. 100µl of 2 x 106 cells ml-1 L. major cells were 
added to all wells in 96 well plates. Plates were sealed with parafilm and incubated for 5 
days at 25°C. After 5 days, 20µl of filter sterile reazurin solution (12.5mg reazurin salt in 
100ml PBS) (Sigma) was added to each of the wells and the plate incubated for a further 
24 hours at 25°C. Absorption was read using an Envision plate reader (Perkin Elmer) with 
excitation at 540nm and emission at 590nm to assess the biological effect of the 
compounds. 
2.4.7 Macrophage infection assays and drugging.  
Day 1: Peritoneal macrophages (mφ) were harvested by lavage as described in section 
2.2.1 and incubated at 37°C, 5% CO2 for 24 hours. Day 2: Macrophage cells were infected 
   
 
61 
with L. major promastigotes: stationary phase promastigote L. major cells were counted as 
described in section 2.3.2 and diluted to a density of 4 x 106 cells ml-1 in RPMI 1640 
medium supplemented with 10% HIFCS. This allowed for a desired infection ratio of 8 to 
1 (L. major to macrophages). 100µl of L. major promastigote cells were added to each of 
the wells and the slides incubated for a further 24 hours at 37°C with 5% CO2.  Day 3: To 
determine if there was a suitably high infection after 24 hours for the experiment to 
proceed, one slide was processed by removing the medium with a pasteur pipette and 
washed 2 x with fresh RPMI 1640 medium supplemented with 10% HIFCS. Cells were 
fixed with 100% methanol and stained with 10% Giemsa’s stain (BDH) for 10 minutes. 
Infectivity after 24 hours was determined by light microscopy under oil immersion, and 
where suitably high (where ~80% of macrophages were infected), the experiment 
proceeded. The remaining slides had their medium removed with a pasteur pipette and 
were washed 2 x with fresh RPMI 1640 medium supplemented with 10% HIFCS. 
Compounds to be assayed were set up in five-fold dilution series in RPMI 1640 medium 
supplemented with 10% HIFCS. 200µl of compound were added to the wells in serial 
dilution and slides incubated for 72 hours at 37°C with 5% CO2. Day 6: The slides had 
their medium removed and were washed as previously described. Compounds were 
prepared as described for the first drugging on day 3 and were added to the macrophage 
cells to ensure the compound concentrations were kept at the desired level for the duration 
of the experiment. The slides were incubated for a further 48 hours at 37°C with 5% CO2. 
Day 8: The experiment was stopped by removing the medium from the slides and washing 
as previously described. The cells were fixed with 100% methanol and stained with 10% 
Giemsa’s stain for 10 minutes. The percentage of infected macrophages and number of 
amastigotes per macrophage were determined by light microscopy under oil immersion. 
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2.5 Biochemical methods: 
2.5.1 General protein purification. 
Escherichia coli BL21 (DE3) pLys-S strains were transformed with the relevant DNA 
plasmid and plated onto an LB-agar plate supplemented with the relevant antibiotics. A 
single colony was used to inoculate 5ml of LB-media with the appropriate antibiotics and 
grown with agitation overnight at 37ºC. Bacterial cultures were bulked up to an appropriate 
volume and grown at 37οC in LB-media supplemented with the appropriate antibiotics to 
an optical density of 0.7 at a wavelength of 600nm (O.D.600nm). Cultures were shifted to 
their induction temperature for 30 minutes and protein expression was induced over night 
using Isopropyl-β-D-Thiogalactopyranoside (IPTG) at the appropriate concentration and 
induction temperature for the relevant protein. Cells were harvested at 4000 x g for 15 
minutes and resuspended in ice-cold PBS, pH 7.4 supplemented with DNAse-I (10µg ml-1) 
and Lysozyme (100µg ml-1) and incubated for 60  minutes on ice. The cell lysate was 
sonicated 5 x 15 seconds (1sec. on/1sec. off) to break open the cells. The lysate was 
harvested at 12000 x g for 20 minutes. The proteins were purified via BioCAD 
chromatography using a metal chelate Ni2+ charged column. For L. major CYC6 only, Ni2+ 
purification was followed by purification on a strong anion exchange Poros HQ 10 micron 
4.6mmD/100mmL column (Applied Biosystems). Proteins were loaded onto the Ni2+ 
column and the flow through collected. The column was washed with Ni2+ column 
loading/wash buffer to remove non-specific proteins bound to the column, and the wash 
collected. Proteins were eluted using the Ni2+ column elution buffer with a gradient of 50-
500mM imidazole over 10 column volumes (1 column volume = 1.75ml). The fractions 
showing peaks of protein were pooled and passed through a PD-10 desalting column 
(Amersham) before being loaded onto the strong anion exchange column. The flow 
through from the column was collected and pooled. Proteins were eluted using the anion 
exchange column elution buffer and the fractions collected. Proteins were analysed as 
described in section 2.5. 
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2.5.2 Leishmania CRK3:CYC6 protein complex purification. 
E. coli BL21 (DE3) pLys-S cells were transformed with plasmid pGL1218 (CYC6his) and 
plated on an LB-agar plate with the appropriate antibiotics. A single colony was picked 
and competent cells prepared as described in 2.1.4. CYC6 competent cells were re-
transformed with plasmid pGL751a (CRK3his) and plated onto an LB-agar plate 
supplemented with the relevant antibiotics. A single colony of co-transformed E. coli BL21 
(DE3) pLys-S cells were used to inoculate 5ml of LB-media with the relevant antibiotics 
and grown with agitation at 37ºC overnight. The 5ml bacterial culture was bulked up to a 
volume of l litre and the culture grown at 37οC to 0.7 O.D.600 nm. The 1 litre culture was 
shifted to an induction temperature of 19°C for 30 minutes and protein expression induced 
with 1mM IPTG. Cultures were induced at 19οC over night with agitation. After 16 hours 
cells were harvested at 4000 x g for 15 minutes and resuspended in ice-cold PBS pH 7.4 
supplemented with DNAse-1 (10µg ml-1) (Invitrogen) and Lysozyme (100µg ml-1) (Sigma) 
for 60 minutes on ice. The cell lysate was sonicated 4 x 30 sec (30sec. on/30sec. off). The 
cell lysate was harvested at 12000 x g for 20 minutes and the soluble extract filtered 
through a 0.2µm filter syringe. The proteins were purified via BioCAD chromatography 
using a metal chelate Ni2+ charged column followed by a Hiload 16/60 Superdex-200 gel 
filtration column. The protein complex was loaded onto the Ni2+ column pre-equilibrated 
with Ni2+ column loading/wash buffer and the flow through collected. The column was 
washed with the Ni2+ column loading/wash buffer to remove non-specific proteins bound 
to the column and the wash collected. CRK3:CYC6 was eluted at 1ml min-1 with Ni2+ 
column elution buffer with a linear gradient of 50-500mM imidazole over 10 column 
volumes (1 column volume = 1.75ml). The fractions showing peaks of protein were pooled 
and loaded onto a Hiload 16/60 Superdex-200 gel filtration column pre-equilibrated with 
gel filtration buffer/enzyme storage buffer. The complex was eluted at 1ml min-1 with gel 
filtration buffer/enzyme storage buffer and the fractions collected. The protein samples 
were analysed as described in section 2.5. The fractions showing CRK3his and CYC6his 
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proteins were pooled together, had glycerol added to 10% of the final volume along with 
Roche EDTA-free, complete protease inhibitors, were aliquoted and stored at -80°C. 
2.6 SDS- PAGE. 
Protein samples were added to 4 x SDS-PAGE sample buffer (Invitrogen) and 10 x sample 
reducing agent (Invitrogen) to a final concentration of 1 x for each. Samples were boiled at 
100ºC for 5 minutes to denature the proteins. Protein samples were separated by SDS-
PAGE on 12% acrylamide mini-gels (per 15ml: 6ml 30% acrylamide; 3.8ml 1.5M Tris, pH 
8.8; 150µl 10% sodium dodecyl sulphate; 150µl 10% ammonium persulfate; 6µl TEMED: 
4.9ml H2O), prepared using a gel casting cassette system (Invitrogen). Proteins were 
electrophoresed in an XCell SureLock Mini-Cell (Invitrogen) with 1 x SDS-PAGE running 
buffer at 180 volts for approximately 1 hour until the dye front reached the foot of the gel. 
2.6.1 Coomassie gel staining. 
SDS-PAGE acrylamide gels were incubated with agitation in Coomassie blue R250 stain 
for approximately 20 minutes and rinsed with milli-Q H2O. The Coomassie blue R250 
stain was removed by incubating gels with agitation in destain solution, changing the 
solution several times until the gel was free of Coomassie blue R250 and proteins of 
interest were visible.  
2.6.2 Western blotting. 
Following SDS-PAGE, separated proteins were transferred to Hybond-C nitrocellulose 
membrane (Amersham) by electroblotting using a NOVEX XCell II blotting module 
(Invitrogen). The transfer sandwich was assembled according to the manufacturer’s 
protocol and proteins transferred in 1 x NuPage transfer buffer (Invitrogen) supplemented 
with 10% methanol (v/v) at 30 volts for 1 hour. The nitrocellulose membrane was 
transferred to a 50ml Falcon tube and incubated in protein rich Blocking solution 1 
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overnight at 4ºC, to block the remainder of the membrane which was protein free and 
prevent non-specific binding of antibodies to the membrane.  
2.6.2.1 Antibody detection of proteins. 
Nitrocellulose membranes were incubated with primary antibodies in Blocking solution 2 
for 1 hour at room temperature. Blots were washed 3 x 10 minutes with PBS-Tween 
(PBST) and incubated with secondary antibodies (anti-mouse IgG or ant-rabbit IgG) 
conjugated to horseradish peroxidise (HRP) (Promega). Secondary antibodies were 
generally used at a 1 in 5000 dilution in Blocking solution 2 and incubated for 1 hour at 
room temperature. Blots were washed in PBST as before. Antibody binding and protein 
detection was detected by Supersignal West Pico Chemiluminescent substrate reagents 
(Pierce) according to the manufacturer’s protocol. Fluorescence was detected by 
autoradiography film (Kodak) and developed by a Kodak X-omat automated developer. 
2.6.3 Protein quantification. 
Purified proteins were quantified using a Micro BCA Protein Assay kit (Pierce) and 
Coomassie (Bradford) Protein Assay kit (Pierce) both according to the manufacturer’s 
protocols. 
2.7 Protein kinase assays: 
2.7.1 γ-32P radiometric assays: 
2.7.1.1 Gel-based assays. 
Protein kinase assays were performed using CRK3, CYC6 and Civ1 cell cycle proteins in a 
final volume of 20µl. Assays were performed using the kinase assay buffer (KAB) 
supplemented with 4µM ATP, 0.5µCi of γ-32P ATP and histone H1 as a substrate used at 
0.25mg ml-1. Assays were carried out for 30 minutes at 30ºC before stopping the reaction 
by the addition of 7.5µl of 4 x SDS-PAGE sample buffer. The samples were incubated at 
100ºC for 5 minutes and electrophoressed on a 12% SDS-PAGE gel as described in section 
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2.5. Gels were processed as described in section 2.5.1 and dried before overnight exposure 
to KODAK autoradiography film, and developed by a Kodak X-omat automated 
developer. Gels were also analysed by exposure to a Typhoon Phosphor Imager to quantify 
the band intensities. 
2.7.1.2 Plate-based assays. 
Leishmania CRK3:CYC6 protein kinase assays were performed in 96-well microtiter 
plates in a final volume of 25µl. Each assay point contained approximately 7.5ng of co-
expressed Leishmania CRK3:CYC6 protein kinase complex diluted in enzyme dilution 
buffer (EDB). Assays were performed using the assay development buffer (ADB) 
supplemented with 100µM ATP, 0.5µCi of γ-32P ATP and histone H1 as a substrate used at 
0.4mg ml-1. Two and three-fold titrations were set up to determine the concentration of 
enzyme to be used per assay point and to determine the concentrations of selected 
inhibitors required for 50% inhibition of Leishmania CRK3:CYC6 protein kinase activity 
(IC50 values), respectively. For IC50 determinations, assay mixes contained DMSO to a 
final concentration of 2%, plus or minus the inhibitor. Mammalian protein kinase assays 
were carried out according to the assay protocols developed at Cyclacel. Assays were 
carried out for 30 minutes at 30°C before stopping the reaction by the addition of an equal 
volume (25µl) of 75mM phosphoric acid. Samples were spotted onto a p81 cellulose 
filterplate (Nunc) and a vacuum applied. Wells were washed 3 x 200µl with 75mM 
phosphoric acid and the bottom of the plate sealed. 50µl of Microscint 40 (Perkin Elmer) 
was added per well before incorporation of radioactivity was determined on a Topcount 
microplate scintillation counter.  
2.7.2 IMAPTM fluorescence polarization assays. 
Protein kinase assays were performed in 384-well non-treated black plates (Nunc) in a 
final volume of 20µl. Each assay point contained approximately 1.25ng of co-expressed 
Leishmania CRK3:CYC6 protein kinase complex. Assays were performed using enzyme 
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complex, 100nM fluorescently labelled peptide substrate (5FAM-GGGRSPGRRRRK-OH) 
(Molecular Devices), 100µM ATP and plus or minus an inhibitor. The enzyme complex, 
peptide and ATP were made up in the IMAPTM complete reaction buffer (CRB). Assays 
were carried out for 1 hour 20 minutes at room temperature and the reaction stopped by the 
addition of 50µl of the IMAPTM progressive binding reagent. The assay was left to proceed 
for a further 1 hour 20 minutes at room temperature and the fluorescence polarization read 
in a Perkin Elmer Fusion microplate reader, with excitation at 485nm and emission at 
535nm.  
2.8 HTS robotic technology. 
HTS assays were carried out using robotic technology at Cyclacel. Assay and compound 
plates were placed by hand in a Cytomat Plate Hotel (Heraeus). The assay was then fully 
automated as described. The plates were taken from the Cytomat by a Microlab ML-Swap 
1400 robotic arm (Hamilton Robotics) and assembled on the deck of a Microlab ML-4200 
MPH96 liquid handling robot (Hamilton Robotics). The assay components were added by 
a 96-needled liquid dispenser as part of the liquid handling robot. Once the components 
were added, the assay and compound plates were returned to the Cytomat by the Swap 
arm. The process was repeated to the assay plates to add the IMAPTM progressive binding 
reagent. Once the assay was complete, the Swap arm placed the assay plates in a Fusion 
Alpha-FP plate reader (Packard Bioscience) and the fluorescence polarization was 
determined. 
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Chapter 3  
Leishmania biology 1: The Leishmania CRK3:CYC6 protein 
kinase complex and radiometric assay development. 
3.1 Chapter introduction and objectives. 
Cyclin-dependent kinases (CDKs) are serine/threonine protein kinases that are ubiquitous 
in eukaryotes. They play crucial roles in the regulation of the cell cycle. A number of CDK 
homologues have been identified in Leishmania (Hammarton et al., 2003b; Mottram, 
1994) one of which, CRK3, has been studied in detail. The CRK3 homologues from three 
species of Leishmania have been cloned and are almost identical (Grant et al., 1998; Wang 
et al., 1998; Ali, 2002). There is a single amino acid change out of 311, in a non-conserved 
region in other CDKs, between L. mexicana, L. major and L. donovani CRK3. This implies 
that CRK3 plays an important and highly conserved role across the three Leishmania 
species and that CRK3 may therefore be exploited for drug discovery. 
The literature supports CRK3 as the functional homologue of mammalian CDK1 where 
CRK3 has been shown to be an essential gene in L. mexicana (Hassan et al., 2001). In L. 
mexicana promastigotes, CRK3 histone H1 kinase activity peaks at the G2/M phase 
transition and CRK3 appears to play an essential role in cell cycle control (Hassan et al., 
2001). 
CRK3 from Trypanosoma brucei, showing 78% homology to Leishmania CRK3, was 
shown to interact with the mitotic cyclin TbCYC6 (Hammarton et al., 2003a). This 
complex is essential for entry into mitosis in both procyclic and bloodstream form 
trypanosomes (Hammarton et al., 2003a). Using this rationale, we identified a putative 
mitotic cyclin from L. major and have shown this can activate L. mexicana CRK3 in vitro.  
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In an attempt to elucidate the function of L. mexicana CRK3, targeted gene knockout was 
performed but was unsuccessful (Hassan et al., 2001). In each case, the parasite underwent 
changes in its ploidy to ensure it retained at least one copy of the CRK3 gene, which is 
considered an indication of gene essentiality (Barrett et al., 1999). These gene knockout 
experiments suggest that CRK3 is essential (Hassan et al., 2001). In addition, the histone 
H1 kinase activity of CRK3, purified from leishmanial lysates was inhibited in vitro by 
Flavopiridol®, a known CDK inhibitor, with an IC50 value of 100nM. Incubation of L. 
mexicana with Flavopiridol® caused cell cycle arrest and parasite death, consistent with 
intracellular inhibition of a CDK (Hassan et al., 2001). This demonstrated that a compound 
that inhibited parasite enzyme activity in vitro could prevent parasite replication, further 
validating CRK3 as a potential drug target. In T. brucei, RNAi knockdown of the cyclin in 
the CRK3:CYC6 protein kinase complex blocks mitosis causing an irreversible 
catastrophic cell cycle defect (Hammarton et al., 2003a). We predict that a similar effect 
would be seen for the Leishmania CRK3:CYC6 protein kinase complex. 
CDKs do not function as monomers; for kinase activity they require to bind a regulatory 
subunit protein, a cyclin partner, and to have the correct phosphorylation status (Doerig et 
al., 2002). A transgenic Leishmania cell line expressing a hexa-histidine tagged CRK3 was 
developed (Grant et al., 1998). This expression and purification system allowed the CRK3 
to be expressed in its native state and bind its natural cyclin partner for full activation. 
CRK3his was used to develop a 96-well microtitre plate-based assay and a small chemical 
library screened as a result (Knockaert et al., 2002). The most potent inhibitors of CRK3 
were investigated further. Twenty seven of the most potent CRK3 inhibitors were tested 
against Leishmania infected macrophages in vitro. 60% of the compounds displayed 
antileishmanial activity with 7% toxic towards the macrophages (Grant et al., 2004). The 
screen showed proof of principle in the identification of hits that could be developed into 
lead compounds for drug design to treat the leishmaniases. 
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The transgenic CRK3 developed could not be produced in sufficient active quantities for 
further assay development suitable for screening larger compound libraries. Furthermore, 
there were problems with the variability of protein quantity between purifications. When 
purifying the transgenic CRK3 it is possible that there could be a mix of CDKs that are 
purified and not just CRK3, or that CRK3 is bound to different cyclins other that CYC6. 
As a result, this chapter will focus on the generation of a recombinant L. mexicana CRK3 
in complex with L. major CYC6 expressed in E. coli. Initial activity was established 
through gel-based protein kinase assays with the view to further assay development. The 
active protein kinase complex was used to develop a radiometric γ-32P-ATP 96-well filter 
plate assay, capable of low to medium throughput compound screening. The radiometric 
assay was used as a reference assay and as a basis for the future development of a high 
throughput screening (HTS) assay. The HTS assay was used to screen a compound library 
provided by Cyclacel under license from Lexicon Pharmaceuticals Inc. (formerly 
Coelacanth Corporation), which was carried out at Cyclacel Limited in Dundee. This was 
with the intention of identifying hits specific to L. mexicana CRK3 which could be 
developed into lead compounds for drug design to treat the leishmaniases. 
3.1.1 Assay development, validation and performance. 
There are factors to take into consideration when planning to develop an assay suitable for 
compound screening. These include quality control of the assay and assay performance. 
Once the target enzyme has been chosen (Leishmania CRK3:CYC6 in this study), assay 
development is carried out. Initially, a suitable substrate must be identified and with this, a 
signal window of activity can then be generated, validating suitable quantities of protein 
and substrate. This is carried out by determining the Km for the substrate and then selecting 
a quantity sufficiently above the Km to provide sufficient substrate for the enzyme while 
not saturating the assay. When developing a protein kinase assay, this is also carried out 
for ATP. In order to establish the quantity of enzyme which will provide a signal 
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sufficiently above a background signal (no enzyme) and is in the linear phase of the assay, 
an enzyme titration is carried out. Determining the linearity with a suitable quantity of 
enzyme identifies when the assay has run to completion and highlights the time points 
when the assay is in the linear phase and therefore suitable for compound screening. For 
example, a suitable signal:background window employed at Cyclacel, in the linear phase of 
the assay, is 10:1. Once these parameters are determined an assay can be validated and its 
performance monitored.   
 
In order to validate an assay, the Z’ score and the coefficient of variation are both 
determined. The Z’ score is a statistical parameter which measures the validity and 
robustness of an assay using the controls and without the intervention of compounds. 
Similarly, the Z factor is used to evaluate the performance of an assay in the presence of 
compounds. In order to calculate the Z’ score, three independent assays are carried out, 
each with a sample and control plate. The sample plate is set up with the kinase, substrate, 
ATP and the solvent which the compounds are in (DMSO in this study), in each well of the 
plate. The control plate is set up with the same components minus the enzyme (control). 
The standard deviation and mean signal for each sample and control plate are determined 
and the Z’ calculation carried out for each of the three determinations (Table 3.1). The 
criteria used to evaluate a Z factor can be used for the Z’ score (Table 3.1). The ideal assay 
would return a Z‘ score of 1, however; an assay with a Z’ score >0.5 is considered 
excellent and satisfactory for compound screening. The Z’ score is an indication of assay 
quality which is essential as it important to have confidence in the assay so that the “hits” 
identified can be considered real. The coefficient of variation measures plate uniformity 
highlighting a drift in signal within a plate. In order for an assay to be validated at 
Cyclacel, a coefficient of variation must be <10% (a variability in signal within a plate of 
<10%). This parameter can also be used to evaluate inter-plate variability by comparing 
values, another statistic to evaluate the performance of the assay. 
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Table 3.1 – The characterisation of screening assay quality by the value of the Z 
factor. Included is the Z score calculation. Taken from  Journal of Biomolecular Screening 
(Zhang et al., 1999). 
 It is vital to monitor the performance of an assay to ensure it is functioning as expected 
and required. Quality control of an assay is carried out with positive and negative controls 
on each assay plate. When carrying out compound screening, a no enzyme control with the 
solvent in which the compounds are stored in, is used. This is used as a negative control, 
and is the background signal for the assay. As a positive control, the enzyme without any 
inhibitor or in the case of a kinase assay, a pre-phosphorylated substrate can be used, 
generating the “maximum signal”. In addition, including an inhibitor with a known IC50 
value against the enzyme of choice, (Staurosporine for CRK3:CYC6) also allows the assay 
performance to be monitored on each plate. If these quality controls regularly return the 
signal values expected then it can be said with confidence that the assay is performing as 
expected. 
                                 
Once an assay is validated and its performance satisfactory, compound screening can be 
carried out. It is important to validate the hits identified from a screen in addition to having 
a validated assay. Any hits identified from a high throughput screen for example, can be 
re-screened using another assay platform such as a radiometric assay format to further 
confirm their activity against the target enzyme. The structure and purity of compounds 
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taken into potency assays can be checked using liquid chromatography-mass spectrometry 
(LCMS). In addition, it is standard practice in drug development to re-synthesise the 
identified hits. These would be assayed against the target to confirm their activity and 
validate them as genuine hits. 
3.2 Cloning: To obtain the Leishmania CRK3 and CYC6 genes: 
3.2.1 L. mexicana CRK3 cloning. 
The CRK3 gene from L. mexicana was previously cloned in the Mottram laboratory by 
Karen Grant (Grant et al., 1998). The L. mexicana CRK3 gene amplified through a PCR 
reaction was ligated into a pGEM-T cloning vector and sequenced. Using oligonucleotide 
225 (5’ GAATTCCATATGTCTTCGTTTGGCCGTGTGA 3’) and oligonucleotide 894 
(5’ GGCGAGCAAGGTAGAGCAC 3’), the CRK3 gene was amplified further in this 
study to generate NdeI and XhoI restriction sites, respectively. This was sub-cloned into 
pET-28a(+) previously digested with NdeI and XhoI. The pET-28a(+) construct added an 
N-terminal tag comprising six histidines to aid purification by Ni-NTA affinity 
chromatography and was named pGL751a (Figure 3.1, upper map). This plasmid was used 
to express and affinity purify the CRK3his protein via the his-tag. 
3.2.2 L. major CYC6 cloning. 
The CYC6 gene from L. major, LmjF32.3320, identified from GeneDB (www.genedb.org) 
was amplified by PCR. This was performed using Deep Vent DNA polymerase, L. major 
genomic DNA and oligonucleotides 1515 (5’ 
GCATATGTTCGTGGAACGAGAGCGGCAGG 3’) and 1516 (5’ GCTCGAGTCACAG 
CGCCGGCAGCTCGTTAGGC 3’). The PCR product was gel purified and ligated into 
PCR-Script cloning vector generating pGL1169. The DNA sequence was confirmed by 
sequencing. The PCR product from pGL1169 was sub-cloned in the expression vector 
pET-15b(+) using XhoI and NdeI. This construct added an N-terminal tag comprising six 
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histidines and was named pGL1218 (Figure 3.1, lower map). This plasmid was used to 
express and affinity purify the CYC6his protein via the his-tag.      
                                    
pGL751a
6229 bp
KAN
lacI
CRK3 ORF
His Tag
T7 promoter
f1 origin
Nde I (1099)
Xho I (159)
                                                     
        
pGL1218
6617 bp
CYC6 ORF
lac operator
AMP
T7 Promoter
T7 Terminator
His-tag
Nde I (5376)
Xho I (6290)
 
Figure 3.1 – Vector NTI maps of the L. mexicana CRK3 protein expression construct 
pGL751a and L. major CYC6 protein expression construct pGL1218. The CRK3 open 
reading frame (ORF) sub-cloned into NdeI and XhoI digested pET-28a(+) with a 
kanamycin  resistance marker (KAN) and an N-terminal hexa-his tag (Upper map). The 
CYC6 open reading frame sub-cloned into NdeI and XhoI digested pET-15b(+) with an 
ampicillin (AMP) resistance marker and an N-terminal hexa-his tag (Lower map). 
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3.3 Purification of cell cycle proteins: 
3.3.1 L. mexicana CRK3his. 
Escherichia coli BL21 (DE3) pLys-S cells were transformed with pGL751a to express the 
CRK3his protein. Protein expression using an induction temperature of 19ºC with 300µM 
IPTG was carried out overnight. E. coli BL21 (DE3) pLys-S cells were lysed and CRK3his 
purified via a Ni-NTA affinity column. Samples were loaded on a 12% acrylamide mini-
gel and separated by SDS-PAGE. CRK3his was detected by Coomassie blue R250 gel 
staining (Figure 3.2, upper panel). These samples were also assessed using Western blot 
analysis with an anti-tetra-his antibody and the CRK3his protein detected at ~38kDa 
(Figure 3.2, lower panel). This was the expected size of CRK3his and was purified to give 
a yield of 1mg litre-1. 
3.3.2 L. major CYC6his. 
E. coli BL21 (DE3) pLys-S cells were transformed with pGL1218 to express the CYC6his 
protein. Protein expression using an induction temperature of 19ºC with 1mM IPTG was 
carried out overnight. E. coli BL21 (DE3) pLys-S cells were lysed and CYC6his purified 
via Ni-NTA affinity and strong anion exchange columns. Samples were loaded on a 12% 
acrylamide mini-gel and separated by SDS-PAGE. CYC6his was detected by Coomassie 
blue R250 gel staining (Figure 3.3). Western blot analysis with an anti-tetra-his antibody 
was used to detect CYC6his with initial expression and purifications (data not shown). 
However, due to the continuous successful purification of CYC6, it was deemed 
unnecessary to perform Western blot analysis on each purification from the anion 
exchange column. CYC6his was obtained at the expected size of ~35kDa and was purified 
to 0.5mg litre-1. However, contaminant proteins were observed in the purification, likely to 
be additional bacterial proteins which bind the Ni-NTA and strong anion exchange 
columns, and peptides as a result of cleavage by bacterial peptidases. 
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3.3.3 L. mexicana CRK3T178Ehis. 
E. coli BL21 (DE3) pLys-S cells were transformed with pGL665 to express a mutant of the 
L. mexicana CRK3 protein, CRK3T178Ehis (Nahla Ali, Ph.D thesis, 2002). Protein 
expression using an induction temperature of 25ºC with 50µM IPTG was carried out 
overnight. E. coli BL21 (DE3) pLys-S cells were lysed and CRK3T178Ehis purified via a 
Ni-NTA affinity column. Samples were loaded onto a 12% polyacrylamide mini-gel and 
separated by SDS-PAGE. CRK3T178Ehis protein detection was via Coomassie blue R250 
gel staining (Figure 3.4, upper panel) and via Western blotting with an anti-histidine (tetra-
his) antibody (Figure 3.4, lower panel). CRK3T178Ehis was detected at 38kDa which is the 
same size as the native CRK3his protein (Figure 3.2) and was purified to give a yield of 
3.5mg litre-1. 
3.3.4 Saccharomyces cerevisiae GST-Civ1. 
E. coli BL21 (DE3) pLys-S cells were transformed with pGL716, a pGEX vector obtained 
from Jane Endicott, University of Oxford, to express the GST-Civ1 protein (Thuret et al., 
1996). GST-Civ1 was expressed and purified using established conditions (Brown et al., 
1999a). E. coli BL21 (DE3) pLys-S cells were lysed and GST-Civ1 purified via a GST 
affinity column. Samples were loaded on a 12% acrylamide mini-gel and separated by 
SDS-PAGE. GST-Civ1 protein detection was via Coomassie blue R250 staining (Figure 
3.5, upper panel) and Western blotting with an anti-GST antibody (Figure 3.5, lower 
panel). The GST-Civ1 protein was detected at 75kDa, as expected; however, other 
contaminant bands were also present in the purification. This has been seen previously 
when purifying GST-Civ1 with regard to the higher molecular weight protein bands. 
(Brown et al., 1999a). The lower weight proteins are likely to be a result of cleavage by 
bacterial peptidases as protease inhibitors were not used in the purification of GST-Civ1. 
The protein purification was purified to give a yield of 15mg litre-1. 
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Figure 3.2 – L. mexicana CRK3 protein purification. Top panel: CRK3his protein 
detection via Coomassie blue R250 gel staining. Bottom panel: CRK3his protein detection 
via Western blotting with an anti-tetra-histidine antibody (Sigma). Lane 1, insoluble 
protein fraction. Lane 2, soluble protein fraction. Lane 3; unbound protein fraction. Lanes 
4-8; protein fractions eluted from the Ni-NTA affinity column. Lane 9, molecular weight 
protein standards. 
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Figure 3.3 – L. major CYC6 protein expression. CYC6his protein detection via 
Coomassie blue R250 gel staining. Lane 1, CYC6his fraction purified from a Ni-NTA 
column and loaded onto the anion exchange column. Lane 2-9 protein fractions eluted 
from the anion exchange column. Lane 10, molecular weight protein standards. 
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Figure 3.4 – L. mexicana CRK3T178E protein purification. Top panel: CRK3T178his 
protein detection via Coomassie blue R250 gel staining. Bottom panel: CRK3T178his 
protein detection via Western blotting with an anti-tetra-histidine antibody. Lane 1, 
insoluble protein fraction. Lane 2, soluble protein fraction. Lane 3, unbound protein 
fraction. Lanes 4-8, protein fractions eluted from the Ni-NTA affinity column. Lane 9, 
molecular weight protein standards. 
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Figure 3.5 – S. cerevisiae GST-Civ1 protein purification. Top panel: GST-Civ1 protein 
detection via Coomassie blue R250 gel staining. Bottom panel: GST-Civ1 protein 
detection via Western blotting with an anti-GST antibody. Lane 1, insoluble protein 
fraction. Lane 2, unbound protein fraction. Lanes 3-8, protein fractions eluted from a GST 
column. Lane 9, molecular weight protein standards. 
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3.4 Protein kinase assays: gel-based assay: 
3.4.1 Activation of the Leishmania CRK3:CYC6 protein kinase complex. 
Monomeric CRK3 does not have protein kinase activity and requires the binding of cyclin 
protein to become active. Cyclin binding provides domains important for substrate 
selection thereby creating a substrate binding pocket. The L. major cyclin, CYC6, was 
used to activate L. mexicana CRK3. Following purification and quantification of the 
CRK3his and CYC6his proteins, a radiometric kinase assay was carried out to assess 
CRK3 activation by CYC6. A quantity of 1.25µg of CRK3his was used throughout the 
assay with increasing quantities of CYC6his added to the CRK3his. Histone H1 was used 
as a CRK3 substrate to analyse CRK3 activity. A background activity of CRK3his was 
observed which may be a result of a contaminant kinase in the purification of CRK3his 
phosphorylating histone H1 (Figure 3.6, lane 1). As increasing CYC6his quantities were 
added to CRK3his, increased activity was observed, validating CYC6 from L. major as an 
active functional cyclin (Figure 3.6). 
3.5 Leishmania CRK3his:CYC6his protein stoichiometry optimisation. 
In order to establish the quantity of CRK3his in relation to CYC6his required for optimum 
activity, analysis of varying CRK3his and CYC6his ratios was carried out. As the 
molecular weights of CRK3his and CYC6his are almost identical (38 kDa and 35 kDa, 
respectively), a 1:1 weight ratio of the proteins would equate to an approximate 1:1 molar 
ratio of proteins.  A kinase assay was carried out to establish whether the predicted 
optimum ratio of 1:1 Leishmania CRK3:CYC6 proteins would result in the most 
CRK3:CYC6 protein kinase activity. The assay was carried out with protein ratios ranging 
from CRK3his 2:1 CYC6his to CRK3his 1:2 CYC6his. The highest activity is seen in 
lanes 4 and 5, where the ratio of Leishmania CRK3his and CYC6his proteins is 
approximately 1:1 as predicted (Figure 3.7). A 1:1 ratio of CRK3his and CYC6his was 
used for all subsequent kinase assays. 
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Figure 3.6 – Activation of the Leishmania CRK3:CYC6 protein kinase complex. 
Activity of L. mexicana CRK3 was assessed by its ability to phosphorylate a histone H1 
substrate. 1.25µg of CRK3his was included in lanes 1-7. Increasing quantities of CYC6his 
were added from lanes 2-7: Lane 2, 0.025µg. Lane 3, 0.05µg. Lane 4, 0.075µg. Lane 5, 
0.1µg. Lane 6, 0.125µg. Lane 7, 0.15µg. Lane 1 has 1.25µg of CRK3his only while lane 8 
has 0.3µg of CYC6his only, as controls.  
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Figure 3.7 – Optimisation of the ratio of Leishmania CRK3 and CYC6 proteins.  The 
optimum ratio of Leishmania CRK3 and CYC6 proteins was assessed by the ability of the 
complex to phosphorylate a histone H1 substrate. 4.4µg of CRK3his was included in lanes 
1-7. Increasing quantities of CYC6his were added to lanes 2-7 corresponding to the ratios 
above. Lane 2, 2.2µg. Lane 3, 3.3µg. Lane 4, 4.4µg. Lane 5, 5.8µg Lane 6, 7.2µg. Lane 7, 
8.8µg. This resulted in double the quantity of CRK3his as CYC6his in lane 2, progressing 
to a 1:1 ratio in lane 4, and to double the quantity of CYC6his as CRK3his in lane 7. Lane 
8 contains 4µg of CYC6his as a negative control. 
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3.6 Leishmania CRK3:CYC6 protein kinase stability analysis. 
The Leishmania CRK3 and CYC6 proteins were stored in the following buffer system 
provided by Cyclacel: 20mM HEPES, pH 7.4, 50mM NaCl, 2mM DTT, 1mM EGTA, 10% 
glycerol and 0.02% Brij-35. The proteins were stored separately and as a 1:1 complex at -
80°C with Roche complete protease inhibitors. A kinase assay was carried out to determine 
whether the proteins remained active after four weeks of storage and whether they retain 
highest activity when stored separately or as a 1:1 complex (Figure 3.8). Assays with the 
Leishmania CRK3:CYC6 proteins stored as a complex (Lane 1) and proteins stored 
separately and mixed together on the day of the assay (Lane 2, mix) were carried out. 
CRK3his (Lane 3) and CYC6his (Lane 4) stored separately were included as controls. The 
proteins are still similarly active after four weeks when stored as a complex or when added 
together in a 1:1 ratio on the day of the assay (Figure 3.8). The controls show that there is 
no auto activity of CRK3his or CYC6his and the proteins are inactive when assayed after 
being stored separately. The activity levels of the complex and the mix of proteins is 
comparable; however, the stored complex is possibly more active. The buffer system is 
therefore successful in stabilizing and retaining the activity of the two proteins. 
3.7 Leishmania mexicana CRK3T178Ehis:CYC6his activity assay. 
L. major CYC6his was used to try to activate a previously constructed mutant of L. 
mexicana CRK3, CRK3T178E (Ali, 2002). The critical T-loop residue of CRK3, threonine 
178 (T178), was mutated to a glutamic acid (E178) and the protein expressed. Mutation of 
this activation loop residue can mimic a phosphorylated protein (Nishiyama et al., 2000). 
CRK3T178Ehis (Lane 1), CYC6his (lane 8) and Leishmania CRK3:CYC6 protein kinase 
complex as a positive control (lane 9) were included. Lanes 2-7 have increasing quantities 
of CYC6his added to 3.5µg of CRK3his. However, there is no activity of CRK3T178Ehis 
(Figure 3.9). This shows that CYC6his cannot activate CRK3T178E and the mutation renders 
the CRK3 kinase dead, abolishing histone H1 kinase activity.  
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3.8 S. cerevisiae GST-Civ1 
It was predicted that S. cerevisiae Civ1 may enhance the activity of the Leishmania 
CRK3:CYC6 protein kinase complex as was shown for L. mexicana CRK3:CYCA (F. 
Gomes and J.C. Mottram, unpublished). An activity assay with GST-Civ1 and histone H1 
proteins was carried out to confirm that GST-Civ1 does not phosphorylate histone H1 
independently (Figure 3.10). Histone H1 (Lane 1) and GST-Civ1 (lane 8) were included as 
controls. Increasing quantities of GST-Civ1 were added to histone H1 (Lanes 2-7). No 
increase in phosphorylation of the histone H1 substrate was observed by adding GST-Civ1 
(Figure 3.10). This shows that GST-Civ1 independent of CRK3 does not phosphorylate 
histone H1. However, there is background activity of histone H1 seen in the assay. This is 
possibly due to the presence of a contaminant kinase in the GST-Civ1 preparation or 
histone H1 substrate. 
To determine if GST-Civ1 would enhance the activity of the Leishmania CRK3:CYC6 
protein kinase complex, a kinase assay was carried out (Figure 3.11). Leishmania 
CRK3:CYC6 protein kinase complex in a 1:1 ratio was included as a control (Lane 1). 
Lanes 2-7 had increasing quantities of GST-Civ1 added to the complex. Phosphorylation 
of CRK3his increases with increasing quantities of GST-Civ1 (Figure 3.11, upper arrow). 
However, no increase in activity of the CRK3:CYC6 protein kinase complex with 
increasing quantities of GST-Civ1 was observed (Figure 3.11, lower arrow). A further 
experiment was carried out with GST-Civ1 being added to L. mexicana CRK3his every 
five minutes for 20 minutes (data not shown). This was to maximise the phosphorylation of 
the threonine 178 residue of CRK3his. L. major CYC6 was then added to complete the 
complex. This again did not show any increase in activity of the complex, suggesting GST-
Civ1 does not have a role in activating the Leishmania CRK3:CYC6 protein kinase 
complex, possibly because it is a yeast enzyme. 
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Figure 3.8 – Stability of the Leishmania CRK3 and CYC6 proteins. Proteins were 
stored at -80°C with Roche complete protease inhibitors in enzyme storage buffer. All 
proteins used were stored for four weeks. They were assessed for the ability to 
phosphorylate a histone H1 substrate. Lane 1, 4µg of Leishmania CRK3:CYC6 protein 
kinase complex stored in a 1:1 ratio. Lane 2, 2µg of CRK3his and 2µg of CYC6his stored 
separately and mixed for the assay. Lane 3, 2µg CRK3his only. Lane 4, 2µg CYC6his 
only. 
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Figure 3.9 – Lack of activation of CRK3T178E by L. major CYC6. The ability of 
Leishmania major CYC6his to activate CRK3T178Ehis was assessed by the ability of the 
CRK3T178Ehis:CYC6his protein kinase complex to phosphorylate a histone H1 substrate. 
Lanes 1-7 include 3.5µg of CRK3T178Ehis. Increasing quantities of CYC6his were added to 
CRK3T178Ehis in lanes 2-7. Lane 2, 0.6µg. Lane 3, 1.2µg. Lane 4, 1.8µg. Lane 5, 2.4µg. 
Lane 6, 3µg. Lane 7, 3.5µg Lane 8 includes 3.5µg of CYC6his only as a negative control. 
As a positive control, 3.5µg of active 1:1 Leishmania CRK3:CYC6 protein kinase complex 
was included in lane 9. 
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Figure 3.10 – S. cerevisiae Civ1:histone H1 activity assay. Activity of S. cerevisiae 
GST-Civ1 was assessed by it ability to phosphorylate a histone H1 substrate. Lanes 1-7 
include 0.25µg of histone H1 substrate. Increasing quantities of GST-Civ1 were added to 
lanes 2-7. Lane 1, 0.3µg. Lane 2, 0.6µg. Lane 3, 0.9µg. Lane 5, 1.2µg. Lane 6, 1.5µg. Lane 
7, 1.8µg. Lane 1 contains 0.25µg of histone H1 only and lane 8 has 3µg of GST-Civ1 only 
as controls. 
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Figure 3.11 – Activation of the Leishmania CRK3:CYC6 protein kinase complex with 
S. cerevisiae Civ1. The ability of S. cerevisiae GST-Civ1 to activate the Leishmania 
CRK3:CYC6 protein kinase complex further was assessed by the phosphorylation of a 
histone H1 substrate (Lower arrow). Lane 1 includes CRK3 only as a control. Lanes 2-7 
includes 5µg of Leishmania CRK3:CYC6 protein kinase complex in a 1:1 ratio. Increasing 
quantities of GST-Civ1 were added to lanes 2-7. Lane 2, 0.3µg. Lane 3, 0.6µg. Lane 4, 
0.9µg. Lane 5, 1.2µg. Lane 6, 1.5µg. Lane 7, 1.8µg. The upper band (upper arrow) is 
CRK3his, which is being phosphorylated by GST-Civ1 on threonine 178. 
 
   
 
90 
3.9 Large scale Leishmania CRK3:CYC6 protein purification for radiometric 
assay development: 
3.9.1 Co-expression and co-purification of Leishmania CRK3:CYC6. 
E. coli BL21 (DE3) pLys-S cells were transformed with plasmid pGL1218 (CYC6his) and 
competent cells produced. The CYC6his competent cells were re-transformed with plasmid 
pGL751a (CRK3his) and the protein complex expressed. The protein complex was purified 
via nickel chelate and gel filtration columns. Following purification, the samples were 
loaded onto a 12% SDS-PAGE polyacrylamide gel. The Leishmania CRK3:CYC6 proteins 
were detected by Coomassie blue R250 gel staining (Figure 3.12). The CRK3his and 
CYC6his proteins were detected at their expected sizes of 38kDa and 35kDa, respectively 
(Lane 1) in an approximate 1:1 ratio. Some minor contaminant proteins were observed in 
the purification, likely to be additional bacterial proteins and proteins as a result of 
cleavage by bacterial peptidases. As there was protein kinase activity in the preparation, no 
further purification of the protein kinase complex was carried out.  Individually purified 
CRK3his and CYC6his proteins are included in lanes 2 and 3, respectively. The identities 
of the proteins in lane 1 were confirmed by peptide mass fingerprinting and the yield of the 
complex determined at 4.5 mg litre-1. 
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Figure 3.12 – Expression and purification of the L. mexicana CRK3 and L. major 
CYC6 cell cycle proteins. CRK3his and CYC6his were co-expressed in E. coli and 
purified via Ni-NTA and gel filtration columns. Lane 1, CRK3his, 38kDa and CYC6his, 
35kDa. CRK3his and CYC6his were individually expressed in E. coli and purified via a 
Ni-NTA column. Lane 2, CRK3his, 38kDa. Lane 3, CYC6his, 35kDa. Lane 4, molecular 
weight protein standards. 
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3.10 Protein kinase assays: Radiometric protein kinase assays: 
3.10.1 Leishmania CRK3:CYC6 protein kinase activity assay. 
A plate based kinase assay was carried out to assess the activity of the Leishmania 
CRK3:CYC6 protein kinase complex. Such assays are adaptable to low to medium 
throughput screening, unlike the previous in-gel assay. This was performed with the co-
purified Leishmania CRK3:CYC6 protein kinase complex with each assay point carried 
out in duplicate. A ten-point, two-fold enzyme titration of Leishmania CRK3:CYC6 was 
carried out with a top quantity of 1500ng. Activity increases in a linear fashion as 
increasing quantities of CRK3:CYC6 protein kinase complex is used in the assay until the 
assay plateaus due to enzyme saturation. The greatest activity observed is with neat 
complex with approximately 100,000 counts per minute, and although the assay is 
saturated at this point, it shows the proteins are active and the assay is functional (Figure 
3.13). This identified 7.5ng of protein complex producing a signal of approximately 15,000 
counts per minute, in the linear phase of the assay, with a signal to background ratio of 
approximately 15:1. This was an acceptable starting point for further assay development 
and 7.5ng of protein complex was used in all subsequent radiometric assays. 
3.11 Leishmania CRK3:CYC6 time course assay. 
A time course assay was carried out to establish the linearity period for the radiometric 
assay developed for the Leishmania CRK3:CYC6 protein kinase complex. The assay was 
carried out over 60 minutes at 30ºC using 7.5ng per assay point and was stopped at 0, 5, 
10, 20, 30, 45 and 60 minute time points. The assay was shown to be linear over the 60 
min period examined (Figure 3.14). For subsequent assays, 30 minutes was chosen as the 
time point to carry out the assays owing to its good signal to background ratio and its 
linearity. The assay was validated with a Z’ score of 0.67 which is considered excellent in 
terms of assay quality (Zhang et al., 1999; Iversen et al., 2006).  
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Figure 3.13 – Plate based activity assay of the Leishmania CRK3:CYC6 protein 
kinase complex. Activity of the Leishmania CRK3:CYC6 protein kinase complex was 
assayed in plate based form by its ability to phosphorylate a histone H1 substrate. A two-
fold Leishmania CRK3:CYC6 enzyme titration was carried out. This identified that 7.5ng 
of enzyme complex could be used per assay point. Graphical analysis was carried out using 
XLfit 4.0 software from IDBS (www.idbs.com). 
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Figure 3.14 – Linearity of the Leishmania CRK3:CYC6 radiometric assay. The 
linearity of the assay developed for the Leishmania CRK3:CYC6 protein kinase complex 
was determined over 60 minutes. 7.5ng of Leishmania CRK3:CYC6, 0.4mg ml-1 (3.6µM) 
histone H1 substrate and 100µM [γ-32P]-Mg-ATP were incubated at 30°C. The assay was 
stopped at various time points by the addition of orthophosphoric acid. The reaction was 
spotted onto a P81 filter plate and following washing with orthophosphoric acid, was 
counted for the incorporation of radioactivity. Graphical analysis was carried out using 
XLfit 4.0 software from IDBS (www.idbs.com). 
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3.12 Leishmania CRK3:CYC6 ATP and histone H1 substrate Km 
determinations. 
Kinase assays were performed to establish the Km values of ATP and the histone H1 
substrate for the Leishmania CRK3:CYC6 protein kinase complex. A two-fold titration of 
ATP was set up resulting in concentrations of ATP ranging from 2µM to 1mM in the assay 
to determine whether the complex follows Michaelis-Menten kinetics. The Km value of 
ATP was determined at 64µM ± 26µM for CRK3:CYC6 (Figure 3.15, upper graph). 
Similarly, a two-fold titration of the histone H1 substrate was set up with concentrations 
ranging from 0.45µM to 232µM in the assay. The Km for the histone H1 substrate was 
determined as 2.4µM ± 0.48µM (Figure 3.15, lower graph). 
3.13 Staurosporine and olomoucine IC50 determinations for the Leishmania 
CRK3:CYC6 protein kinase complex. 
The IC50 values for staurosporine and olomoucine were determined for the Leishmania 
CRK3:CYC6 protein kinase complex. The IC50 value for staurosporine was determined at 
37nM (Figure 3.16, upper graph) and 51µM for olomoucine (Figure 3.16, lower graph). 
The IC50 value for olomoucine is consistent with the IC50 value of 42µM determined for 
CRK3his purified from L. mexicana parasites (Grant et al., 1998). 
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Figure 3.15 – ATP and substrate Km determinations for the Leishmania CRK3:CYC6 
protein kinase complex. Km values for ATP (Upper graph) and a histone H1 substrate 
(Lower graph) determined for the Leishmania CRK3:CYC6 protein kinase complex. 
Graphical analysis was carried out using XLfit 4.0 software from IDBS (www.idbs.com) 
with a Km determination model. 
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Figure 3.16 – Staurosporine and olomoucine IC50 determinations for the Leishmania 
CRK3:CYC6 protein kinase complex. The IC50 values for staurosporine (Upper graph) 
and olomoucine (Lower graph) protein kinase inhibitors determined for the Leishmania 
CRK3:CYC6 protein kinase complex. Graphical analysis was carried out using XLfit 4.0 
software from IDBS (www.idbs.com). 
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3.14 Preliminary compound screen against Leishmania CRK3:CYC6. 
A compound subset of 193 compounds from a number of Cyclacel in-house libraries was 
screened against the Leishmania CRK3:CYC6 protein kinase complex. Approximately 
75% of the compounds were selected randomly from the Cyclacel library (Table 4.1). The 
remainder were selected for their known activities against one or more of the CDKs, 
Aurora kinases, Polo-like kinase 1 (PLK1) or Glycogen Synthase Kinase 3 (GSK-3) and 
included as positive controls. The compounds were screened at a fixed concentration of 
10µM with 39/193 (20%) exhibiting >50% inhibition of Leishmania CRK3:CYC6 protein 
kinase activity. Thirty of these hits were known to be potent inhibitors of human 
CDK2:CycE and were not pursued for secondary screening against the Leishmania 
CRK3:CYC6 protein kinase complex. The remaining 9 compounds were secondary 
screened against the Leishmania CRK3:CYC6 protein kinase complex to determine their 
IC50 values. This showed that 5/9 were false positives and did not inhibit Leishmania 
CRK3:CYC6 protein kinase activity, returning IC50 values >50µM. This was possibly a 
result of carrying over more potent compounds from adjacent wells on the pipette tips 
when using the robotic technology, which has been seen at Cyclacel previously. The 
remaining 4/9 inhibited Leishmania CRK3:CYC6 protein kinase activity with IC50 values 
ranging from 0.86µM to 13.4µM; however, two of these were screened and shown to be 
inhibitors of human CDK2:CycE with IC50 values of 240nM and 1.2µM. The remaining 
2/4, Vx-680 (Vertex) and compound A (ChemDiv) were inactive against human 
CDK2:CycE with IC50 values of >50µM and their structures shown (Figure 3.17). The 
upper compound is Vx-680 from Vertex with an IC50 of 6.2µM for the Leishmania 
CRK3:CYC6 protein kinase complex. The lower compound is from ChemDiv with an IC50 
of 13.4µM for the Leishmania CRK3:CYC6 protein kinase complex. 
  
99 
                    
 
                       
N
N N
N
S
N N
N
N
O
                           
                                                               Vertex Vx-680 
 
 
                                
N
S
NO
S
N
N
O
O
 
                                             Compound A (ChemDiv) 
Figure 3.17 – Structures of the compound hits from the Leishmania CRK3:CYC6 
preliminary compound screen. The upper compound is Vx-680 from Vertex and the 
lower, compound A from ChemDiv. 
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3.15 Chapter discussion 
A recombinant L. major CYC6 was cloned, sequenced and the protein shown to activate L. 
mexicana CRK3 in vitro to provide an active protein kinase complex. This complex was 
suitably active for radiometric assay development and compound screening. CRK3 
homologues from three species of Leishmania have been cloned and are almost identical 
(Ali, 2002; Grant et al., 1998; Wang et al., 1998). There is a single amino acid change out 
of 311, in a non-conserved region in other CDKs, between L. mexicana, L. major and L. 
donovani CRK3. Therefore, the Leishmania CRK3:CYC6 protein kinase complex is 
essentially an L. major protein kinase complex with one amino acid difference. 
CRK3, a cdc2-related protein kinase from  L. mexicana (Grant et al., 1998; Hassan et al., 
2001) was expressed and purified using the pET expression system (Figure 3.1, upper 
map). This provided a large quantity of CRK3his (~1mg litre-1) as CRK3his is a relatively 
well expressed protein (Figure 3.2). CYC6his, a putative mitotic cyclin from L. major, was 
also cloned, sequenced and expressed using the pET expression system (Figure 3.1, lower 
map). L. major CYC6 is a homologue of T. brucei CYC6, which has been shown to 
associate with T. brucei CRK3 in vivo (Hammarton et al., 2003a). Using this rationale, it 
was predicted that L. major CYC6 could associate with L. mexicana CRK3. When 
expressed in E. coli, it is notable that CYC6his is not present in as large a quantity (~0.5mg 
litre-1) (Figure 3.3) as CRK3his (Figure 3.2), despite the expression conditions being 
optimised for CYC6his; an induction temperature of 19ºC with 1mM IPTG in comparison 
with 19ºC with 300µM IPTG for CRK3his. Using a higher concentration of IPTG to 
express CYC6his does not result in the level of protein expression seen with CRK3his. 
This is perhaps due to increased levels of CYC6his being toxic to the E. coli BL21 (DE3) 
pLys-S cells and interfering with bacterial growth. Therefore, the E. coli BL21 (DE3) 
pLys-S cells may control the expression levels of CYC6his by actively limiting it. The 
DE3 IPTG inducible systems are under control of the lacUV5 promoter and it is known 
that this system leads to high mRNA and protein production. This can cause ribosome 
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destruction and E. coli cell death (Baneyx, 1999), another possible explanation accounting 
for the low level of CYC6 expression. Alternatively, expressing CYC6 in the absence of a 
kinase partner may lead to degradation of the protein. 
L. major CYC6his and L. mexicana CRK3his were used in a gel-based kinase assay and 
protein kinase activity was observed when L. major CYC6his was added, thereby 
validating it as a functional cyclin (Figure 3.6). The optimal ratio of Leishmania CRK3his 
and CYC6his proteins was established in order to obtain a fully active CRK3his, where the 
greatest activity observed is present around the 1:1 ratio of Leishmania CRK3:CYC6 
proteins (Figure 3.7). This is predicted to be the optimum ratio for full activation of 
CRK3his as there is one PSTAIRE binding motif in CDKs capable of binding cyclins via 
the conserved cyclin box. As opposed to bacterial protein expression as used for 
Leishmania CRK3:CYC6, at Cyclacel, protein expression via baculovirus infected insect 
cells is carried out to produce active CDK:Cyclin complexes. Co-infection with a CDK and 
cyclin partner is a successful method of producing active CDK:Cyclin protein kinase 
complexes (Lawrie et al., 2001) producing large quantities of protein in the process. This 
expression method allows for the optimal ratio of CDK to cyclin binding, predicted to be 
one CDK molecule to one cyclin, providing active protein kinase complexes. 
The S. cerevisiae CDK activating kinase, Civ1, has been shown to phosphorylate and 
activate CDKs and is essential for cell viability in budding yeast (Thuret et al., 1996). 
GST-Civ1 has been shown in the Mottram laboratory to phosphorylate CRK3his on the T-
loop T178 residue and that this further activates the L. mexicana CRK3:CYCA complex 
showing 3-5-fold higher activity (F.C. Gomes and J.C. Mottram, unpublished data). In 
order to determine whether a Leishmania CRK3:CYC6 protein kinase complex showing 
greater activity could be obtained through Civ1 activation, S. cerevisiae GST-Civ1 was 
purified (Figure 3.5). GST-Civ1 did not phosphorylate histone H1 itself (Figure 3.10) and 
was added to the Leishmania CRK3:CYC6 protein kinase complex and assayed for its 
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ability to activate the complex further. The increasing intensity of the upper band (Figure 
3.11, upper arrow) highlights GST-Civ1 phosphorylating CRK3 on the T178 residue; 
however, no increase in the activity of the Leishmania CRK3:CYC6 protein kinase 
complex was seen (Figure 3.11, lower arrow). GST-Civ1 was therefore not used to activate 
the Leishmania CRK3:CYC6 protein kinase complex further in subsequent assays. This 
unexpected result highlights an interesting difference between the two Leishmania 
CRK3:CYC6 and CRK3:CYCA protein kinase complexes, and raises the question as to 
why GST-Civ1 activates the L. mexicana CRK3:CYCA protein kinase complex 3-5 fold 
but not the Leishmania CRK3:CYC6 protein kinase complex. Structural determination of 
these complexes may provide the answer. 
A new expression and purification system for the histidine tagged Leishmania 
CRK3:CYC6 protein kinase complex was employed to obtain high quantities of active 
soluble protein for further assay development. The method previously used to purify 
CRK3his and CYC6his separately and mix the proteins together in a 1:1 ratio proved 
unacceptable for further assay development. The quantity of active soluble protein 
obtained was insufficient to screen the number of compounds required and so fresh protein 
would need to have been prepared on a weekly basis. Furthermore, there was a problem in 
expressing and purifying soluble L. major CYC6his from bacterial cells at Cyclacel. 
Different cell lines including E. coli BL21 (DE3) pLys-S, Rosetta (DE3) pLys-S, Origami 
(DE3) pLys-S  and Rosetta-Gami (DE3) pLys-S were used in an attempt to obtain large 
quantities of L. major CYC6 but were unsuccessful (data not shown). In the event of no or 
low level protein expression using E. coli, infecting insect cells with baculovirus was 
considered as an alternative expression system. As mentioned, Cyclacel have experience 
with this expression system which has become one of the most widely used systems for the 
production of recombinant proteins (Kost et al., 2005). Furthermore, an advantage that 
baculovirus has over bacterial expression is that proteins that undergo post-translational 
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modifications such as phosphorylation (in this instance, the conserved T-loop T178 residue 
in CRK3) may be obtained in their natural functional form (Fuchs et al., 1995). 
The new method, suggested by Professor Malcolm Walkinshaw at the Edinburgh 
Structural Biochemistry Group was co-expression and co-purification the Leishmania 
CRK3his and CYC6his proteins. Co-expression in E. coli has a number of advantages over 
reconstituting a complex from two separate proteins (Novy et al., 2002), as was performed 
initially with CRK3 and CYC6 for in-gel kinase assays. These include enhanced solubility 
and proper folding of each protein, producing an enhanced yield of active protein complex. 
Co-expression has been performed previously in E. coli with human GST-CDK2 and S. 
cerevisiae GST-Civ1 to phosphorylate CDK2 on the T160 residue. This complex was 
subsequently co-purified with human cyclin A3, to provide a fully phosphorylated active 
CDK2:CycA protein kinase complex (Brown et al., 1999b). However, the co-expression of 
two plasmids in the same cell line has historically had two prerequisites: that the plasmids 
have distinct resistance markers and distinct origins of replication (Yang et al., 2001). It is 
widely believed that plasmids with the same replicon using the same replication machinery 
cannot coexist stably in E. coli and are thereby incompatible plasmids (Datta, 1979). This 
is because the plasmids will compete with each other during replication resulting in the 
cells containing one or the other, but not both plasmids after a few cell generations 
(Sambrook et al., 1989). The generation of co-expression systems has been carried out to 
alleviate this problem, where two plasmids have distinct resistance markers and compatible 
origins of replication (Fribourg et al., 2001) or one plasmid has two multiple cloning sites, 
allowing the expression of two genes (Novy et al., 2002).  
However, Leishmania CRK3:CYC6 was expressed via incompatible plasmids (section 
2.4.2 and figure 3.1) (CRK3 in pET28a and CYC6 in pET15b) which according to the 
literature is likely to be unsuccessful. Although these pET vectors have two distinct 
antibiotic resistance markers (pET28a, kanamycin and pET15b, ampicillin), they have a 
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common origin of replication, pBR322, and therefore only one plasmid could remain as 
previously discussed. Co-expression of CRK3:CYC6 from T. brucei previously proved 
unsuccessful (E. Brown and J.C. Mottram, unpublished). In relation to the co-expression of 
Leishmania CRK3:CYC6, it has previously been described that two incompatible plasmids 
(pET21a and pET28a, Novagen) had been co-expressed in E. coli due to the selection 
pressure of the antibiotics for 14 hours (Yang et al., 2001). Co-purification has also been 
successfully carried out with His-tagged human cyclin B1 and HA-tagged human Cdc2 
expressed in insect cells (Moore et al., 1999). These examples show that co-expression and 
co-purification methods are successful in producing active protein kinase complexes. From 
1 litre of bacterial culture, co-expression and co-purification produced 4.5mg of 
Leishmania CRK3:CYC6 protein kinase complex whose activity was suitable for further 
radiometric assay development. This quantity of Leishmania CRK3:CYC6 was sufficient 
and active enough, expressing the complex in a 1:1 ratio and therefore baculovirus 
expression was not required.  
Leishmania CRK3:CYC6 protein kinase activation was established in a gel-based assay; 
however, it was vital this activity could be transferred to a plate based assay, as this is the 
method used at Cyclacel for low to medium throughput compound screening. In order to 
be useful for compound screening, assay criteria at Cyclacel require an assay to have a 
signal to background ratio of at least 10:1. An important aspect of assay development is to 
optimize the assay conditions in order to obtain a high signal to background ratio. This 
would enable compounds that are genuine inhibitors of the target to be identified with 
confidence from a background signal within the signal window. An initial activity assay 
carried out identified 7.5ng of protein complex producing counts of approximately 15,000 
per minute compared to a background of approximately 1000 counts per minute, a signal to 
background ratio of approximately 15:1. Leishmania CRK3:CYC6 protein kinase activity 
was therefore suitably high to proceed with further assay development (Figure 3.13). The 
activity and signal to background ratio of the CRK3:CYC6 assay was comparable with a 
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number of other protein kinase assays developed at Cyclacel, which were used in the 
counter screening of the HTS hits against mammalian CDKs (section 4.12). By 
comparison, the plate-based assay was validated using 7.5ng of Leishmania CRK3:CYC6 
protein kinase complex per assay point, which is significantly lower than that used in the 
in-gel assays, where micrograms (µg) of Leishmania CRK3:CYC6 proteins were being 
used to visualise protein kinase activity.  
In initial experiments to establish whether to use recombinant Leishmania CRK3:CYC6 
protein kinase complex or CRK3his purified from L. mexicana parasites for assay 
development; some biochemical analysis was carried out on the Leishmania CRK3:CYC6 
protein kinase complex. The Km values for ATP and a histone H1 substrate were 
determined (Figure 3.15). The Km of ATP for the purified enzyme from the parasite is 
35µM as determined by Karen Grant. The Km of ATP for the Leishmania CRK3:CYC6 
complex was 64µM ± 26µM, within two-fold of the parasite enzyme (Figure 3.15, upper 
graph), suggesting that the two CRK3 enzymes are biochemically similar. The Km for the 
histone H1 substrate was determined at 2.4µM ± 0.48µM (Figure 3.15, lower graph); 
however, this has not been determined for the purified enzyme from L. mexicana parasites. 
In the radiometric assay, 100µM ATP and 3.6µM of histone H1 substrate are used per 
assay point. These quantities are sufficiently above the Km values, generating an acceptable 
signal window, without saturating the assay.      
Further analysis of the Leishmania CRK3:CYC6 protein kinase complex was carried out to 
determine the IC50 values for staurosporine, a broad range kinase inhibitor, and 
olomoucine, a potent inhibitor of mammalian cdc2 with a narrow range of selectivity 
(Meijer, 1996). The IC50 value for staurosporine was 37nM (Figure 3.16, upper graph) and 
was potent towards Leishmania CRK3:CYC6 protein kinase activity as expected. 
However, the IC50 value for staurosporine against L. mexicana parasite CRK3 is currently 
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unknown and therefore could not be compared with the recombinant complex. The IC50 
value for olomoucine against CRK3 purified from L. mexicana parasites is 42µM (Grant et 
al., 1998) and was determined as 51µM against the Leishmania CRK3:CYC6 protein 
kinase complex (Figure 3.16, lower graph). These values are almost identical, further 
suggesting that the two enzymes are biochemically similar. Therefore it could be 
hypothesised that active CRK3 purified from Leishmania may be in complex with CYC6, 
and that CYC6 could be an in vivo partner of CRK3. On the other hand, parasite CRK3 
may be in complex with another cyclin such as CYCA, whose complex may share similar 
biochemical characteristics to those of recombinant Leishmania CRK3:CYC6. Purifying 
CRK3 from Leishmania and analysing it via SDS-PAGE and Colloidal Blue staining may 
identify other proteins associated with CRK3. These could be analysed by peptide mass 
fingerprinting to help identify in vivo partners of CRK3, of which, CYC6 may be one. As 
the biochemical analysis suggested both the recombinant and parasite purified enzymes 
were similar, it was decided to use the recombinant Leishmania CRK3:CYC6 protein 
kinase complex for future assay development, as significant active quantities could be 
purified.     
A preliminary screen of compounds from a number of in-house compound libraries was 
carried out to assess the developed radiometric assay and as a basis for the future high 
throughput screening of the Leishmania CRK3:CYC6 protein kinase complex. The screen 
returned four compounds which were active towards CRK3:CYC6 and were screened to 
determine their IC50 values. IC50 determinations showed two were potent inhibitors of 
human CDK2:CycE and were not pursued, with the remaining two inactive towards human 
CDK2:CycE. The structures of the two compounds active against the Leishmania 
CRK3:CYC6 protein kinase complex and inactive against human CDK2:CycE are shown 
in Figure 3.17. However, although Vx-680 is inactive towards human CDK2:CycE, it has 
been shown to be potent towards all three Aurora kinases. The apparent inhibition 
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constants (Ki (app)) were 0.6, 18 and 4.6nM for Aurora-A, Aurora-B and Aurora-C, 
respectively (Harrington et al., 2004). Intellectual properties not withstanding, these two 
compounds could be possible starting pharmacophores for structural chemistry to make 
compounds more potent towards the Leishmania CRK3:CYC6 protein kinase complex. 
However, a wider library screen of approximately 25,000 compounds from the Cyclacel 
library was undertaken using a high throughput screening platform to identify more 
suitable candidates (Chapter 4). 
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Chapter 4 
High throughput assay development and screening. 
4.1 Chapter introduction and objectives. 
The radiometric 32P assay developed for the Leishmania CRK3:CYC6 protein kinase 
complex described in chapter 3 is suitable for low to medium throughput compound 
screening; however, it is not a suitable platform for high throughput screening. This is due 
to the high quantities of radiation required for the assays and the time restraints imposed by 
the assay protocol, as it is carried out manually. As a result, the radiometric Leishmania 
CRK3:CYC6 assay was used as a reference assay to develop and validate a high 
throughput assay platform suitable for screening the 25,000 compound Cyclacel library. 
The high throughput screening approach utilised Cyclacel’s experience in library screening 
by using the automated assay facilities capable of processing up to 10,000 assay points per 
day. 
Three high throughput screening platforms were considered for the screen; ALPHA-
screenTM luminescence from Perkin Elmer (www.perkinelmer.com), IQTM fluorescence 
quenching from Pierce Biotechnology (www.piercenet.com) and IMAPTM fluorescence 
polarization from Molecular Devices (www.moleculardevices.com). The ALPHA-
screenTM (Amplified Luminescent Proximity Homogenous Assay) platform is a 
luminescence assay that uses a substrate bound to a donor bead and a phospho-specific 
antibody bound to an acceptor bead. Antibody binding to the phosphorylated substrate 
brings the acceptor bead into close proximity with the donor bead, resulting in light 
emission (www.perkinelmer.com). The IQTM (Intensity Quenching) platform is a 
fluorescence quenching assay that uses a proprietary iron-containing compound that reacts 
with phosphate groups on a fluorescently labelled peptide. Binding results in a change in 
relative fluorescence units which correlates directly to the number of peptides containing 
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phosphate groups (www.piercenet.com). The IMAPTM (Immobilized Metal Affinity-based 
fluorescence Polarization) technology is a fluorescence polarization assay that uses 
technology based on the specific, high-affinity interaction of trivalent metal containing 
nanoparticles with phosphogroups. Fluorescently-labelled peptides are phosphorylated in a 
kinase reaction. Addition of the IMAP binding system stops the kinase reaction and 
specifically binds the phosphorylated substrates. Phosphorylation and subsequent binding 
of the substrate to the beads can be detected by fluorescence polarization (Figure 4.1) 
(www.moleculardevices.com).  
The IMAPTM platform (Figure 4.1) was chosen to carry out the high throughput screen. 
This was because the IMAPTM technology was the most up-to-date and because the other 
assay formats had prior requirements unlike the IMAPTM assay. The ALPHA-screenTM 
assay required an antibody and substrate pair and the IQTM assay required a specific 
peptide substrate which was unavailable commercially and required synthesizing at a large 
cost. As the IMAPTM platform did not have these prerequisites it was used for the high 
throughput screening of Leishmania CRK3:CYC6. 
This chapter will focus on the IMAPTM assay that was developed, optimised and validated 
for Leishmania CRK3:CYC6. With this, the high throughput screening of Leishmania 
CRK3:CYC6 was carried out in order to identify inhibitors of Leishmania CRK3:CYC6 
protein kinase activity within the Cyclacel library. Counter screening of the hits against 
mammalian kinases was carried out to determine the selectivity of the inhibitors towards 
Leishmania CRK3:CYC6. Follow up and related work on the identified hits will also be 
discussed in the chapter.  
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Figure 4.1 – IMAPTM fluorescence polarisation assay schematic. The kinase reaction 
(enzyme, fluorescent substrate, ATP and plus or minus inhibitor) is set up in a volume of 
20µl and incubated for 1 hour 20 minutes at room temperature. The kinase adds a 
phosphate (PO43-) group from the ATP onto the substrate. 50µl of the binding reagent 
(orange) is added to both stop the reaction and bind the fluorescently labelled phospho-
peptide. This results in a reduction in rotational speed and an increase in fluorescence 
polarization which is detected in a microplate reader. 
www.moleculardevices.com 
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4.2 Optimum substrate identification for Leishmania CRK3:CYC6. 
In order to identify the optimal substrate for CRK3:CYC6 for use in the IMAPTM HTS 
format, a substrate finder assay was carried out. The plate had 61 potential serine/threonine 
protein kinase substrates and the specific substrate finder assay protocol is shown in Figure 
4.2. The raw data (Fluorescence polarization, mP) was pasted in to a data analysis 
programme provided by Molecular Devices, which generated a bar chart highlighting the 
background signal and specific signal for each peptide substrate and pre-phosphorylated 
calibrator peptides (Figure 4.3). The background signal was subtracted leaving the specific 
signal for each peptide substrate (Figure 4.4). Of the 61 peptide substrates on the plate, 6 
showed a specific signal (∆mP) of >100mP. The greatest ∆mP was with a generic 
serine/threonine kinase substrate peptide sequence GGGRSPGRRRRK (310mP), then a 
histone H1 derived peptide GGGPATPKKAKKL (295mP), then a short histone H1 
derived peptide (amino acids 9-18) PKTPKKAKKL (280mP), then DYRKtide 
RRRFRPASPLRGPPK (190mP), then a CDK7 derived peptide FLAKSFGSPNRAYKK 
(180mP) and recombinant histone H1 protein (100mP) (Figure 4.4). Analysis of the 6 
peptide substrates highlighted that they all contained a sequence pattern xS/TPxR/K, which 
is in accordance with the optimal recognition motif for CDKs, x
-1(S/T0)P+1x+2(K/R+3) 
(Stevenson-Lindert et al., 2003) (Figure 4.5). The generic peptide substrate was chosen as 
the optimum substrate and used in all subsequent IMAPTM assays. 
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Figure 4.2 – IMAPTM substrate finder assay schematic. The fluorescently labelled 
peptide substrates are reconstituted via the addition of ATP in the complete reaction buffer 
(CRB). CRB ± enzyme is added and incubated for 1 hour 20 minutes at room temperature. 
The IMAPTM binding solution is added, and the reaction incubated for a further 1 hour 20 
minutes at room temperature before the plate was read in a microplate reader. 
www.moleculardevices.com 
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Figure 4.3 – IMAPTM substrate finder assay analysis using Molecular Devices data 
analysis software. Fluorescence polarization data was analysed using the data analysis 
macro provided by Molecular Devices. The bar chart shows the corresponding background 
and specific polarization signal (mP) generated by each of the 61 substrates and pre-
phosphorylated control peptides.  
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Figure 4.4 – IMAPTM substrate finder assay to identify the best substrates of 
CRK3:CYC6 for the HTS assay. A substrate plate containing 61 potential 
serine/threonine kinase substrates was assayed as described in Figure 4.2. Six substrates 
were identified showing a fluorescence polarization change >100mP. The generic sequence 
peptide was the optimum substrate for CRK3:CYC6 showing the greatest change in 
fluorescence polarization (∆mP).  
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Figure 4.5 – IMAPTM substrate finder sequence analysis. The five peptides identified as 
substrates for CRK3:CYC6 were analysed by sequence alignment. The consensus 
sequence pattern follows the optimal recognition motif identified for mammalian CDKs. 
Highlighted in red are the serine/threonine amino acid residues (in the 0 position) which 
are phosphorylated by the CRK3:CYC6 protein kinase complex. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Amino acid position: 
 
     -1 0 +1 +2 +3 
histone H1 derived:       G G G P A T P K K A K K L 
 
Generic sequence:          G G G R S P G R R R R K 
 
Short histone H1 derived:         P K T P K K A K K L  
 
DYRKtide:        R R R F R P A S P L R G P P K 
 
CDK7 derived:     F L A K S F G S P N R A Y K K   
Optimal recognition motif for CDKs: x
-1 (S/T0) P+1 x+2 (K/R+3) 
Sequence pattern:  x S/T P x R/K 
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4.3 Leishmania CRK3:CYC6 two-fold enzyme titration. 
In order to establish the quantity of CRK3:CYC6 to be used in the IMAPTM HTS assays, a 
two-fold enzyme titration was carried out (Figure 4.6). Carrying out the assay as described 
in 2.6.2, the titration identified that 1.25ng of kinase complex could be used per assay 
point. When running the assay for 1 hour 20 minutes, this produced a signal of 
approximately 280mP with a ∆mP of 180mP and was in the linear phase of the assay. The 
assay was validated under these conditions with a Z’ score of 0.71 which is considered 
excellent in terms of assay quality (Zhang et al., 1999; Iversen et al., 2006) where the 
assay is reliable, robust and suitable for HTS (Yuhong et al., 2007).  
4.4 Leishmania CRK3:CYC6 ATP Km determination. 
A kinase assay was performed in order to establish the Km value of ATP in the HTS format 
(Figure 4.7), to compare with the radiometric assay determination (Figure 3.15, Upper 
graph). A two-fold titration of ATP was set up resulting in concentrations of ATP ranging 
from 2µM to 1mM in the assay. The Km value of ATP was determined to be 152µM ± 
13.4µM for CRK3:CYC6.  
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Figure 4.6 – CRK3:CYC6 IMAPTM assay development and validation – enzyme 
titration. Using the generic sequence peptide as the substrate, a two-fold enzyme titration 
was carried out. The kinase assay was carried out as described in 2.6.2. This identified that 
1.25ng of CRK3:CYC6 could be used in the IMAP high throughput screen format. 
Graphical analysis was carried out using XLfit 4.0 software from IDBS (www.idbs.com). 
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Figure 4.7 – ATP Km determination for CRK3:CYC6 using the IMAPTM HTS assay. 
The Km value for ATP was determined for the CRK3:CYC6 complex. This was 
determined at 154µM ± 13µM. Graphical analysis was carried out using XLfit 4.0 software 
from IDBS (www.idbs.com) with a Km determination model. 
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4.5 Staurosporine and olomoucine IC50 determinations for Leishmania 
CRK3:CYC6. 
The IC50 values for staurosporine and olomoucine were determined for the CRK3:CYC6 
complex in the HTS format (Figure 4.8), to compare with those determined in the 
radiometric assay (Figure 3.16). The IC50 value for staurosporine was determined at 20nM 
(Figure 4.8, upper graph) and >10µM for olomoucine (Figure 4.8, lower graph).  
4.6 Preliminary compound screen against Leishmania CRK3:CYC6. 
The 193 compound preliminary screen in chapter 3 was repeated using the HTS format to 
determine if the newly developed assay would identify the same hits as found in the 
radiometric assay. 34 hits were expected, as 5/39 found were false positives in the 
radiometric assay. As expected, these 34 hits were all identified showing the developed 
assay was functional and valid (data not shown).  
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Figure 4.8 – Biochemical characteristics of CRK3:CYC6 using the IMAPTM HTS 
assay. The IC50 values for staurosporine (upper graph) and olomoucine (lower graph) 
protein kinase inhibitors against CRK3:CYC6 were determined. Graphical analysis was 
carried out using XLfit 4.0 software from IDBS (www.idbs.com). 
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4.7 Development of an IMAPTM assay suitable for counter screening against 
human CDK2:CycA: 
4.7.1 Human CDK2:CycA two-fold enzyme titration. 
In order to establish the quantity of CDK2:CycA to be used in the IMAPTM HTS assays, a 
two-fold enzyme titration was carried out (Figure 4.9). The CDK2:CycA kinase complex 
was produced in-house at Cyclacel via baculovirus protein expression. Carrying out the 
assay as described in figure 4.1, the titration identified that 33ng of CDK2:CycA could be 
used per assay point. When running the assay for 1 hour 20 minutes, this produced a ∆mP 
signal of approximately 200mP and was in the linear phase of the assay. The assay was 
fully validated under these conditions with a Z’ score of 0.67.  
4.8 High throughput screening of the Cyclacel compound library: 
4.8.1 Leishmania CRK3:CYC6 and human CDK2:CycA IMAPTM fluorescence 
polarization HTS assays. 
The Cyclacel compound library screened against CRK3:CYC6 and CDK2:CycA contained 
approximately 25,000 compounds. This was comprised of two subset libraries which are 
described in Table 4.1. The Cyclacel library was screened against Leishmania 
CRK3:CYC6 and mammalian CDK2:CycA using IMAPTM fluorescence polarization 
technology (Figure 4.1). The assays were carried out as described in the methods section 
using the high throughput screening robotic technology at Cyclacel. The compound library 
was initially screened against Leishmania CRK3:CYC6 at a fixed concentration of 10µM 
and the data analysed using IDBS Activity Base software (www.idbs.com). 
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Figure 4.9 – Human CDK2:CycA IMAPTM assay development and validation. Using 
the generic sequence peptide identified, a two-fold enzyme titration was carried out. The 
kinase assay was carried out as described in figure 4.1. This identified that 33ng of human 
CDK2:CycA can be used in the IMAPTM high throughput screen format. Graphical 
analysis was carried out using XLfit 4.0 software from IDBS (www.idbs.com). 
CDK2/A 2-fold Enzyme Titration 
Fit CDK2/A titration plate 2, dilution 1
Fl
u
o
re
sc
e
n
ce
 
Po
la
riz
a
tio
n
 
(m
P)
Enzyme dilution 
0 0.04 0.08 0.12 0.16 0.2
140
160
180
200
220
240
260
280
300
320
340
360
380
400
= 33ng 
  
123 
 
 
Natural product mimic library: kinase 
inhibitor themes, sugar nucleoside 
mimics, protease inhibitor themes, 
steriod mimics, aminoglycoside mimics 
and phosphatase inhibitor themes.
Desirable pharmaceutical properties 
(Lipinski rules, ADME properties)
Published Adenine, Pyrimidine, 
Quinazoline and Quinoxaline CDK 
inhibitors.
10 heterocyclic themes
Heterocycle library 1 (HL-1)6 synthetic themes
~8,000 compounds~16,000 compounds
Kinase Inhibitor Theme libraryHeterocycle Library 2 (HL-2)
  
Table 4.1 – The Cyclacel compound library breakdown. The compound library is 
composed of two sub-libraries, the heterocycle 2 and kinase inhibitor theme libraries. They 
include known kinase inhibitors and natural product mimics as well as synthetic 
compounds. The heterocycle 2 compounds were designed with desirable pharmaceutical 
properties. 
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The screen identified 43 Cyclacel compounds that produced a ≥50% inhibition of 
Leishmania CRK3:CYC6 protein kinase activity (Table 4.2, columns 1-4). The Cyclacel 
library was subsequently screened against human CDK2:CycA to both filter out any of the 
CRK3:CYC6 hits that target the human kinase, and to potentially provide more useful 
structure activity relationship (SAR) data as the library had not previously been screened 
against human CDK2:CycA. None of the 43 CRK3:CYC6 hits inhibited human 
CDK2:CycA significantly (Table 4.2, column 5) and therefore all were taken forward for 
secondary screening against CRK3:CYC6 to determine their IC50 values. The IC50 value 
determinations were carried out using the radiometric 32P assay resulting in values ranging 
from 2.6µM to >50µM (Table 4.2, column 6).  
In order to confirm the 43 hits did not significantly target mammalian CDK2:CycA, IC50 
values were determined for this kinase complex. All 43 compounds returned IC50 values 
>50µM (Table 4.2, column 7) confirming the primary screen data for mammalian 
CDK2:CycA (Table 4.2, column 5). Based on the results, the compounds were divided into 
three groups; the top 18 which were taken forward for mammalian kinase counter 
screening (Table 4.2, Red); compounds not analysed further (Table 4.2, Blue) and 
compounds which were false positives and did not target CRK3:CYC6 (Table 4.2, Black). 
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Compound
Molecular                    
Weight                     
(g/mol)
Structure  % inhibition of CRK3:CYC6 
% inhibition of 
CDK2:CycA 
CRK3:CYC6 
IC50 (µM)
CDK2:CycA 
IC50 (µM)
Compound 1 541.69 69.9 13.2 2.6 >50
Compound 2 314.39 59 3.7 2.67 >50
Compound 3 491.67 67.7 6 3.42 >50
Compound 4 345.48 57.5 9.4 3.62 >50
Compound 5 396.49 70.6 5.3 4.35 >50
Compound 6 465.59 72.3 5.3 4.38 >50
Compound 7 422.52 70.6 11.9 5.27 >50
Compound 8 378.47 65.7 9.1 5.79 >50
Compound 9 394.51 60 14 5.98 >50
Compound 10 436.55 73.1 12.3 6.9 >50
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Compound
Molecular                    
Weight                     
(g/mol)
Structure  % inhibition of CRK3:CYC6 
% inhibition of 
CDK2:CycA 
CRK3:CYC6 
IC50 (µM)
CDK2:CycA 
IC50 (µM)
Compound 11 356.47 57.4 14.1 7.14 >50
Compound 12 539.71 69.8 0.8 7.83 >50
Compound 13 408.54 55.2 7 8.12 >50
Compound 14 380.49 52.7 15.7 8.76 >50
Compound 15 427.54 53.2 -4.9 8.94 >50
Compound 16 550.69 67.9 1.4 10.12 >50
Compound 17 539.67 58.8 16.6 10.26 >50
Compound 18 438.57 60.9 4.3 10.69 >50
Compound 19 422.52 63.3 3.6 11.76 >50
Compound 20 418.49 60.8 -12.1 12.78 >50
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Compound
Molecular                    
Weight                     
(g/mol)
Structure  % inhibition of CRK3:CYC6 
% inhibition of 
CDK2:CycA 
CRK3:CYC6 
IC50 (µM)
CDK2:CycA 
IC50 (µM)
Compound 21 317.43 53.4 -20.8 15.4 >50
Compound 22 422.57 67.5 2.3 15.68 >50
Compound 23 505.69 63.8 11.2 15.78 >50
Compound 24 503.68 58.1 2.8 16.18 >50
Compound 25 485.57 53.1 4.3 16.96 >50
Compound 26 489.66 63.3 1.6 17.9 >50
Compound 27 502.61 60.7 3.9 18.1 >50
Compound 28 460.57 48 2.1 21.16 >50
Compound 29 350.45 64 2 21.98 >50
Compound 30 433.59 54.3 4.5 22.73 >50
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Compound
Molecular                    
Weight                     
(g/mol)
Structure  % inhibition of CRK3:CYC6 
% inhibition of 
CDK2:CycA 
CRK3:CYC6 
IC50 (µM)
CDK2:CycA 
IC50 (µM)
Compound 31 438.57 47.6 4.9 23.03 >50
Compound 32 431.61 47 9.9 27.71 >50
Compound 33 350.49 48 1.9 29.07 >50
Compound 34 391.55 52.6 2.5 29.32 >50
Compound 35 423.55 49.1 8.8 30.15 >50
Compound 36 428.53 48 10.1 41.07 >50
Compound 37 302.42 61.2 8.1 41.22 >50
Compound 38 423.55 56 14.7 >50 >50
Compound 39 473.54 52 1.1 >50 >50
Compound 40 360.45 50.2 23 >50 >50
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Compound
Molecular                    
Weight                     
(g/mol)
Structure  % inhibition of CRK3:CYC6 
% inhibition of 
CDK2:CycA 
CRK3:CYC6 
IC50 (µM)
CDK2:CycA 
IC50 (µM)
Compound 41 343.47 50 3.7 >50 >50
Compound 42 359.51 47.6 4.3 >50 >50
Compound 43 401.55 45.3 15.9 >50 >50
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Table 4.2 – CRK3:CYC6 and CDK2:CycA primary and secondary screening 
summary. The compound numbers and structures are shown for the 43 hits identified from 
the HTS and are ranked, top to bottom, in order of their IC50 value towards CRK3:CYC6 
(Column 6) . The primary screening data (% inhibition) and secondary screening data (IC50 
value) for the 43 hits identified from the HTS are shown for CRK3:CYC6 (Columns 4 and 
6, respectively) and CDK2:CycA (columns 5 and 7, respectively). Compounds in red are 
those that were taken forward for screening against the mammalian kinase counter 
screening panel (Table 4.6). Those in blue are compounds that were not taken forward for 
further analysis. Those in black were determined to be false positives and not active 
towards CRK3:CYC6. 
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4.9 Structural analysis of the high throughput screen hits. 
The secondary data confirmed there were 6 false positive hits from the CRK3:CYC6 high 
throughput screen. This resulted in 37 Cyclacel compounds that targeted CRK3:CYC6. 
The 18 compounds that had IC50 values ranging from 2.6µM to approximately 10µM were 
chosen and taken forward for further mammalian kinase counter screening. The chemical 
structures of these 18 compounds were analysed and two distinct pharmacophores were 
identified, azapurine and aminopyridazine-3-carboxamide (Figure 4.10). Of the 18 
structures, 14 were azapurines and 4 were aminopyridazine-3-carboxamides. 
4.10 Structure activity relationship of the azapurines towards Leishmania 
CRK3:CYC6. 
In order to determine some further SAR data for the azapurine class of compounds, the 
effect of modifications of the bulky groups on positions 2 and 9 of the azapurine ring was 
analysed. This focused on the methoxybenzene ring on the 9 position and the 
cyclohexylmethyl group on the 2 position (Figure 4.11).  
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                               Aminopyridazine-3-carboxamide core structure 
 
 
Figure 4.10 – Main compound core structures identified from the CRK3:CYC6 high 
throughput screen. The azapurine (upper structure circled in red) had a variable R1 
group, a methoxybenzene ring on the 9 position and a cyclohexylmethyl group on the 2 
position. The aminopyridazine-3-carboxamide (lower structure circled in red) had variable 
R1 and R2 groups and had a cyclohexylmethyl group attached to the nitrogen atom on the 
3 position. 
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Figure 4.11 – Azapurine core structures minus the methoxybenzene ring (upper 
structure) and the cyclohexylmethyl groups (lower structure). Homologues of the 
azapurine structure with the modifications at the 2 and 9 positions shown above were 
chosen and screened. This was to highlight the importance of these particular groups in the 
molecules inhibiting CRK3:CYC6 protein kinase activity. 
Modified 2 position 
Modified 9 position 
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Initially, 4 hits from the Leishmania CRK3:CYC6 screen were chosen, compound 3, 
compound 6, compound 18 and compound 9 (Tables 4.3, 4.4 and 4.5 in red). With regard 
to the methoxybenzene ring group changes, one homologue of each hit was chosen which 
had identical R1 and cyclohexylmethyl groups but a modified methoxybenzene group at 
the 9 position of the azapurine ring (Figure 4.11, upper structure and Table 4.3, compounds 
in black). Replacement of the methoxybenzene ring at the 9 position resulted in at least a 
5-fold loss of activity against Leishmania CRK3:CYC6.  
This approach was also used to determine if modifications to the cyclohexylmethyl group 
contributed to any loss of activity. Two homologues of each hit were chosen with identical 
R1 groups and a methoxybenzene ring on the 9 position, with replacements in the 2 
position (Figure 4.11, lower structure and tables 4.4 and 4.5, compounds in black). 
Deletion of the cyclohexylmethyl group and its replacement by a less bulky group also 
resulted in at least a 5-fold loss of activity against the target enzyme.  
These compounds with modifications were inactive towards Leishmania CRK3:CYC6, all 
returning IC50 values >50µM (Tables 4.3, 4.4 and 4.5). This highlights the importance of 
the methoxybenzene and cyclohexylmethyl groups at their appropriate positions within the 
azapurine ring structure for inhibiting Leishmania CRK3:CYC6 protein kinase activity. 
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Table 4.3 – Analysis of the azapurine methoxybenzene ring modifications at the 9 
position. Four azapurine hits identified from the CRK3:CYC6 HTS were chosen (red). A 
homologue of each, with the same R1 and cyclohexylmethyl groups but with a modified 
group in place of the methoxybenzene ring was chosen (black). The IC50 values of the hits 
and their homologues are shown highlighting the importance of the methoxybenzene ring 
in inhibiting CRK3:CYC6 protein kinase activity. 
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Table 4.4 – Analysis of the azapurine cyclohexylmethyl group modifications at the 2 
position (1). Two azapurine hits identified from the CRK3:CYC6 HTS were chosen (red). 
Two homologues of each, with the same R1 and methoxybenzene ring groups but with a 
modified group in place of the cyclohexylmethyl were chosen (black). The IC50 values of 
the hits and their homologues are shown highlighting the importance of the 
cyclohexylmethyl group in inhibiting CRK3:CYC6 protein kinase activity. 
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Table 4.5 – Analysis of the azapurine cyclohexylmethyl group modifications at the 2 
position (2). Two additional azapurine hits identified from the CRK3:CYC6 HTS were 
chosen (red.) Two homologues of each, with the same R1 and methoxybenzene ring 
groups but with a modified group in place of the cyclohexylmethyl were chosen (black). 
The IC50 values of the hits and their homologues are shown again highlighting the 
importance of the cyclohexylmethyl group in inhibiting CRK3:CYC6 protein kinase 
activity. 
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4.11 Mammalian kinase counter screening of the Leishmania CRK3:CYC6 
hits. 
The 18 compounds chosen were taken forward to screen against an expanded protein 
kinase panel to determine their selectivity. Ten mammalian protein kinases were selected 
from Cyclacel’s in-house protein kinase panel and are shown in Table 4.6. The 18 
compounds were screened against the 10 mammalian kinases to determine their IC50 values 
for each. The 9 most potent compounds are shown ranked in order of their potency towards 
CRK3:CYC6 (Table 4.7, right hand column in red). Similarly, the remainder of the 18 hits 
screened are shown, again ranked in order of their potency against CRK3:CYC6 (Table 
4.8, right hand column in red). The majority of the 18 compounds are inactive against all 
10 kinases generating IC50 values >50µM with the following exceptions. Compound 3 has 
an IC50 value of 33.12µM against Plk1 while compound 13 and compound 18 have IC50 
values of 13.1µM and 9.68µM, respectively against Abl.  
Of most interest with regard to the selectivity question is the CDK4:CycD1 data, where it 
is seen that all but four compounds show a degree of inhibition of CDK4:CycD1. The four 
compounds that do not show inhibition of the enzyme, compound 2, compound 4 (Table 
4.7), compound 11 and compound 15 (Table 4.8) are all aminopyridazine-3-carboxamides. 
The remaining 14 compounds that do inhibit CDK4:CycD1, with IC50 values <30µM, are 
all azapurines. This highlights a useful structure activity relationship (SAR) data for the 
two pharmacophores identified from the Leishmania CRK3:CYC6 HTS and will be 
discussed in more detail later in this chapter. 
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CDKCMGCSer/ThrCDK9:CycT1
PDGFRTKRTKFlt3
AblTKTKAbl
AUROtherSer/ThrAurora A
PLKOtherSer/ThrPlk1
GSKCMGCSer/ThrGSK3
CDKCMGCSer/ThrCDK7:CycH
CDKCMGCSer/ThrCDK4:CycD1
CDKCMGCSer/ThrCDK1:CycB
AKTAGCSer/ThrAkt/PKB
FamilyGroupClassKinase 
     
 
Table 4.6 – Protein kinase counter screening panel. The table shows the 10 protein 
kinases chosen to counter screen with the CRK3:CYC6 HTS hits. These were chosen to 
include a number of kinases from the serine/threonine class and some from the tyrosine 
kinase class. 
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4.12. Alternative approaches to identify Leishmania CRK3:CYC6 inhibitors. 
In addition to screening the Cyclacel library, alternative approaches were employed to 
identify inhibitors of Leishmania CRK3:CYC6 protein kinase activity. This involved 
molecular modelling and an in silico screen as well as testing additional compounds on the 
Leishmania CRK3:CYC6 protein kinase complex. 
4.12.1 Screening of Naphthostyril derivatives against Leishmania 
CRK3:CYC6. 
A L. mexicana CRK3 homology model based on mammalian CDK2 was generated by Kirk 
Malone at the Manchester Interdisciplinary Biocentre (MIB). The molecular modelling 
was carried out using Accelrys Discovery Studio software 
(www.accelrys.com/products/dstudio/). An in silico screen was carried out against the 
CRK3 homology model using the virtual compound library accompanying the software. 
Naphthostyril was the top hit identified, which gave the best docking score against CRK3 
and whose binding mode compared favourably to the binding of known inhibitors of 
CDK2. Subsequently, Naphthostyril (Figure 4.12, top left structure) and 11 derivatives of 
the naphthostyril structure were synthesised and screened against CRK3:CYC6 to 
determine their potency by IC50 value determination. All 12 compounds tested, however, 
proved to be inactive against CRK3:CYC6, with IC50 values >50µM (data not shown). 
4.12.2 Screening of Indirubin derivatives against Leishmania CRK3:CYC6. 
The Indirubin compounds are known inhibitors of CDKs (Hoessel et al., 1999; 
Polychronopoulos et al., 2004). Based on the structure in figure 4.13 (top left), a number of 
indirubin derivatives were obtained from Karen Grant at the University of Lancaster and 
Nick Westwood at the University of St. Andrews (Figure 4.13). Four of the compounds, 
TW3, TW21, TW23 and TW27 have been screened against transgenic CRK3 to determine 
their IC50 values but had not been tested against promastigote Leishmania or macrophages 
(Table 4.9). Similarly, compounds whose activity is described as ND (not determined) 
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were not tested against Leishmania infected macrophages. The remainder of the 
compounds were tested against promastigote Leishmania and amastigote Leishmania in a 
macrophage infection at a single concentration of 10µM by Karen Grant. A brief 
description of the effect of each compound on the cell cycle of promastigote Leishmania 
and the activity against amastigotes in an infection assay (clearing amastigotes from 
macrophages and reducing the infection) is included in Table 4.9, columns 6 and 7, 
respectively.  
The indirubin derivatives were screened at 10µM against CRK3:CYC6 and human 
CDK2:CycA. IC50 determinations for CRK3:CYC6 were performed and selected 
compounds were taken forward for screening against human CDK2:CycA and 
CDK1:CycB. Of the 55 Indirubins screened against CRK3:CYC6, 10 had IC50 values 
<1µM, only one of which, DT-IND-83 showed good selectivity over the two human CDKs 
(Table 4.9). Of those others tested, a further three showed selectivity towards CRK3:CYC6 
(Table 4.9, red asterisk) and two towards mammalian CDK2:CycA over CRK3:CYC6 
(Table 4.9, blue asterisk).  
  
143 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NH
O
OHO
O OH
N
HO
OHO
    Naphthostyril         KM15 CAS 605-70-9 
 
N
HO
N
H
O
N
HO
N
H
O
N
H
O
O
 KM51    KM28 
N
HO
N
H
O N
N
HO
NHO
Cl
N
HO
N
H
O O
  KM33  KM34_2   KM50 
  
144 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12 – The chemical structure of Naphthostyril and derivatives. The top left 
structure (page 141), naphthostyril, identified through an in silico screen as a potential 
compound to target CRK3:CYC6 was used as a scaffold to generate 11 derivatives which 
were screened against Leishmania CRK3:CYC6. 
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Figure 4.13 – The chemical structure of Indirubin and derivatives. The top left 
compound (page 143), Indirubin, a known inhibitor of GSK3 and CDKs, was used as a 
scaffold to generate several derivatives, which were screened against CRK3:CYC6. 
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4.13 Chapter discussion 
The optimum fluorescent peptide substrate for Leishmania CRK3:CYC6 was identified 
from a plate containing 61 potential serine/threonine kinase substrates identified from the 
literature. Of the 61 peptide substrates on the plate, 6 showed a specific signal (∆mP) of 
>100mP (Figures 4.3 and 4.4). The greatest ∆mP values were for a generic peptide 
sequence (GGGRSPGRRRRK), a histone H1 derived peptide (GGGPATPKKAKKL), a 
short histone H1 derived peptide (amino acids 9-18) (PKTPKKAKKL), DYRKtide 
(RRRFRPASPLRGPPK), a CDK7 derived peptide (FLAKSFGSPNRAYKK) and 
recombinant histone H1 protein. Interestingly, the recombinant histone H1 as used in the 
radiometric assay is not the optimum substrate for Leishmania CRK3:CYC6 in the 
IMAPTM assay, producing a ∆mP approximately one third of the generic peptide i.e. 
100mP versus 300mP (Figure 4.4). This is because fluorescence polarization works best 
with peptides rather than proteins in an IMAPTM format. Sequence alignment and analysis 
showed that the five peptide substrates identified exhibited a consensus sequence pattern: x 
S/T P x R/K (Figure 4.5). This consensus sequence pattern follows the minimal recognition 
motif identified for mammalian CDKs: x
-1 (S/T0) P+1 x+2 (K/R+3) (Stevenson-Lindert et al., 
2003). The generic peptide is a consensus phosphorylation site derived from several 
proteins (Srinivasan et al., 1995) and was chosen as the optimum substrate and used in all 
IMAPTM assays.    
In order to establish the quantity of CRK3:CYC6 needed per assay point for the HTS, a 
two-fold enzyme titration was carried out (Figure 4.6). A 1:250 dilution of the complex 
equating to 6ng of protein was the top concentration assayed and was diluted two-fold in a 
10-point dilution curve. This highlighted that a 1:1200 dilution equating to 1.25ng of 
complex could be used per assay point. Using this quantity produced a mP signal of 
approximately 280mP and a ∆mP of 200mP using significantly less Leishmania 
CRK3:CYC6 than the radiometric assay. The radiometric assay required 7.5ng of protein 
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complex per assay point (Figure 3.13), whereas 1.25ng was used in the HTS assay (Figure 
4.6), highlighting that the IMAPTM HTS format miniaturises the assay by requiring six 
times less Leishmania CRK3:CYC6 protein kinase complex per assay point.      
HTS assay development was carried out by determining the Km for ATP using the IMAPTM 
assay format (Figure 4.7) and comparing it with that determined using the radiometric 
assay platform. A two-fold dilution series of ATP was set up ranging from 1mM to 2µM 
ATP. The Km determined was 154µM ± 13µM approximately two-fold higher than 
determined in the radiometric assay (Figure 3.15, upper graph). This is possibly an artefact 
of the IMAPTM assay due to the tri-valent metal containing nanoparticles in the stop 
solution also binding to the phosphate groups of ATP at the higher ATP concentrations. 
This would possibly have the effect of shifting the curve to the right resulting in a slightly 
higher Km for ATP than expected. It could also be due to variability between assays.    
Further assay development was carried out to determine the IC50 values for staurosporine 
and olomoucine against the Leishmania CRK3:CYC6 protein kinase complex using the 
IMAPTM format. The IC50 value for staurosporine was 20nM (Figure 4.8, upper graph) in 
comparison with 37nM in the radiometric assay (Figure 3.16, upper graph). The values are 
within two-fold of one another and are therefore in close agreement. The IC50 determined 
for olomoucine was >10µm (Figure 4.8, lower graph), in comparison with 51µM in the 
radiometric assay (Figure 3.16, lower graph), again demonstrating it is not a potent 
inhibitor of CRK3:CYC6. The IMAPTM assay with olomoucine was carried out using a 
lower top concentration of inhibitor than in the radiometric assay, which explains the 
imprecise >10µM IC50 result. These results suggest the IMAPTM assay is performing 
similarly to the radiometric platform, and is suitable for continuing with compound 
screening.      
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The preliminary screen on 193 compounds was repeated using the IMAPTM format (data 
not shown). This was to confirm the developed assay was functional and comparable with 
the radiometric assay. The 193 compounds were screened at 10µM to establish if the hits 
identified in the radiometric assay, were also identified in the HTS assay. The 34 hits from 
the radiometric assay were identified in the HTS format showing the assay was functional. 
Interestingly, the five false positives picked up in the radiometric assay were not picked up 
in the HTS format showing the IMAPTM assay is perhaps more stringent.          
 In order to identify inhibitors of Leishmania CRK3:CYC6 a high throughput screen (HTS) 
of the Cyclacel compound library (Table 4.1) was carried out at Cyclacel using the 
IMAPTM fluorescent polarization assay. The IMAPTM HTS assays were carried out as 
described in sections 2.6.2 and 4.2.1. The primary screen carried out at 10µM yielded 43 
hits that had approximately 50% or greater inhibition of Leishmania CRK3:CYC6 protein 
kinase activity (Table 4.2, column 4). The compound identification numbers (Table 4.2, 
column 1), molecular weights (Table 4.2, column 2) and structures (Table 4.2, column 3) 
for the hits are also included. Initial analysis of the compound hit rate (43/25,000) showed 
that 0.17% of the compounds in the Cyclacel library inhibited Leishmania CRK3:CYC6 
protein kinase activity. This hit rate is in accordance with the two previous HTS carried out 
at Cyclacel with this compound library. The mammalian CDK7:CycH hit rate was 0.32% 
and mammalian Polo Like Kinase 1 (Plk1) was 0.7%. Subsequent screening of the hits 
against Plk1 showed a 40% rate of attrition, indicating the real hit rate was approximately 
0.4%. However, both these HTS were performed using the ALPHA-screenTM format rather 
than IMAPTM.  
The IMAPTM format was also chosen as the platform for carrying out a human 
CDK2:CycA counter screen. Molecular Devices had previously validated an IMAPTM 
peptide substrate for CDK2:CycA which was the same fluorescent peptide (generic peptide 
sequence, GGGRSPGRRRRK) used for Leishmania CRK3:CYC6 in these studies. In 
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preparation for the counter screen, assay development was carried out to establish the 
quantity of enzyme required for the assay. The CDK2:CycA enzyme used was expressed in 
baculovirus and purified at Cyclacel. A 1:5 dilution of the complex equating to 0.4µg of 
protein was diluted two-fold in a 10-point dilution curve (Figure 4.9). This highlighted that 
a 1:60 dilution equating to 33ng of complex could be used per assay point, approximately 
four times as much as Leishmania CRK3:CYC6. Using this quantity produced a mP signal 
of approximately 280mP with a ∆mp of 200mP. The CDK2:CycA HTS assay was 
developed and validated with this quantity of enzyme, and was functional for carrying out 
the counter screen. 
The Cyclacel compound library was counter screened against human CDK2:CycA using 
the IMAPTM assay at a single compound concentration of 10µM. The counter screen was 
carried out to filter against the 43 compounds hits that targeted the Leishmania 
CRK3:CYC6 protein kinase complex, thereby identifying any that targeted a human 
kinase. None of the 43 compound hits from Table 4.2 targeted mammalian CDK2:CycA 
(Table 4.2, column 5) and as a result, all 43 compounds were taken forward for secondary 
screening against CRK3:CYC6 to determine their potency. Their IC50 values were 
determined using the previously developed 32P radiometric assay for Leishmania 
CRK3:CYC6 and are shown in Table 4.2, column 6 (ranked in order of potency towards 
Leishmania CRK3:CYC6 protein kinase activity). The most potent compound was 
compound 1 with an IC50 value of 2.6µM towards the Leishmania CRK3:CYC6 protein 
kinase complex. This is not greatly potent towards the complex as it is a low µM inhibitor 
and not a nM inhibitor as desired. However, correspondence with Cyclacel suggested that 
identifying hits with IC50 values lower than 1µM would be unlikely with this library, and 
identifying those with low micromolar potency, at best, was indeed a successful screen. 
These compounds can be used as a starting point for chemistry to improve potencies 
towards Leishmania CRK3:CYC6. The library is only 25,000 compounds strong and in 
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order to get nM potency, it has been proposed you need to screen at least 24,000,000 
distinct compounds (Wintner and Moallemi, 2000). Alternatively, it is possible to screen a 
more focussed kinase selective library to attempt to achieve nM potency, a method adopted 
by the Drug Discovery Initiative at the University of Dundee (Brenk et al., 2007) although 
such potent compounds may also prove to be pan-kinase inhibitors. The screen highlighted 
6 compounds that were false positive hits and did not target Leishmania CRK3:CYC6 with 
a >50% IC50 value (Table 4.2, compounds in black). Therefore, 6/43 giving a 14% rate of 
attrition for the HTS assay, better than that described for the Plk1 HTS assay above, where 
the rate of attrition was 40%, suggesting that IMAPTM may be a more stringent assay 
platform than ALPHA-screenTM. In order to confirm the 43 hits did not target mammalian 
CDK2:CycA, secondary screening against the kinase complex was carried out. All 
returned IC50 values of >50µM (Table 4.2, column 7) confirming the primary screen data 
(Table 4.2, column 5) that human CDK2:CycA was not a target for any of the 43 hits. 
Taking into account the 6 false positive hits, there were 37 Leishmania CRK3:CYC6 hits 
in total. Those with an IC50 value <10µM (18 in total) were taken forward for mammalian 
kinase counter screening (Table 4.2, compounds in red), the remaining 19 were not 
analysed further (Table 4.2, compounds in blue). 
 
The structures of the 18 hits taken forward for mammalian kinase counter screening were 
analysed in detail and this identified two main pharmacophores, azapurine (Figure 4.10, 
upper structure) and aminopyridazine-3-carboxamide (Figure 4.10, lower structure), with 
the majority of the hits (14/18) being azapurines. The activity of the azapurine compounds 
towards Leishmania CRK3:CYC6 is in accordance with the literature where azapurines 
have recently been identified as new inhibitors of cyclin-dependent kinases (Havlicek et 
al., 2005). 
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As the majority of the hits were azapurine compounds, these were studied further to 
develop structure activity relationship (SAR) data. This study focussed on examining 
modifications of the methoxybenzene ring and the cyclohexylmethyl group at the 9 and 2 
positions, respectively of the azapurine structure (Figure 4.11). Initially four hits from the 
Leishmania CRK3:CYC6 HTS were chosen, compound 3, compound 6, compound 18 and 
compound 9 (Tables 4.3, 4.4 and 4.5 in red). Homologues of each hit were chosen which 
had the same R1 group and cyclohexylmethyl group at the 2 position but a modified 9 
position in order to study the importance of the methoxybenzene ring (Figure 4.11, upper 
structure and Table 4.3). The homologues when screened against Leishmania CRK3:CYC6 
all returned IC50 values >50µM showing they had lost their activity towards the complex 
and highlighting the importance of the existing group at the 9 position (Table 4.3).  
In addition, a similar study was carried out looking at modifying the 2 position whilst 
keeping the R1 group and the methoxybenzene ring at the 9 position constant to study the 
importance of the cyclohexylmethyl group (Figure 4.11, lower structure and Tables 4.4 and 
4.5). When screened against CRK3:CYC6 these homologues also returned IC50 values 
>50µM (Tables 4.4 and 4.5) demonstrating they had lost their activity towards the enzyme 
complex and thus highlighting the importance of the cyclohexylmethyl group at the 2 
position.  
These studies indicate the importance of the two hydrophobic groups in the interaction 
with and inhibition of Leishmania CRK3:CYC6 by the azapurine compounds. This 
highlights areas of the azapurine compounds where the structure possibly can and cannot 
be modified by iterative chemistry when developing a compound hit into a lead. 
Interestingly it seems the azapurines may tolerate a number of substitutions in the R1 
position without losing their ability to inhibit Leishmania CRK3:CYC6. The groups in this 
position are generally large and it would be interesting to probe this position with some 
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smaller group substitutions in order to develop more potent Leishmania CRK3:CYC6 
compounds. 
In addition, many of the hits in Table 4.2 are of high molecular weight and this may also 
limit the number of modifications that can be made to develop the hits into leads. When 
considering Lipinski’s rule of 5 for intestinal drug absorption, one of the criteria (for an 
orally administered compound) is that poor absorption is more likely when the molecular 
weight of a compound exceeds 500. Additionally, compounds should ideally have no more 
than 5 hydrogen bond donors, nor more than 10 hydrogen bond acceptors and a logP value 
under 5. However, analysis of drugs and their parent leads suggests there is a clear 
distinction. Drugs tend to have a higher molecular weight and logP values where the 
development from hit-to-lead to drug is accompanied by the addition of lipophillic 
moieties and therefore increases in molecular weight. Therefore, it has been proposed that 
screening compounds should be lead-like with molecular weights <350 and logP <3 
(Teague et al., 1999). Therefore, the hits from Table 4.2 with high molecular weight would 
have to be subject to subtle modifications in order to improve their potency whilst ideally 
not exceeding a molecular weight of 500 and being able to meet the additional criteria 
above. 
 The 18 most potent Leishmania CRK3:CYC6 HTS hits were taken forward and screened 
against an expanded kinase panel. The kinases were chosen from Cyclacel’s in-house 
kinase panel. The 10 kinases chosen (Table 4.6) all had previously developed 32P 
radiometric assays in place suitable for compound screening. The kinases were chosen 
largely to represent the serine/threonine class and family of cyclin-dependent kinases as L. 
mexicana CRK3 is a serine/threonine cyclin-dependent kinase. In addition, a tyrosine 
kinase (Abl) and a receptor tyrosine kinase (Flt3) were chosen to represent the other 
classes of kinases in the Cyclacel database. The 18 compounds were secondary screened 
against the 10 kinases to determine their potency by IC50 determination (Tables 4.7 and 
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4.8). The IC50 values of the 9 most potent hits against CRK3:CYC6 for the kinases in the 
mammalian kinase counter screen panel are shown in Table 4.7. The remainder of the 18 
hits IC50 values are shown in table 4.8. The majority of the compounds did not show 
activity towards any of the mammalian kinases with IC50 values >50µM, showing 
selectivity towards Leishmania CRK3:CYC6. However, this is with the exception of 
mammalian CDK4:CycD1 where all of the azapurines, but not the aminopyridazine-3-
carboxamides target the kinase with IC50 values <30µM. This highlights structure activity 
relationship (SAR) data for the two pharmacophores which has been studied in 
collaboration with Malcolm Walkinshaw and Matt Nowicki at the University of 
Edinburgh. The binding mode of kinase inhibitors has been shown to be via a hydrogen 
bond donor-acceptor-donor (D-A-D) motif that interacts with the backbone residues of 
CDK2, Leu83 and Glu81, which is common to most, if not all, CDK2 inhibitors (Figure 
4.14, upper structure). Interestingly, the azapurine compounds have no obvious H-bond 
donating atom and therefore binding to the ATP pocket must be driven by hydrophobic 
interactions and accepting H-bonding atoms from the protein. The azapurine compounds 
were modelled into the CRK3 ATP site by keeping the hydrophobic interactions of the 
cyclohexylmethyl moiety (an area of conservation between CDK2 and CRK3) and placing 
N7 and N8 of the triazole moiety within the limits of H-bond accepting to the backbone of 
Val102 (Leu83 in CDK2). The result showed that the O atom of the methoxybenzene 
group is situated in a position whereby it is able to H-bond with Tyr101. A third H-
bonding interaction is evident between an aromatic H-atom and the backbone carbonyl of 
Val102. Three H-bonding interactions are evident between the protein and the azapurine 
inhibitors, but the motif is changed to A-D-A which is not possible in CDK2 as Tyr101 is 
replace by Phe82 and is therefore unable to donate an H-bonding atom (Figure 4.14, lower 
structure). In CDK4, the tyrosine residue is replaced by histidine which would still be able 
to facilitate the A-D-A binding motif; therefore, the model also explains why the azapurine 
compounds exhibit a lesser selectivity for CRK3 over CDK4.      
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Figure 4.14 – Binding motifs of CDK2 and CRK3 with their respective inhibitors. The 
binding motif of CDK2 and the inhibitor NU6102 is via a hydrogen bonding D-A-D motif 
with CDK2 backbone residues (upper structure). The binding motif of CRK3 and an 
azapurine compound is via a hydrogen bonding A-D-A motif with CRK3 backbone 
residues (lower structure). Provided by Matt Nowicki, University of Edinburgh. 
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In collaboration with Nick Turner and Kirk Malone at the University of Manchester a 
number of additional compounds were generated and screened against the Leishmania 
CRK3:CYC6 protein kinase complex. Accelrys Discovery Studio software was used to 
carry out molecular modelling using a homology model of L. mexicana CRK3 based on 
human CDK2. The homology model was used as a base for an in silico screen using the 
Accelrys compound database accompanying the software. Naphthostyril (Figure 4.12, top 
left structure) was the top hit, which gave the best docking score and whose binding mode 
made compared favourably to the binding of known inhibitors of CDK2 (Liu et al., 2003). 
Attempts were made to achieve selectivity by comparing the CRK3 model to the crystal 
structure of human CDK2 and looking for differences. It appeared that there was 'more 
space' in the active site of CRK3 than CDK2. Based on this, the Naphthostyril structure 
and 11 derivatives (Figure 4.12) were synthesised and all 12 were screened against the 
Leishmania CRK3:CYC6 protein kinase complex. However, none of the compounds 
inhibited CRK3:CYC6, all returning IC50 values >50µM. This could be a result of 
limitations in the model itself and/or within the docking programme or due to the limited 
virtual library. Although unsuccessful, it is worth noting that the in silico screen was used 
to generate ideas using the Accelrys software with the compound database supplied, and 
that subsequent virtual libraries could be screened in the future. 
In collaboration with Karen Grant at the University of Lancaster and Nicholas Westwood 
at the University of St. Andrews, 55 indirubin compounds were synthesised and screened 
against the Leishmania CRK3:CYC6 protein kinase complex. Indirubin (Figure 4.13, top 
left structure) is the active ingredient in the traditional Chinese medicine Dang Gui Long 
Hui Wan (Tang and Eisenbrand, 1992) which has been shown to be effective in the 
treatment of chronic myeloid leukaemia (Xiao et al., 2002). In addition, indirubins may 
have a potential application against neurodegenerative diseases such as Alzheimer’s 
disease as they are known cyclin-dependent kinase and GSK-3 inhibitors (Hoessel et al., 
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1999; Polychronopoulos et al., 2004). The 55 derivatives of Indirubin were grouped 
according to their activity against CRK3his from transgenic promastigote L. mexicana or 
by their relationship to the other indirubins. Initially 8 compounds which were previously 
screened against CRK3his from transgenic promastigote L. mexicana by Karen Grant were 
screened against the Leishmania CRK3:CYC6 protein kinase complex. This was to 
establish whether there was a correlation in IC50 values between the native or recombinant 
CRK3 protein kinases. IC50 values for 4 of the compounds (named TW in Table 4.9) show 
that there is a discrepancy between the two CRK3 protein kinases. This was also the case 
for the other 4 TW compounds (data not shown). This may be a result of two factors: the 
first is, the assays using transgenic CRK3his were carried out at an ATP concentration of 
4µM whereas the recombinant Leishmania CRK3:CYC6 assays were carried out at 
100µM, the ATP concentration at which the assay was validated. Depending on the 
enzyme’s Km for ATP, a higher ATP concentration can result in a higher IC50 value due to 
there being more ATP for the compound to compete with. This is not the case, however, 
for compounds TW21 and TW27 in table 7 where they have a lower IC50 when compared 
to the transgenic CRK3his. The second factor that may account for the IC50 discrepancies 
is the cyclin partner of CRK3. The in vivo partner of CRK3 has been shown to be CYCA 
(F.C. Gomes and J.C. Mottram, unpublished). In addition, the homologue of CYCA in L. 
donovani has been identified, LdCYC1, (Banerjee et al., 2003) and shown to form a 
complex with L. donovani CRK3 (Banerjee et al., 2006). However, despite CYC6his 
activating CRK3his in vitro, it remains to be shown if it is a partner of CRK3 in vivo. A 
variety of cyclin partners which activate CRK3 in vivo could account for difference in 
transgenic CRK3 activity when compared to the CRK3his activity as a result of CYC6his 
binding. This in turn may affect the IC50 values of the indirubin compounds tested. For 
example, it is known that the same compound can inhibit CDK2 with vastly different 
potencies depending on what cyclin partner (CycA or CycE) the enzyme is bound to 
(Cyclacel data, unpublished).     
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The 55 compounds were secondary screened against Leishmania CRK3:CYC6 to 
determine their IC50 values. This resulted in 10 with IC50 values <1µM and 3 with IC50 
values between 1µM and 2µM. Eighteen compounds were analysed further by secondary 
screening against mammalian CDK1:CycB and mammalian CDK2:CycA to determine any 
initial selectivity towards Leishmania CRK3:CYC6 (Table 4.9). Of those tested, 4 showed 
selectivity towards Leishmania CRK3:CYC6 (Table 4.9, red asterisk) and 2 towards 
mammalian CDK2:CycA (Table 4.9, blue asterisk). None of the compounds tested were 
selective towards mammalian CDK1:CycB over the other two enzymes. One of the most 
potent compounds against Leishmania CRK3:CYC6 (IC50 130nM) was DT-IND-83 which 
showed significant selectivity over CDKs 1 and 2 and also activity towards promastigote 
and amastigote Leishmania (Table 4.9, columns 6 and 7, respectively). As indirubins are 
known GSK-3 inhibitors, DT-IND-83 was screened against mammalian GSK-3 and 
returned an IC50 value of 15nM (data not shown) highlighting that it is more potent against 
this enzyme over Leishmania CRK3:CYC6. Despite the known activity of indirubins 
against mammalian GSK-3, it would be interesting to establish their activity against 
parasite GSK-3 whose presence has been identified as a result of Tri-tryp kinome analysis 
(Parsons et al., 2005). 
Although the indirubin compounds may not be exclusively selective towards Leishmania 
CRK3:CYC6, they are, however, potent and may be an avenue to explore in developing 
leads against the Leishmania CRK3:CYC6 protein kinase complex. This is directly 
opposite to what was observed with the azapurine and aminopyridazin-3-carboxamide hits 
from the HTS where selectivity towards Leishmania CRK3:CYC6 is achieved, but the 
potency is not.  Therefore, the hits require an iterative medicinal chemistry input in order 
to turn them into potent leads suitable for developing into drug candidates.
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Chapter 5 
Leishmania biology 2: The Leishmania CRK3:CYC6 protein 
kinase complex and in vitro compound analysis. 
5.1 Chapter introduction and objectives. 
The IMAPTM HTS assay developed in chapter 4 was used to carry out a HTS against the 
Leishmania CRK3:CYC6 protein kinase complex. The two pharmacophores identified, 
azapurine and aminopyridazine-3-carboxamide, showed inhibition of and selectivity 
towards Leishmania CRK3:CYC6 protein kinase activity. Although the hits showed 
activity towards the complex in vitro, it is vital to test whether they show biological 
activity towards Leishmania and ultimately against the parasite in vivo. The in vitro model 
may not be mirrored in vivo. The focus of this chapter will be to report on testing the HTS 
hits against Leishmania promastigotes and in macrophage infection assays. In addition, 
work towards attempting to elucidate whether CYC6 is an in vivo partner of CRK3 will be 
discussed. 
When targeting CRK3 in the promastigote life cycle stage of Leishmania, the compounds 
are required to cross the cell membrane and nuclear membrane to inhibit the enzyme. 
Therefore, the compounds need to be sufficiently “drug like” in order to cross the 
membranes required to get to the target enzyme. The situation is further complicated when 
targeting CRK3 in the amastigote life cycle stage of Leishmania. The compounds must 
first cross the macrophage cell membrane, followed by the parasitophorous vacuolar 
membrane, the amastigote cell membrane itself and the nuclear membrane (Figure 5.1). 
When considering Lipinski’s rule of 5 to evaluate the “drug like” criteria of a compound, 
compounds must possess certain characteristics in order to be likely candidates for orally 
active drugs in humans. Compounds being sufficiently lipophillic is vital so they can cross 
cellular membranes to get to their target (Lipinski et al., 2001). 
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There are significant differences between promastigote and amastigote Leishmania in 
biochemistry and sensitivity to standard and experimental drugs (Croft et al., 2006a). One 
example is with the first line drug Sodium stibogluconate (Pentostam, SSG), a pentavalent 
antimonial used to treat the visceral form of leishmaniases. This was shown to have 
activity towards Leishmania amastigotes but not towards promastigote Leishmania (Neal 
and Croft, 1984). Therefore, it is possible to target the amastigote life cycle stage despite a 
number of membranes being required to be crossed by a compound.  
5.2 Analysis of the biological activity of the Cyclacel library high throughput 
screen hits against cultured L. major parasites: 
5.2.1 Against cultured L. major promastigote parasites. 
The 10 compounds showing the greatest activity towards Leishmania CRK3:CYC6 protein 
kinase activity (Table 4.2, column 6) were tested against promastigote L. major cells in 
vitro. This was to analyse the biological activity of the compounds that were shown to be 
active against the Leishmania CRK3:CYC6 protein kinase complex (carried out in 
collaboration with Elaine Brown). A six-fold dilution series of each compound, with a top 
screening concentration of 10µM, with DMSO included as a control was set up and an 
Alamar blue absorption assay carried out as described in section 2.3.6. This highlighted 
one compound, compound 7, which had activity towards promastigote L. major with an 
IC50 value of 8.57µM. The remainder of the 10 compounds returned IC50 values >10µM 
suggesting they are essentially inactive towards promastigote L. major (Table 5.1). One 
compound, compound 5, reported an increase in cell growth (228.9%) at a concentration of 
10µM, more than double that of the corresponding DMSO control, suggesting this 
compound may stimulate cell growth. Therefore, it is possible that compound 5 may 
induce host factors which can stimulate cell growth and proliferation. However, due to 
limited compound material, analysis of five of these compounds (compound 1, compound 
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2, compound 3, compound 4 and compound 6) was performed only once and therefore 
needs to be repeated to obtain more definitive data on their biological activity against 
Leishmania. The remaining five compounds plus another one from the HTS which were re-
synthesised by Kirk Malone, University of Manchester (Figure 5.3) were tested against 
Leishmania in vitro to obtain more accurate data on their biological activity which is 
discussed in section 5.4.1.  
5.2.2 Against amastigote L. major in a macrophage infection. 
The 10 compounds showing the greatest activity towards Leishmania CRK3:CYC6 protein 
kinase activity were also tested against promastigote L. major infected macrophages in 
vitro. This was to analyse the biological activity of the compounds against L. major 
amastigotes. A five-fold dilution series of each compound, with a top screening 
concentration of 50µM was set up and a macrophage infection assay carried out as 
described in section 2.3.7. DMSO and Pentamidine were included as negative and positive 
controls, respectively. Infectivity of approximately 85% was observed with macrophages 
treated with DMSO only, an infection rate which has been observed previously in these 
assays. The IC50 value for Pentamidine was 7.7µM, the concentration which cleared L. 
major amastigotes from 50% of the macrophage population. The assay highlighted one 
compound, compound 3, which returned an IC50 value of 38.4µM. The remainder of the 
compounds returned IC50 values >50µM (Table 5.2). This suggests that the compounds are 
essentially inactive towards L. major amastigotes. Due to limited compound material, 
analysis of five of these compounds (compound 1, compound 2, compound 3, compound 4 
and compound 6) was performed only once and therefore requires repeating to obtain more 
definitive data on their biological activity against Leishmania. The remaining five 
compounds plus another one from the HTS which were re-synthesised (Figure 5.3) were 
tested against Leishmania amastigotes in vitro to obtain more accurate data on their 
biological activity which is discussed in section 5.4.2.  
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Figure 5.1 – Life cycle stages of Leishmania highlighting cellular membranes. The 
promastigote life cycle stage of Leishmania (Upper schematic) and amastigote life cycle 
stage within a macrophage cell (Lower schematic) are shown. Compounds are required to 
cross the cell membrane and the nuclear membrane to target CRK3 (Upper schematic). In 
the amastigote life cycle stage, the macrophage cell membrane, parasitophorous vacuolar 
membrane, amastigote cell membrane and the nuclear membrane must be crossed to target 
CRK3 (Lower schematic). 
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5.3 Analysis of the re-synthesised high throughput screen hits and 
azapurine derivatives against the Leishmania CRK3:CYC6 protein kinase 
complex.  
It is standard practice in drug development to re-synthesise active HTS hits to fully 
evaluate their activity and potential as drug candidates. It is unwise to fully trust hits that 
are identified from master plates from a compound library, and they should only be treated 
as an indication of compounds or pharmacophores that should be investigated further. As a 
result six of the azapurine HTS hits were re-synthesised due to the ease of the chemical 
synthesis involved. In addition, iterative chemistry was performed on the azapurine 
pharmacophore identified from the Leishmania CRK3:CYC6 HTS. The re-synthesised 
azapurine HTS hits and azapurine derivatives were synthesised by Kirk Malone at the 
Manchester Interdisciplinary Biocentre (MIB), University of Manchester, and their activity 
towards Leishmania CRK3:CYC6 established by IC50 determination. The structures of the 
16 derivatives (Figure 5.2) and the six re-synthesised HTS hits (Figure 5.3) which were 
assayed are shown. The 16 derivatives and six re-synthesised HTS hit had their IC50 values 
determined at Cyclacel, Dundee in collaboration with Graeme Thomson using the 
radiometric assay platform. This highlighted nine compounds KM59_2 (15.9µM), 
KM63_3 (39.1µM), KM114_C (4.2µM) (re-synthesised compound 7), KM114_D 
(30.3µM), KM117A (>50µM) (re-synthesised compound 8), KM117B (>50µM) (re-
synthesised compound 9), KM117C (37.9µM) (re-synthesised compound 14), KM117D 
(4.4µM) (re-synthesised compound 10) and KM117E (24.2µM) (re-synthesised compound 
5) which were active or were predicted to be active towards Leishmania CRK3:CYC6. 
Initial screening of compound 7 at Cyclacel returned an IC50 value of 5.3µM (Table 4.2) 
which is almost identical to that of KM114_C. However, compound 8 returned 5.79µM 
versus 50µM for KM117_A, compound 9 returned 5.9µM versus >50µM for KM117_B, 
compound 14 returned 8.8µM versus 37.9µM for KM117_C, and compound 5 returned 
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4.4µM versus 24.2µM for KM117_E. These values, surprisingly, are not in accordance 
with the IC50 values determined for their corresponding re-synthesised compounds (KM 
compounds mentioned above). Only one other compound, compound 10 returned had an 
IC50 value of 6.9µM which was in close agreement with the IC50 value determined for its 
re-synthesised partner, KM117D (4.4µM). To clarify matters, the HTS hits from Cyclacel 
and the re-synthesised hits should be screened side-by-side; however, this was not possible 
due to limited HTS compound material available. The remainder of the 16 derivatives 
screened were inactive, returning IC50 values of >50µM. As discussed, the re-synthesised 
HTS hits were tested against Leishmania in vitro (section 5.4).  
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Figure 5.2 – Azapurine derivatives tested against the Leishmania CRK3:CYC6 
protein kinase complex. The azapurine structure (Figure 4.10, upper structure) identified 
from the CRK3:CYC6 HTS, was used as a scaffold to generate 16 derivatives. The IC50 
values were determined for the 16 derivatives screened against Leishmania CRK3:CYC6.  
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Figure 5.3 – Re-synthesised azapurine HTS hits tested against the Leishmania 
CRK3:CYC6 protein kinase complex and Leishmania in vitro. Six of the azapurine hits 
identified from the CRK3:CYC6 HTS were re-synthesised. Compound 7 was re-
synthesised as KM114_C, Compound 8 re-synthesised as KM117_A, Compound 9 re-
synthesised as KM117_B, Compound 14 re-synthesised as KM117_C, Compound 10 re-
synthesised as KM117_D and Compound 5 re-synthesised as KM117_E.  
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5.4 Analysis of the biological activity of the azapurines against cultured L. 
major parasites: 
5.4.1 Against cultured L. major promastigote parasites. 
Nine compounds were assayed against promastigote L. major to analyse their biological 
activity. From the previous experiment against promastigote L. major (section 5.2.1), a top 
screening concentration of 10µM was not high enough to observe any biological effect 
against the parasites (Table 5.1). Therefore, a higher top screening concentration of 50µM 
was chosen for subsequent assays. The first assay highlighted seven of the nine compounds 
with activity towards L. major promastigotes with the most active being compound 
KM114_C with an IC50 value of 3µM, with KM59_2 and KM117_B both inactive (Table 
5.3). As a positive control, Pentamidine was included, returning an IC50 value of 2.2µM, 
which is in accordance with that seen in previous assays. In order to confirm the activity of 
the compounds, the assay was repeated. However, in order to determine more accurate IC50 
values, the assay was carried out with an extensive range of concentrations for each 
compound (Table 5.4) Included in this assay was compound KM114_E, despite being 
inactive towards Leishmania CRK3:CYC6. This was due to the collaboration with Karen 
Grant, University of Lancaster, showing that KM114_E was active towards promastigote 
L. major, causing a growth arrest at 10µM (K.M. Grant, unpublished). This assay 
confirmed the activity of the compounds with the exception of compound KM117_A 
whose IC50 was >40µM (Table 5.4) in comparison with 9µM (Table 5.3). The IC50 value 
for Pentamidine in this assay was 1.7µM. The assay was repeated a final time with four 
compounds and to repeat the assay for compound KM114_E to confirm the IC50 values 
from the previous determinations (Table 5.5). This confirmed the IC50 values determined in 
the previous assays with the IC50 for Pentamidine 2.4µM. The average IC50 value for each 
compound was calculated and is shown in the summary table (Table 5.8, column 3). In 
summary, it was observed that against promastigote L. major compounds KM59_2, 
KM117_A, and KM117_B were inactive (>50µM) and compounds KM63_3, KM114_C, 
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KM114_D and KM114_E KM117_C, KM117_D and KM117_E were active (Table 5.8, 
column 3). These seven active compounds were taken forward for testing against 
amastigote L. major in a macrophage infection, to determine their biological activity. 
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5.4.2 Against amastigote L. major in a macrophage infection. 
The seven compounds showing activity towards promastigote L. major were tested against 
L. major infected macrophages in vitro with the experiment repeated to verify the 
percentage infections and IC50 values determined. This was to analyse the biological 
activity of the compounds in an L. major infection. Five concentrations of each compound 
were analysed, with a top screening concentration of 50µM and a macrophage infection 
assay carried out as described in section 2.3.7. DMSO and Pentamidine were included as 
negative and positive controls, respectively. Infectivity of approximately 80% was 
observed with macrophages treated with DMSO only, a similar level of infection as seen 
previously (section 5.2.2). The IC50 value for Pentamidine was 5µM, comparable to that 
observed previously (section 5.2.2), where the IC50 value was 7.7µM. At 50µM, compound 
KM63_3 was toxic to the macrophages and therefore the percentage of infection could not 
be determined. At the lower concentrations, the percentage of infection was determined 
and the IC50 value reported was between 5-15µM (Table 5.6 and 5.7). The software used to 
determine the IC50 values was GraFit 5 which requires at least five data points in order to 
generate an IC50 value. However, as only four data points were determined for KM63_3, 
the IC50 value was loosely valued between 5-15µM, based on the percentage of infection 
for each concentration. This was also the case for compounds KM114_C and KM117_E, 
where the IC50 value was determined between 5-15µM (Table 5.6 and 5.7). The IC50 value 
for KM114_D was determined between 15-30µM (Table 5.6 and 5.7). The IC50 value for 
KM114_E was 5.4µM and 6.7µM (Table 5.6 and 5.7, respectively). However, the IC50 
values for KM117_C and KM117_D could not be determined due to the compounds being 
toxic at the higher concentrations (Table 5.6 and 5.7). They do, however, appear to be 
inactive at the other concentrations examined up to the point of becoming toxic to the 
macrophages. In summary, five of the seven compounds were active in the macrophage 
infection assay; KM63_3, KM114_C, KM114_D, KM114_E and KM117_E. (Table 5.8, 
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column 4). Although the precise IC50 values could not be determined for most of these 
compounds, they are active towards amastigote L. major in a macrophage infection. 
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Table 5.8 – Summary table of azapurine inhibition. Compounds displaying NA (not 
analysed) did not have their IC50 values determined against L. major amastigotes due to 
being inactive against L. major promastigotes. The ± values represent the standard 
deviation for each of the average determinations. 
OH
N
NN
N
N
MeO
NH
N
NN
N
N
N
MeO
N
NN
N
N
N
MeO
OH
N
NN
N
N
N
MeO
O
N
NN
N
N
NH
MeO
N
O
N
NN
N
N
NH
MeO
N
NN
N
N
NH
MeO
N
NN
N
N
NH
MeO
N
NN
N
N
N
MeO
OH
N
NN
N
N
NH
MeO
H
OH
5-15µM7.9µM ± 0.35µM24.2µM
KM117_E 
(compound 5)
>50µM27.4µM ± 5µM4.4µM
KM117_D 
(compound 10)
>50µM2.6µM ± 0.6µM37.9µM
KM117_C 
(compound 14)
NA>50µM>50µM
KM117_B 
(compound 9)
NA>40µM>50µM
KM117_A 
(compound 8) 
6.1µM ± 0.9µM8.3µM ± 2.1µM>50µMKM114_E 
15-30µM
28.7µM ±
17.5µM
30.3µMKM114_D  
5-15µM19.4µM ± 8.4µM4.2µM
KM114_C 
(Compound 7)
5-15µM7.4µM ± 2.2µM39.1µMKM63_3
NA>50µM15.9µMKM59_2
Average 
Amastigote           
L. major IC50
Average 
Promastigote         
L. major IC50
Leishmania
CRK3:CYC6 IC50
StructureCompound
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5.5. Leishmania CRK3:CYC6 in vivo protein kinase complex. 
The Leishmania CRK3:CYC6 protein kinase complex used in these studies is an in vitro 
complex. Therefore work was carried out in order to determine if Leishmania CRK3 and 
CYC6 are true binding partners that interact in vivo to form a functional in vivo protein 
kinase complex. This was carried out by adding N or C-terminal HA-tags to CYC6 and co-
immunoprecipitating the protein via the HA-tags to attempt to identify CRK3 as a binding 
partner. 
Both N and C-terminally tagged HA-CYC6 constructs were made in case a tag at either the 
N or C terminus would interfere with the CYC6 gene, and hence its expression and CYC6 
activity. 
5.5.1 L. major HA-tagged CYC6 episomal constructs: 
Episomal expression of HA-tagged CYC6 was chosen as these constructs would not 
require chromosomal integration into the Leishmania genome and could express the 
protein in the cytoplasm. This expression system yields stable protein production at high 
levels.   
5.5.1.1 N-terminal HA-tagged L. major CYC6. 
The CYC6 gene with an N-terminal HA-tag was amplified by PCR. Amplification was 
carried out using Deep Vent DNA polymerase, pGL1169 (L. major CYC6 in PCR-script) 
as template DNA and oligonucleotides 1901 (5’ CAGCGCCGGCAGCTCGTTACC 
TAGG 3’) and 1902 (5’ GCCCGGGATGTACCCCTACGACGTCCCGGACTATGCC 
TTCGTGGAACGAGAGC 3’) (to generate the N-terminal HA-tag (Underlined in bold)). 
The PCR product was purified and ligated into pGL102, a pXG episomal expression vector 
using Xma1 and BamH1. This plasmid was named pGL1391 (Figure 5.4, upper map). 
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5.5.1.2 C-terminal HA-tagged L. major CYC6. 
The CYC6 gene with a C-terminal HA-tag was amplified by PCR. Amplification was 
carried out using Deep Vent DNA polymerase, pGL1169 (L. major CYC6 in PCR-script) 
as template DNA and oligonucleotides 1899 (5’ CGCCCGGGATGTTCGTGGAACGAG 
3’) and 1900 (5’ TCAGGATCCCGGCATAGTCCGGGACGTCGTAGGGGTA 
CAGCGCCGGCAGCTCGTTAGGCA 3’) (to generate the C-terminal HA-tag (underlined 
in bold)). The PCR product was purified and ligated into pGL102 using Xma1 and BamH1. 
This plasmid was named pGL1390 (Figure 5.4, lower map). 
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Figure 5.4 – Vector NTI maps of the L. major N and C-terminal HA-tagged CYC6 
episomal expression constructs pGL1391 and pGL1390. The N and C-terminal HA-
tagged CYC6 open reading frames, with Xma1 and BamH1 restriction sites, were obtained 
via PCR amplification. These were sub-cloned into a similarly digested pXG vector with a 
neomycin (G418) resistance marker (NEO) and prokaryotic promoter (5’DST). The N-
terminal HA-tagged CYC6 construct, pGL1391 is shown in the upper panel, and the C-
terminal HA-tagged CYC6 construct, pGL1390, shown in the lower panel.       
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5.5.2 L. major HA-tagged CYC6 ribosomal integration constructs: 
Due to episomal expression of HA-tagged CYC6 proving unsuccessful, an alternative 
method was employed. N and C-terminally HA-tagged CYC6 open reading frames were 
sub-cloned into the pRIB ribosomal integration vector. This was to integrate HA-tagged 
CYC6 into the ribosomal locus of L. major which is likely to provide constitutive and 
therefore high protein production (Mißlitz et al., 2000). 
5.5.2.1 N-terminal HA-tagged L. major CYC6. 
The CYC6 gene with an N-terminal HA-tag was amplified by PCR. Amplification was 
carried out using Deep Vent DNA polymerase, pGL1169 (L. major CYC6 in PCR-script) 
as template DNA and oligonucleotides 2156 (5’ CCTCGAGATG TACCCCTACGACG 
TCCCGGACTATGCCATGTTCGTGGAACGAGAGC 3’) (to generate the N-terminal 
HA-tag (underlined in bold)) and 2157 (5’ CGCGGCCGCTCACAGCGCCGGCAG 3’) 
The PCR product was purified and ligated into pGL631, a pRIB ribosomal integration 
vector using Xho1 and Not1. This plasmid was named pGL1484 (Figure 5.5, upper map). 
5.5.2.2 C-terminal HA-tagged L. major CYC6. 
The CYC6 gene with a C-terminal HA-tag was amplified by PCR. Amplification was 
carried out using Deep Vent DNA polymerase, pGL1169 (L. major CYC6 in PCR-script) 
as template DNA and oligonucleotides 2154 (5’ CCTCGAGATGTTCG 
TGGAACGAGAG 3’) and 2155 (5’ CCGCGGCCGCTCA GGCATAGTCCGGGACG 
TCGTAGGGGTAGGGGTACAGCGCCGGCAGCTCGTTAG 3’) (to generate the C-
terminal HA-tag (underlined in bold)). The PCR product was purified and ligated into 
pGL631 using Xho1 and Not1. This plasmid was named pGL1483 (Figure 5.5, lower map). 
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Figure 5.5 – Vector NTI maps of the L. major N and C-terminal HA-tagged CYC6 
ribosomal integration constructs pGL1484 and pGL1483. The N and C-terminal HA-
tagged CYC6 open reading frames, with Xho1 and Not1 restriction sites, were obtained via 
PCR amplification. These were sub-cloned into a similarly digested pRIB vector with a 
puromycin resistance marker (PAC) between the 5’ and 3’ ribosomal flanking sequences 
(3’ and 5’ 18S). The N-terminal HA-tagged CYC6 construct, pGL1484 is shown in the 
upper map, and the C-terminal HA-tagged CYC6 construct, pGL1483, shown in the lower 
map. 
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5.6 Purification and detection of L. major HA-tagged CYC6. 
5.6.1 CRK3:CYC6 co-immunoprecipitation and pull down assay. 
Analysis was carried out to determine if CRK3 and CYC6 form an in vivo complex in L. 
major. The episomal HA-tagged CYC6 constructs pGL1390 and 1391 were transfected 
into wild type L. major as described in section 2.3.3.2. However, the episomal HA-tagged 
CYC6 transfectants failed to proliferate in the presence of the selecting drug (G418). As 
previously discussed, ribosomal integration of HA-tagged CYC6 was then carried out. The 
HA-tagged CYC6 ribosomal integration constructs pGL1483 and 1484 were successfully 
transfected into wild type L. major as described in section 2.3.3.3. Protein preparation from 
L. major was carried out as described in section 2.3.4 and Western blot analysis of the HA-
tagged CYC6 S100 fractions carried out. Wild type L. major was included as a negative 
control. Included as a positive control, was an E. coli whole cell lysate containing a 41 kDa 
recombinant protein expressing 11 different epitope tags (Abcam), one of which was an 
HA-tag (amino acid sequence, YPYDVPDYA). No HA-tagged CYC6 was detected in 
lanes 2 and 3 with the positive control detected at the expected size of 41kDa (Figure 5.6). 
The S100 fractions were not used for further analysis of the CRK3 and CYC6 in vivo 
complex. 
  
187 
                   
                                    
1 2 3 4 5 kDa
- 175
- 83
- 62
- 47.5
- 32.5 
- 25
- 16.5
 
Figure 5.6 – Western blot analysis of N and C-terminal HA-tagged CYC6 purified 
form L. major. The S100 fractions from 200ml of 1 x 107 mid-log phase promastigote L. 
major cells expressing N and C-terminal HA-tagged CYC6 were analysed by Western blot. 
Lane 1 is the wild type L. major control. Lane 2 is the C-terminal HA-tagged CYC6. Lane 
3 is the N-terminal HA-tagged CYC6. Lane 4 is the E. coli positive control and lane 5 the 
molecular weight protein standards. 
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5.7 Chapter discussion. 
In order to determine the biological activity of the compound hits identified from the HTS, 
analysis against promastigote L. major in vitro was carried out. The 10 compounds 
showing the greatest activity towards Leishmania CRK3:CYC6 protein kinase activity 
(Table 4.2, column 6) were tested. Activity of the HTS compounds towards promastigote 
L. major was determined by an Alamar blue absorption assay carried out as described in 
section 2.3.6. In the assay, cells that are viable metabolise the reazurin salt, which turns 
pink in colour. If the cells are dead, the reazurin salt is not metabolised and remains blue in 
colour. This highlighted one compound, compound 7, which had activity towards 
promastigote L. major cells with an IC50 value of 8.6µM. Conversely, compound 5 
appeared to stimulate cell growth, an effect which has been seen previously with drugs 
tested against Leishmania (Kaur et al., 1988b). Leishmania were genetically engineered to 
lack the folate-methotrexate transporter and were resistant to methotrexate (a potent 
dihydrofolate reductase inhibitor). Upon the addition of methotrexate, stimulated growth of 
wild type Leishmania and those lacking the transporter was observed in media deficient of 
folate. This suggested the antifolate analogs were serving as a pteridine source for the 
parasite and stimulated growth (Kaur et al., 1988a). The remainder of the 10 compounds 
returned IC50 values >10µM suggesting these are inactive towards promastigote L. major 
(Table 5.1) which could be due to a variety of reasons. As the HTS hits were active 
towards Leishmania CRK3:CYC6 protein kinase activity in the micromolar range (Table 
4.2, column 6), it would be reasonable to assume that the compounds would be less active 
towards the parasites at the IC50 values determined for CRK3:CYC6. Therefore a higher 
concentration of compound would be required to determine IC50 values for the 10 HTS 
compounds towards promastigote L. major and observe a significant reduction in cell 
survival. Furthermore, in Leishmania CRK3:CYC6 protein kinase activity assays, 
compounds were assayed directly with the Leishmania CRK3:CYC6 protein kinase 
complex. When tested against promastigote L. major, the compounds must first cross the 
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parasite cell membrane and nuclear membrane in order to inhibit CRK3 activity, which the 
compounds may not have been able to do.  
As CRK3 is the homologue of mammalian CDK1, we can predict that Leishmania CRK3 
would also be located in the same cellular locations. CDK1, was shown to be a nuclear and 
centrosomal protein required for mitosis in mammals (Riabowol et al., 1989). These 
subcellular locations of CDK1:CycB are vital to its function. The complex must locate to 
the nucleus in order to phosphorylate a variety of nuclear substrates which are necessary 
for the onset of mitosis (Porter and Donoghue, 2003). The location of CDK1 is in part, 
dependent on the isotype of its cyclin B partner, whose intracellular localization also 
varies. CDK1:CycB1 colocalize with cytoplasmic microtubules during interphase (Porter 
and Donoghue, 2003; Migone et al., 2006), and translocates to the nucleus to initiate 
mitosis. CDK1:CycB2 colocalize with the golgi apparatus and CDK1:CycB3 is constantly 
located in the nucleus (Porter and Donoghue, 2003). As CRK3 would be predicted to be in 
both the nucleus and cytoplasm, the compounds would need to cross at least one 
membrane in order to target CRK3. Although the majority of the compounds in the 
Cyclacel library were designed with desirable pharmaceutical properties (Table 4.1), it 
may be the case that the top 10 HTS compounds found in this screen require further 
optimisation. Therefore, these compounds would likely require iterative chemistry in order 
to make them sufficiently “drug like” to cross the cell membrane and inhibit CRK3. 
Furthermore, the compounds may have gone off whilst being stored in the master plates. 
These reasons may explain why little or no inhibition of CRK3 was observed in 
promastigote L. major and why the cells were still viable. 
The 10 compounds showing the greatest activity towards Leishmania CRK3:CYC6 protein 
kinase activity were also tested against promastigote L. major infected macrophages in 
vitro. As mentioned, there are significant differences between promastigote and amastigote 
Leishmania in biochemistry and sensitivity to standard and experimental drugs(Croft et al., 
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2006a). This is highlighted with the first line drug Sodium stibogluconate (Pentostam, 
SSG), used to treat the visceral form of leishmaniasis, with activity towards amastigote 
Leishmania but not towards promastigote Leishmania (Neal and Croft, 1984). Within 
macrophages, Pentostam is metabolised and converted from the pentavalent form into a 
lethal trivalent form which kills amastigote Leishmania. It has recently been reported that 
Pentostam modifies the expression of eight genes in host cell lines, up-regulating six and 
down-regulating two (El Fadili et al., 2008). These genes may therefore be implicated in 
the mode of action of Pentostam. However, the precise mode of action of Pentostam and 
whether it is macrophage or parasite factors which catalyse the conversion to a lethal 
trivalent form remains unknown. Therefore, it is possible the HTS compounds may have 
activity towards amastigote L. major despite the majority not showing activity towards the 
promastigote form. Using this knowledge as scientific rationale, the biological activities of 
the compounds in a Leishmania infection were carried out as described in section 2.3.7. 
This highlighted one compound, compound 3, which returned an IC50 value of 38.4µM 
(Table 5.2). Interestingly, this compound did not show activity towards promastigote L. 
major, as seen with Pentostam. The remainder of the compounds returned IC50 values 
>50µM, including compound 7, which had an IC50 value of 8.57µM towards promastigote 
L. major. This suggests that these compounds are not active towards amastigote L. major 
infected macrophages. This could be for reasons previously discussed for the HTS 
compounds tested against promastigote L. major. The compounds must cross the parasite 
cell membrane and nuclear membrane in order to target CRK3; however, in amastigote 
infected macrophages, four membranes must be crossed. The compounds must first cross 
the macrophage cell membrane, followed by the parasitophorous vacuolar membrane 
surrounding the amastigotes, the amastigote cell membrane itself and finally the nuclear 
membrane. If, as mentioned previously, the compounds are insufficiently “drug like”, it is 
unlikely they will be able to cross four membranes in order to target CRK3. However, it is 
interesting that compound 3 shows activity towards amastigote L. major but not the 
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promastigote form. Despite the apparent lack of activity of the majority of the compounds 
against promastigote and amastigote Leishmania, it was vital that these compounds were 
re-synthesised and re-tested to confirm their biological activity, or lack thereof.  
Due to time constraints and the complexity of chemical synthesis involved, only six of the 
HTS hits were re-synthesised. Others identified from the HTS screen will be synthesised 
and their biological activity evaluated in the future. These six compounds from the 
CRK3:CYC6 HTS were screened against Leishmania CRK3:CYC6, promastigote L. major 
and amastigote L. major in a macrophage infection; KM114_C, KM117_A, KM117_B, 
KM117_C, KM117_D and KM117_E (Figure 5.3). Only two of the re-synthesised HTS 
hits, KM114_C and KM117_D returned IC50 values which were consistent with those of 
the original HTS hits. Furthermore, two of the hits, KM117_A and KM117_B, proved 
inactive towards CRK3:CYC6. This suggests there are discrepancies between the original 
HTS hits and the re-synthesised compounds. It could be that the original hits were not the 
compounds that they were thought to be or that there may be contaminating compounds 
mixed in, as a result of compound carry over from the HTS liquid handler causing a 
synergistic effect against Leishmania CRK3:CYC6. The identification of these compounds 
as inactive validates the re-synthesis process, highlighting that compounds taken directly 
from a master plate in a compound library should be treated with caution when identified 
as hits. 
Although the first set of assays with compounds 1-10 showed the majority of the 
compounds were essentially inactive towards promastigote and amastigote L. major in a 
macrophage infection, activity was observed with a number of the re-synthesised 
compounds, which is promising for future drug development. However, this begs the 
question of what differences there are between the original HTS hits identified and the re-
synthesised compounds when they should be identical. It is possible that partial 
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degradation of the compounds once made up in DMSO solvent and upon long-term storage 
may have occurred, accounting for the discrepancies observed.  
The purine and aminopyridazine pharmacophores identified from the Leishmania 
CRK3:CYC6 HTS have previously been identified as biological inhibitors. For example 
roscovitine, a purine based CDK inhibitor is in Phase II clinical trials for treatment of 
cancer (Havlicek et al., 2005). Furthermore, 2,6,9, trisubstituted purines, such as 
olomoucine, have been shown to inhibit CDKs (Vesely et al., 1994) and it is known the 
2,6,9, trisubstituted purines also inhibit CRK3 protein kinase activity (Grant et al., 2004). 
It has also recently been reported that azapurine derivatives are shown to be inhibitors of 
CDKs (Havlicek et al., 2005). Interestingly, to date, aminopyridazines have not been 
reported to be inhibitors of CDKs. They have, however, been shown to be inhibitors of 
acetylcholinesterase (Contreras et al., 1999) and neuronal damage (Craft et al., 2004), 
which may be important in the treatment of Alzheimer’s disease. Therefore, the 
aminopyridazine compounds may prove to be novel drugs in the treatment of leishmaniasis 
by acting as CDK inhibitors, which further testing will confirm. 
In order to obtain compounds which showed an increase in potency towards Leishmania 
CRK3:CYC6 protein kinase activity, iterative chemistry was performed on the azapurine 
pharmacophore identified from the Leishmania CRK3:CYC6 HTS (Figure 4.10, upper 
structure). 16 derivatives of the azapurine structure were synthesised and the structures are 
shown (Figure 5.2). Three of the compounds, KM-59_2, KM63_3 and KM114_D showed 
activity towards the Leishmania CRK3:CYC6 protein kinase complex, and as mentioned, 
the remainder were inactive, returning IC50 values of >50µM. This is possibly due to 
certain chemical modifications on the R1, R2 and R3 groups, which might render the 
compounds inactive towards Leishmania CRK3:CYC6. Modifications to the R2 and R3 
groups of the azapurine structure as determined in section 4.11 abolish activity towards 
Leishmania CRK3:CYC6 protein kinase activity. This may account for the derivatives that 
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have had R2 and R3 modifications showing no activity. Furthermore, the selectivity of the 
azapurines towards Leishmania CRK3:CYC6 protein kinase activity, vary because of the 
various groups in the R1 position (compare azapurine compounds, Table 4.2). For 
example, compound 1 has an IC50 value towards Leishmania CRK3:CYC6 of 2.6µM and 
compound 26, 17.9µM. These compounds differ only in the R1 group highlighting that 
CRK3:CYC6 selectivity is partially determined by the chemical group on the R1 position. 
Therefore, certain modifications to the R1 group may again render these derivatives 
inactive towards Leishmania CRK3:CYC6.   
Compound KM114_E is interesting as although it returned an IC50 value of >50µM against 
CRK3:CYC6 it proved active towards promastigote L. major. As a result, the four active 
compounds (KM59_2, KM63_3, KM114_D and KM114_E) were tested against 
promastigote L. major, with the view to testing later against the amastigote form of the 
parasite. Compound KM59_2 was inactive against promastigote L. major possible due to 
the compound not crossing the membranes required to target CRK3. The remaining three 
compounds, however, were active including compound KM114_E. This suggests that 
although it is inactive towards CRK3:CYC6, it is likely active against another target in the 
cell, possibly another protein kinase. Although the azapurine compounds were counter-
screened against a small panel of mammalian kinases, showing selectivity towards 
CRK3:CYC6, they were not counter screened against other Leishmania protein kinases. 
Therefore, it is conceivable that the HTS hits and any derivatives will be active against 
other Leishmania cellular protein kinases. The three compounds active against 
promastigote L. major (KM63_3, KM114_D and KM114_E) were tested against 
amastigote L. major in a macrophage infection. All three compounds were active with 
KM114_E the most active returning an average IC50 value of 6.1µM, again suggesting that 
it is active against a target other than CRK3:CYC6. 
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As with some of the re-synthesised azapurine HTS hits showing activity towards 
promastigote and amastigote L. major, activity is also observed with the azapurine 
derivatives. This shows that the azapurine core structure is amenable to subtle chemical 
modifications resulting in some cases in an increased biological activity towards 
Leishmania (compare the re-synthesised compound KM114_C with the azapurine 
derivatives KM114_E and KM117_E). This is encouraging; highlighting that iterative 
chemistry performed on the azapurine pharmacophore is successful. Therefore, future 
derivatives may result in even more potent compounds which can be further developed to 
treat leishmaniasis.   
N and C-terminal HA-tagged CYC6 constructs were made using an L. major episomal 
expression vector, pXG (Figure 5.4). This was carried out in order to over express L. major 
CYC6 and affinity purify CYC6 to identify binding partners in vivo (predicted to be 
CRK3). These HA-tagged constructs were transfected into wild type promastigote L. major 
and selected with G418 antibiotic. However no cells survived after the addition of the 
antibiotic. This is possibly due to the over expression of CYC6 when in complex with 
CRK3 causing an early cell cycle shift into mitosis as CRK3 is a G2-M kinase. Therefore 
the cells may not have fully replicated their genome before the onset of mitosis and 
cytokinesis, causing an irreversible cell cycle defect, resulting in cell death. An alternative 
explanation may be that the cells lost the episome and G418 antibiotic resistance and die 
upon the addition of G418, or that over expression of CYC6 is toxic to the cells.  
Due to the unsuccessful attempts to over express CYC6 with an episomal vector, N and C 
terminal HA-tagged CYC6 constructs were made using a ribosomal integration vector, 
pRIB (Figure 5.5). These HA-tagged constructs were transfected into wild type 
promastigote L. major and selected with puromycin antibiotic. The cells survived upon the 
addition of the antibiotic and were used to detect HA-CYC6 by Western blot analysis with 
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an anti-HA antibody with the view to affinity purifying CYC6 via the HA-tags for further 
analysis. 
The attempted purification of N and C terminal HA-tagged CYC6 from L. major 
promastigote cells was carried out as described in section 2.3.4. Detection of the HA-
tagged CYC6 proteins was attempted by Western blot analysis using an anti-HA antibody. 
However no N or C terminal HA-tagged CYC6 was detected. The positive control was 
detected at the expected size of 41kDa (Figure 5.6). This suggests that the protein is either 
expressed at very low levels, below the detection capability of the Supersignal West Pico 
Chemiluminescent substrate reagents, or not expressed at all. However, as the cells survive 
upon the addition of puromycin, this suggests the puromycin resistance marker in the pRIB 
vector has been retained by the cells. Therefore it is possible that the gene has been 
rearranged by the cells and is no longer expressed due to over expression of CYC6 being 
detrimental to the progression of the cell cycle.  
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Chapter 6 
Final discussion and conclusions 
CDKs which govern the cell cycle are a class of enzymes that are potential targets for anti-
parasite chemotherapy. Proteins, including enzymes specific to the parasite and absent or 
distinct from the host, which are essential in the pathogenic life cycle stage, are considered 
potential therapeutic drug targets. Gene knockout techniques to validate drug targets have 
proved successful tools; however, gene essentiality does not make it an automatic drug 
target. Knocking out a gene removes the gene product completely but in vivo the protein is 
present and it is this that needs to be down regulated. Many compounds do not provide 
100% inhibition of their target and so the enzyme is able to still catalyse its reaction albeit 
at low levels in the cell (Barrett et al., 1999). Despite genetic manipulation validating a 
gene as essential and therefore a potential drug target, chemical validation is also required 
to show a gene product can be targeted in the cell.  
Protein kinases can be targeted with inhibitors and are druggable in the cell, with several 
compounds such as Gleevec® going to market to treat proliferative disorders. Other 
compounds such as Flavopiridol®, a CDK inhibitor, have progressed into clinical trials. 
However, no therapeutics, to date, have been developed against CDKs which have become 
commercially available anti-parasite drugs. None have successfully progressed through the 
drug discovery pipeline (Figure 1.10) fulfilling the criteria required to become a 
drug/clinical development candidate to treat parasitic diseases (Figure 1.11).    
The aim of this work was to identify inhibitors of the Leishmania CDK, CRK3, which 
could ultimately pass through the drug development pipeline to become drug candidates to 
treat parasitic diseases. Initially, active Leishmania CRK3:CYC6 protein kinase complex 
was purified and an expression system suitable for large scale production of the complex 
developed. A HTS assay was developed with this material and the assay validated. Using 
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the HTS assay a chemical compound library was screened, identifying inhibitors of 
Leishmania CRK3:CYC6 protein kinase activity, which were subsequently screened 
against Leishmania in vitro, to evaluate their biological activity. In order to obtain 
compounds with higher potency towards Leishmania CRK3:CYC6 protein kinase activity, 
derivatives of the HTS hits were synthesised in collaboration with Nicholas Turner and 
Kirk Malone at the Manchester Interdisciplinary Biocentre (MIB). Active compounds were 
screened to determine their biological activity against Leishmania in vitro. This was with 
the view to screening the HTS hits and any active derivatives against Leishmania in vivo, 
and initiating pharmacokinetic studies on the active compounds. However due to time 
constraints, the in vivo and pharmacokinetic studies were not carried out. 
Sufficient quantities of active Leishmania CRK3:CYC6 were obtained, which was active 
without phosphorylation on the conserved T178 residue. This is unusual as 
phosphorylation on the conserved T-loop residue is a prerequisite for an active protein 
kinase complex in many CDKs (Ducommun et al., 1991; Solomon et al., 1992). There are 
exceptions, however, as it has been reported that the activation of some CDK complexes 
such as CDK5-p35 and CDK7-cyclinH do not require phosphorylation (Nigg, 1996; Qi et 
al., 1995) at the analogous site in the T-loop. The Leishmania CRK3:CYC6 protein kinase 
complex could therefore be a further example of this, where there is kinase activity without 
phosphorylation. However, Leishmania CRK3:CYC6 is a recombinant protein kinase 
complex and may not possess exactly the same activity and biochemical characteristics of 
active CRK3 in Leishmania. Therefore, is the Leishmania CRK3:CYC6 protein kinase 
complex biochemically similar to active CRK3 in vivo and as a result, a valid screening 
target? Some biochemical characterisation showed that the Km values for ATP were within 
two-fold and the IC50 values for olomoucine were almost identical between the 
recombinant and parasite-purified enzymes. Therefore, this suggests the CRK3:CYC6 
protein kinase complex and CRK3 in Leishmania are biochemically similar and it can be 
said with a degree of confidence that Leishmania CRK3:CYC6 is a valid screening target.  
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The azapurine and aminopyridazine hits identified from the HTS inhibited Leishmania 
CRK3:CYC6 protein kinase activity. However, little or no biological activity was observed 
against either L. major procyclic promastigotes or amastigotes with the compounds taken 
from the original master plates. This begs the question of whether these pharmacophores 
are of sufficient quality to be developed into leads and drug candidates (Figures 1.10 and 
1.11). However, it is standard practice in drug development to re-synthesise active HTS 
hits to fully evaluate their activity and potential as drug candidates. This was carried out 
and some of the re-synthesised HTS hits, based on the azapurine pharmacophore, did show 
biological activity suggesting there are discrepancies between the two sets of compounds, 
thereby justifying the re-synthesis procedure. There may also have been complications 
when performing the assays with the original HTS hits, accounting for their lack of 
activity; however, the precise reason accounting for the differences in activity observed 
between the HTS hits and the re-synthesised hits remains unknown. Despite this, there is 
undoubtedly activity observed with some of the re-synthesised hits towards L. major 
promastigotes and amastigotes, which is encouraging for the progression of azapurine 
based compounds through the drug discovery pipeline. The re-synthesised HTS hits are 
currently at the “validated hits” stage in the drug development pipeline (Figure 1.10) where 
iterative chemistry is being performed to improve their potency. In terms of fulfilling drug 
candidate criteria (Figure 1.11), the re-synthesised HTS hits are showing the characteristics 
of a hit that can be developed into a lead compound, again something the iterative 
chemistry is attempting to achieve.   
It is important to consider these HTS hits with respect to other current antileishmanials in 
similar stages of drug development. There are a number of synthetic compounds and those 
derived from natural products which are currently being evaluated for their antileishmanial 
properties. One such example is the Azaterphenyl diamidines. These were evaluated 
against axenic amastigote Leishmania where a number of the compounds tested reported 
IC50 values of <1µM against axenic amastigotes (Hu et al., 2008). This is an example of 
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compounds in a similar stage of drug development showing a high potency towards 
Leishmania amastigotes, although they were not tested against amastigotes in a 
macrophage infection. Another example of a class of compounds is the 2-(3-Aryl-
oxopropen-1-yl)-9-tert-butyl-paullones. It is known that paullones are CDK inhibitors and 
have been shown to act on CRK3 as previously discussed. These paullones reduce the 
proliferation of axenic amastigotes and show activity against amastigotes at a 
concentration of 5µM in a macrophage infection (Reichwald et al., 2008). These are an 
example of a new chemotype that are active against Leishmania, possibly the situation that 
could be seen with aminopyridazine-3-carboxamide as a novel antileishmanial 
pharmacophore. Synthetic phospholipids also show potent antileishmanial activity, with 
many exhibiting IC50 values <1µM against Leishmania amastigotes, similar to the 
Azaterphenyl diamidines. These were shown to be more active than that of the currently 
registered drug used to treat leishmaniasis, Miltefosine, which is also a phospholipid 
analogue (Seifert et al., 2007). These are potencies which we wish to achieve with the HTS 
hits in order to progress through the drug discovery pipeline. Further examples of 
compounds currently being tested against Leishmania are Amlodipine and Lacidipine, 
which are 1,4-Dihydropyridine derivatives. These were shown to inhibit Leishmania 
infection in vitro and in BALB/c mice when administered orally (Palit and Ali, 2008). One 
of the next steps for the CRK3 HTS hits once the potency is increased is to test them on 
mice infected with Leishmania.   
Another question to ask is “was the Cyclacel library an appropriate and successful library 
to screen in terms of the hits identified?” Correspondence with Cyclacel suggested that this 
type of HTS with the Cyclacel library was successful by comparison with HTS they have 
carried out in the past. CDK inhibitors typically bond via a donor-acceptor-donor hydrogen 
bonding motif (D-A-D) as determined from CDK2 data described in chapter 4. Therefore, 
as a result of the HTS, identifying azapurine hits and elucidating the hydrogen bonding 
acceptor-donor-acceptor motif (A-D-A) of the azapurine pharmacophore with 
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CRK3:CYC6, may contribute to the future design of CDK inhibitors which are selective 
over other cellular kinases. Identifying two classes of compounds which were significantly 
selective towards Leishmania CRK3:CYC6 protein kinase activity is a promising starting 
point for further chemistry to increase the potency and biological effect of the hits. 
Therefore, the project was successful in terms of the HTS but it remains to be seen whether 
it will be successful in terms of being able to convert the hits into lead compounds in the 
future. 
Because of limited compound, analysis of the biological activity of five of the ten most 
potent HTS hits on L. major parasites was only carried out once, thereby remaining 
preliminary data and inconclusive. It will be vital to remake these five HTS hits and re-
screen them against the parasites in vitro to determine whether they do or do not have 
biological activity towards Leishmania as seen with some of the other re-synthesised HTS 
hits. In addition, it will be interesting to continue the synthesis of azapurines derivatives to 
identify compounds which may have increased potency towards Leishmania CRK3:CYC6 
protein kinase activity and biological activity towards Leishmania. This will contribute to 
evaluating the azapurine pharmacophore as a potential for future drug development.  
The chemical synthesis for reproducing the aminopyridazine-3-carboxamide compounds 
and further derivatives proved difficult and as a result, time restraints prohibited their 
synthesis. Therefore, it would be interesting to analyse the biological activity of this class 
of compound towards Leishmania, particularly because they proved more selective 
towards Leishmania CRK3:CYC6 protein kinase activity and did not inhibit mammalian 
CDK4:CycD1 protein kinase activity in comparison to the azapurine compounds. It 
therefore remains to be seen how successful this pharmacophore could be in terms of 
biological activity and further drug development against Leishmania. 
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An in vivo partner of L. mexicana CRK3 has been shown to be L. mexicana CYCA (F.C. 
Gomes and J.C. Mottram, unpublished). Furthermore, the homologue of CYCA in L. 
donovani has been identified, LdCYC1, (Banerjee et al., 2003) and shown to form a 
complex with L. donovani CRK3 (Banerjee et al., 2006), which as mentioned has 99% 
identity to L. mexicana CRK3.  These complexes are implicated in the G1-S-phase of the 
cell cycle. However, CRK3 has been shown to have the properties of G2-M-phase protein 
kinase in Leishmania and continuing work with HA-tagged CYC6 could determine if 
CYC6 can bind and activate CRK3 in vivo in Leishmania. This may show that 
CRK3:CYC6 is the G2-M-phase protein kinase involved in this stage of cell cycle control 
as seen in T. brucei. Additional work with HA-tagged CYC6 constructs would include 
immunofluorescence assays to determine the cellular location of HA-CYC6. As discussed, 
CRK3 may reside in both the nucleus and cytoplasm as predicted from localization studies 
on CDK1. Therefore, CYC6 could be predicted to be in these same subcellular locations as 
CRK3. Furthermore, raising antibodies against recombinant CYC6 could confirm the 
cellular location of the native protein. Additional analysis of CYC6 could be to attempt to 
generate CYC6 null mutants in order to determine whether CYC6 is an essential gene. 
Hammarton et al., showed that CYC6 formed a complex with CRK3 and that CYC6 was 
an essential cyclin in T. brucei (Hammarton et al., 2003a). RNAi of CYC6 caused a 
mitotic block and a growth arrest in both bloodstream form and procyclic form 
trypanosomes, confirming CYC6 was required for mitosis. We have shown L. mexicana 
CRK3 forms a complex with L. major CYC6. Therefore, it could be predicted that CYC6 
would be essential in Leishmania, due to a conserved function with T. brucei CYC6 at the 
G2-M-phase of the cell cycle.  
Although the majority of HTS hits did not show significant biological activity towards L. 
major either against promastigote or amastigote life cycle stages, some of the re-
synthesised hits did exhibit biological activity. Furthermore, a number of the azapurine 
derivatives synthesised also had biological activity towards both forms of the parasite. This 
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shows that the methodology of assay development and screening was successful, in terms 
of the azapurine pharmacophore. It remains to be seen how successful the 
aminopyridazine-3-carboxamide pharmacophore could be. The Cyclacel library was 
therefore a suitable compound library to screen in terms of the hits identified for this 
project. As a result, the azapurine and aminopyridazine-3-carboxamide pharmacophores 
may be useful starting points for further compound synthesis against Leishmania, which 
further biological testing will confirm. In addition it is possible that further compound 
screening of additional libraries using the methodology and protocols developed, may 
provide compounds with increased potent biological activity which can be developed as 
antileishmanials to treat leishmaniasis.  
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